Investigating the role of cofilin oxidation in cancer cell migration and invasion by Cameron, Jenifer Mary
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Cameron, Jenifer Mary (2013) Investigating the role of cofilin oxidation 
in cancer cell migration and invasion. PhD 
 
 
http://theses.gla.ac.uk/4770/ 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given. 
 
 
 
 
 
 
Investigating the role of cofilin oxidation in cancer 
cell migration and invasion 
 
 
 
Jenifer Mary Cameron 
BSc (Hons) 
 
 
 
 
 
 
 
Submitted in fulfilment of the requirements for the  
Degree of Doctor of Philosophy 
 
 
 
September 2013 
 
 
 
The Beatson Institute for Cancer Research 
 
University of Glasgow 
 
 
 
 
 
 
 
© Jenifer Mary Cameron 2013  
2 
 
Abstract 
Cancer cell invasion and metastasis is one of the hallmarks of cancer and is 
frequently the fatal stage in disease progression. One of the key cellular 
processes underlying invasion and metastasis is cell migration, which is highly 
dependent on dynamic changes in the actin cytoskeleton. Reactive oxygen 
species (ROS) are frequently found at elevated levels in cancer and promote 
disease progression particularly by increasing invasion and metastasis. Although 
it is known that ROS, specifically H2O2, mediate their downstream effects 
through the oxidation of proteins on key cysteine residues, very little is known 
about the direct protein targets of ROS and how the resulting protein oxidation 
might contribute to cell migration, invasion and metastasis.  
I have demonstrated that the ROS, H2O2, is produced at increased levels in 
migrating cells, predominantly at the tips of cell protrusions. Furthermore, I 
established that protein oxidation is increased in migrating cells and identified 
the actin binding protein cofilin as one of these oxidised proteins. I have also 
provided evidence that, when oxidised, cofilin forms oligomers and has a 
reduced ability to decrease F-actin levels in vitro, which was dependent on 
cysteine residues 139 and 147. Moreover, I have shown that the oxidation of 
these cysteine residues is important for directional cell migration and adhesion.  
Taken together my results provide a direct link between the increased 
production of ROS at the leading edge of migrating cells and dynamic changes in 
the actin cytoskeleton that take place in this region to enable cell migration. As 
the invasion and metastasis of cancer is largely dependent on cell migration, 
these findings could potentially lead to the development of new ways to target 
this stage in disease progression. 
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1 Introduction 
1.1 Cancer invasion and metastasis 
Cancer cell invasion and metastasis, or the spread of cancer cells into 
surrounding tissues and eventually to distant sites in the body, is one of the 
hallmarks of cancer as described by Hanahan and Weinburg [1]. Metastasis is a 
multi-step process that involves invasion of cancer cells into tissues surrounding 
the primary tumour, intravasation into local blood and lymphatic vessels, 
dissemination to distant sites in the body, extravasation into tissues and finally 
the formation of secondary tumours (Figure 1-1) [2]. A number of cellular 
changes occur that enable a cancer cell to become invasive and metastasise, but 
the main consequences are cells have reduced cell-cell adhesion and increased 
migration. These changes closely mirror those frequently observed during 
embryonic development to allow the remodelling of tissues, a process known as 
epithelial to mesenchymal transition (EMT). Indeed, many transcription factors 
that are activated during EMT have been implicated in cancer invasion and 
metastasis [3]. As the growth of secondary tumours, metastases, is the cause of 
90% of cancer deaths it is essential that we gain an extensive understanding of 
the molecular mechanisms that contribute to this process so we can develop 
ways to target and prevent this fatal step in cancer progression [4].  
1.2 Cell migration 
Cell migration is essential for many processes including embryonic development, 
wound healing and inflammation [5-7]. It also contributes to the development of 
diseases such as cardiovascular disease and cancer [8, 9]. All eukaryotic cells 
will undergo cell migration at some stage whether it is for a defined period such 
as during development and wound healing, or throughout its lifetime as is the 
case for leukocytes. There are a number of ways in which a cell can migrate, 
broadly categorised as individual or collective cell migration. Which method a 
cell adopts will depend on properties of the cell and the nature of the 
extracellular environment in which it is located [10, 11]. 
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Figure 1-1 Cancer cell metastasis 
Diagram illustrating cancer metastasis; the spread of cancer cells from the primary tumour to a 
distant site in the body where secondary tumours can form. Adapted from [12]. 
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1.2.1 Individual cell migration 
The migration of individual cells is important for a number of cell types including 
leukocytes and neural crest cells, and has also been observed to be used by 
some cancer cells [9, 13, 14]. There are two main types of individual cell 
migration; amoeboid and mesenchymal. These differ in a number of key ways 
including morphology, organisation of the actin cytoskeleton, interaction with 
the extracellular matrix (ECM), method of moving through the ECM and speed 
(Figure 1-2) [15] . 
An amoeboid mode of cell migration is used by cells such as immune cells and 
cancer cells [13, 16, 17]. This type of cell migration is characterised by a 
rounded morphology, the presence of cortical actin and low levels of adhesion to 
the ECM [10]. These very weak interactions are thought to be the reason that 
cells utilising this mode of migration are able to move at high speeds of up to 25 
µm/minute [18]. Association of myosin with cortical actin gives these cells 
enhanced cortical actomyosin contractility and therefore allows cells to move 
through the ECM by changing their shape to squeeze through pre-existing spaces. 
This actomyosin contractility can also generate force that enables cells to push 
their way through the ECM. Additionally, the tension created by this cortical 
actomyosin can lead to the formation of membrane blebs, which also contribute 
to migration [17, 19]. Therefore, cells that use an amoeboid mode of cell 
migration can move through the ECM by squeezing through spaces that are 
already present or by pushing their way through by force generated from cortical 
actomyosin and membrane blebs. 
A mesenchymal mode of cell migration is used by cells such as neural crest cells 
and cancer cells [14, 17]. Mesenchymal migration is characterised by an 
elongated, spindle like morphology, the presence of actin stress fibres extending 
between the poles of the cell and high levels of adhesion to the ECM [10]. Cells 
that migrate in this way, move at speeds of 0.1 – 2 µm/minute, which is thought 
to be due to the high levels of adhesion to the ECM and the slow turnover of 
these [20]. There are a number of well defined steps that occur during 
mesenchymal cell migration. Firstly, an actin rich protrusion is formed at the 
front of the cell through which the cell adheres to the ECM and recruits adhesion 
molecules that lead to the formation of focal adhesions. Proteolytic enzymes are 
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also recruited to these focal adhesions to degrade the ECM, generating a path 
that the cell can move through. Loss of cell adhesions at the rear of the cell and 
contraction of actin stress fibres, by the activity of myosin proteins, results in 
the translocation of the cell [15]. This cycle then repeats and the cell moves 
forward. In contrast to amoeboid cell migration, cells that use a mesenchymal 
mode of cell migration move through the ECM by degrading and remodelling it to 
create paths that the cells can move through using their strong cell-matrix 
adhesions and contractile forces. 
1.2.2 Collective cell migration 
Collective cell migration occurs when groups of cells that are attached together 
move simultaneously. This type of migration is essential for many developmental 
processes for example the migration of Drosophila border cells, lateral line 
primordium cells in zebrafish and gastrulation in the embryo of multicellular 
organisms [5, 21, 22]. It is also necessary for wound healing and has been 
observed to occur during the invasion of cancer cells [6, 9]. In collective 
migration, cell-cell contacts are retained, unlike in individual cell migration, 
allowing cells to move as strands, sheets or clusters of cells (Figure 1-2) [10]. In 
these groups of cells it is only those at the leading edge that have properties 
similar to individually migrating cells such as generation of actin rich protrusions 
or blebs, formation of focal adhesions, and degradation and remodelling of the 
ECM [23, 24]. Cells at the rear of the group migrate passively due to their 
physical coupling to the cells at the front that are actively migrating [25]. 
1.2.3 Flexibility in cell migration modes 
Although most cell types have a predominant mode of cell migration, it is now 
appreciated that cells can switch to an alternative type of migration under 
certain circumstances (Figure 1-2). Changes in the extracellular environment or 
properties of the cell that inhibits a particular mode of migration can result in 
the cell shifting to a different mode so that its movement is not stopped 
completely [11]. The ability to change the mode of cell migration is important 
for the maturation of macrophages and endothelial cells and has also been 
observed in the progression and invasion of cancer cells [10]. 
  20 
 
Epithelial to mesenchymal transition (EMT) occurs when cells lose cell-cell 
junctions while maintaining cell-matrix interactions, migratory and ECM 
remodelling capabilities. This enables them to break away from other cells and 
migrate in a mesenchymal mode. EMT is involved in many stages of development 
and thought to be a critical stage in the progression of cancers originating from 
epithelial tissues [3]. In a similar way, if a cell loses cell-matrix interactions in 
addition to cell-cell junctions, it will shift from a collective to amoeboid mode 
of migration. This is known as collective-amoeboid transition (CAT) and has been 
observed in melanoma explants [26]. The reverse of EMT and CAT can also occur 
if cell-cell adhesion is enhanced, resulting in cells migrating collectively rather 
than individually [27, 28]. 
The other shift in migration mode that has been observed to occur is between 
the two types of individual cell migration; amoeboid and mesenchymal. A key 
pathway determining whether an amoeboid or mesenchymal mode of cell 
migration is adopted is the balance between Rho and Rac signalling pathways. 
Increased Rho/Rho-associated coiled-coil containing kinase (ROCK) signalling 
leads to enhanced actomyosin contractility and an amoeboid type migration 
while increased Rac activity results in more cell protrusions and a mesenchymal 
type migration [17, 29]. Additionally, a decrease in cell-matrix interactions or 
loss of proteolytic activity at the leading edge can result in a mesenchymal to 
amoeboid transition (MAT) [30, 31]. Conversely, inhibition of Rho/ROCK 
signalling which results in an amoeboid to mesenchymal transition (AMT), causes 
an increase in cell-matrix interactions and proteolytic activity [32]. Transition 
between mesenchymal and amoeboid modes of cell migration is relatively rapid 
compared to EMT that involves a number of changes to gene transcription. It is 
thought this quick transition allows cells to respond promptly to changes in the 
environment so cell migration is not inhibited [15].  
The range of migration modes used by cells and the transitions between them 
has been extensively studied in cancer cells. This flexibility in migration is likely 
to contribute to invasion and metastasis which requires cells to migrate and 
invade through many tissues that have very different physical properties and 
activate different signalling pathways within the cell. 
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Figure 1-2 Different modes of cell migration 
Diagram illustrating the different modes of cell migration that differ in morphology, organisation of 
the actin cytoskeleton, interaction with the extracellular matrix, method of moving through the ECM 
and speed. Arrows represent the transitions in cell migration modes that can occur. Figure adapted 
from [11]. 
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1.3 Actin cytoskeleton dynamics in cell migration 
The actin cytoskeleton consists of a network of actin filaments (F-actin) which 
are polymerised from actin monomers (G-actin). Each filament has a ‘barbed’ or 
‘plus’ end where new monomers are constantly being added and a ‘pointed’ or 
‘minus’ end that undergoes depolymerisation. Only adenosine triphosphate (ATP) 
loaded G-actin is added to the ‘barbed’ end, and over time the ATP is 
hydrolysed to adenosine diphosphate (ADP) and inorganic phosphate (Pi). The Pi 
is then released leaving ADP loaded F-actin which is depolymerised from the 
‘pointed’ end. The ADP on the released actin monomer is exchanged for ATP and 
the ATP-G-actin is ready to be reincorporated into F-actin. This process is 
constantly occurring and is known as actin treadmilling. In addition to these 
continual changes to each filament, the actin cytoskeleton as a whole undergoes 
constant dynamic changes and this is particularly important during cell migration 
[33, 34]. There are a number of proteins that mediate these changes in the actin 
cytoskeleton but the main mediators and how they contribute to the formation 
of membrane protrusions involved in cell migration are summarised here (Figure 
1-3). 
The Arp2/3 complex binds to the sides of pre-existing actin filaments and 
initiates the formation of new filaments generating a branched actin network. It 
is activated through interactions with members of the WASP family of proteins 
[35]. The Arp2/3 complex is central to the formation of lamellipodia, which are 
flat sheet-like protrusions, and invadopodia which are actin rich protrusions that 
have the ability to degrade the ECM [36, 37]. In some situations it has also been 
found activated in filopodia, which are networks of parallel actin filaments [38]. 
Other well established actin regulators are members of the formin family of 
proteins. Formins can initiate the formation of new actin filaments as well as 
promoting elongation by binding to the barbed end of filaments and allowing the 
addition of new monomers while preventing capping proteins from blocking 
elongation [39]. Formins are major mediators of actin polymerisation that lead 
to the formation of actin stress fibres, filopodia, invadopodia and lamellipodia 
[40-43]. Members of the Ena/VASP family also promote filament elongation by 
preventing capping and therefore blocking of actin polymerisation and have been 
found in the leading edge of lamellipodia and required for the formation of 
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filopodia [44-46]. Additionally, the spire family of proteins can nucleate new 
actin filaments [47].  
As well as proteins that directly increase actin filament nucleation and 
polymerisation, there are regulators that alter the structure of the actin 
cytoskeleton in different ways. Fascin can bundle actin filaments together, 
which has been shown to be important for the stability of filopodia and 
invadopodia [48]. Cofilin severs actin filaments, reducing the length of filaments 
in addition to providing new barbed ends for polymerisation and branching by 
other actin regulators. Cofilin is essential for both lamellipodia and invadopodia 
[49, 50]. Cortactin has been shown to activate the Arp2/3 complex and to 
stabilise branched actin networks and is important for the functions of both 
lamellipodia and invadopodia [51-53]. Profilin can bind to G-actin and has been 
described to promote both actin polymerisation and depolymerisation under 
different circumstances [54]. 
These mediators of actin cytoskeleton dynamics are tightly controlled in cells by 
a range of regulatory mechanisms. In particular, the Rho family of GTPases 
including Rho, Rac and Cdc42 are well known to be key regulators of the actin 
cytoskeleton, acting through proteins such as those described above [55]. 
Signalling through these and other pathways ensures that protrusions are 
generated and cells migrate only when necessary. Indeed, in invasive cancer 
cells many of these proteins and components of their upstream signalling 
pathways are upregulated, contributing to the migration, invasion and 
metastasis of cancer cells [56]. 
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Figure 1-3 Proteins involved in mediating changes in the actin cytoskeleton 
The actin cytoskeleton undergoes constant dynamic changes that are mediated by a number of 
proteins. This diagram illustrates the main proteins involved in altering the structure of the actin 
cytoskeleton. Figure adapted from [55] and [57]. 
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1.4 ADF/cofilin family 
The actin-depolymerising factor (ADF)/cofilin family of small actin binding (15-
21 kDa) proteins have a characteristic three-dimensional (3D) fold known as the 
ADF-homology domain that binds to actin [58, 59]. This domain is also present in 
two structurally and functionally different families of proteins, twinfilins and 
debrin/Abp1s [60]. The ADF/cofilin family are ubiquitously expressed throughout 
eukaryotes, with unicellular eukaryotes such as yeast expressing just one protein 
and multicellular organisms producing several. In mammals there are three 
isoforms; ADF, cofilin-1 and cofilin-2 which have been shown to be expressed in 
different cell types. Cofilin-1 is the main isoform as it is expressed in most cells 
in both embryos and adult mice, with the exception of mature skeletal muscle, 
while cofilin-2 is restricted to muscle and ADF to epithelial and endothelial 
tissues [61, 62]. In addition to being differentially distributed in tissues, these 
three proteins have overlapping but also distinct roles in cells. This was observed 
in cell culture studies where the phenotype of cofilin-1 knockdown cells could be 
rescued by the overexpression of ADF and the reverse was also true [63]. 
Furthermore, loss of the yeast cofilin gene is lethal but can be rescued by both 
mammalian ADF and cofilin [64]. In contrast, knockout of cofilin-1 in mice is 
embryonic lethal and although the resultant ADF overexpression enables 
gastrulation to occur, it is not sufficient to rescue later stages of development 
[65]. In ADF knockout mice, there are no problems during development but 
shortly after birth they become blind due to hyperproliferation of the cornea 
epithelial cells, which is not rescued by the increased cofilin expression 
observed in these mice [66]. Additionally, cofilin-1 and cofilin-2 are both 
expressed in developing muscle but do not have the same affinity for F-actin and 
could therefore have different roles in muscle development [67]. 
As the focus of this project has been cofilin-1, from now on I will refer to this 
isoform as cofilin. 
1.5 Cofilin regulation of actin dynamics 
Cofilin can bind to both G-actin and F-actin [68]. There are two actin binding 
regions in cofilin, one that can bind both G-actin and F-actin and one that binds 
only F-actin. These were highlighted during systematic mutagenesis studies of 
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yeast cofilin and were modelled recently from the crystal structure of human 
cofilin [69, 70]. This modelling, in addition to previous electron cryomicroscopy 
experiments, revealed that cofilin binds to F-actin in a cooperative manner by 
binding to two actin monomers in a filament (Figure 1-4) [71]. Cofilin has a 
higher affinity for ADP-actin monomers than ATP-actin monomers and also 
preferentially binds to older actin filaments where ATP has been hydrolysed to 
ADP [72, 73]. The binding of cofilin to actin can have a number of different 
effects. When bound to F-actin, cofilin induces a conformational twist in the 
filament which reduces the crossover between adjacent actin subunits. This 
weakens the filaments and is proposed to result in severing of the filament [71, 
74-76]. However, more recent studies suggest that the twist in the actin 
filament induced by cofilin is actually stabilised by the binding of cofilin to two 
monomers. In this model, it is the sites distant from cofilin binding that are 
weakened and are the points of severing [77]. Alternatively there is evidence 
supporting the hypothesis that cofilin severing occurs at the boundaries between 
the cofilin-bound and cofilin-unbound regions of F-actin [78, 79]. Although these 
studies suggest that cofilin severs F-actin at different sites, they all agree that 
severing of actin filaments is a major role of cofilin.  
Cofilin has also been shown to increase the rate of actin monomer dissociation 
from the ‘pointed’ end [80]. Although it is highly debated as to whether this is 
indeed a function of cofilin, there are lines of evidence and models that support 
it. The destabilising effect of cofilin on actin filaments could extend to the 
weakening of interactions between actin subunits at the end of the filament, 
thereby increasing monomer dissociation [77]. Cofilin can also enhance the 
release of Pi after ATP bound to actin filaments is hydrolysed, thereby increasing 
the rate of filament maturation and consequently the dissociation of actin 
monomers from the ‘pointed’ end [81]. Additionally cofilin binds to ADP-actin 
and inhibits the exchange of ATP for ADP, therefore altering the concentration 
of ATP-actin available for incorporation into new filaments and consequently 
promoting dissociation [82]. In contrast to the involvement of cofilin in reducing 
F-actin levels by severing or monomer dissociation, it has been shown that 
cofilin can lead to the nucleation of G-actin and the formation of new filaments 
[72]. Furthermore cofilin has been found to promote the formation of actin rods, 
which are F-actin filaments that are bundled together [83, 84]. Cofilin can also 
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regulate the branching of actin filaments by competing with Arp2/3 and 
dissociating it and actin branches from filaments [85]. 
As it has been described, cofilin has a number of roles in the regulation of actin 
dynamics and at times these appear to be opposing. It is likely that the final 
outcome of cofilin activity is determined not just by cofilin alone but the 
presence of other actin regulatory proteins. For example, if there are high levels 
of capping proteins that block polymerisation, it is likely that cofilin severing of 
actin would result in an overall decrease in F-actin. In contrast, high formin, 
Arp2/3 complex and profilin levels could lead to increased polymerisation as 
cofilin would provide additional barbed ends for these proteins for the initiation 
of actin polymerisation. An additional level of control has become apparent 
more recently where the outcome of cofilin activity is dependent on its 
concentration [86]. At low concentrations, cofilin severs actin filaments while at 
high concentrations it promotes nucleation. It is proposed that at intermediate 
levels of cofilin, filaments are stabilised and not severed, which is in line with 
previous findings [77]. Furthermore, at excessively high levels of cofilin, actin 
rods form that are highly decorated with cofilin, sequestering it from performing 
any other functions [84]. 
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Figure 1-4 Model illustrating the regions of cofilin that interact with actin 
The dark blue area highlights the region of cofilin (green) that interacts with G-actin or one actin 
subunit in F-actin (raspberry). The cyan area highlights the region of cofilin that interacts with a 
second actin subunit in F-actin (beige). The red area indicates a region of cofilin that would clash 
with actin, however this model predicts residues in this area would shift to allow an induced fit 
between cofilin and actin.  Model taken from [70]. 
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1.6 Cofilin functions unrelated to actin dynamics 
It is now appreciated that cofilin has several roles that are not related to 
altering the structure of the actin cytoskeleton. One of these is in translocating 
actin to the nucleus. Actin has several functions in the nucleus including 
influencing the transcription activity of all three ribonucleic acid (RNA) 
polymerases and as a component of chromatin remodelling complexes and 
ribonucleoproteins; however, it has no nuclear localisation sequence (NLS) [87]. 
Consequently it must depend on binding to proteins that have an NLS, such as 
cofilin [88]. In support of this theory, ATP depletion in mast cells results in the 
nuclear translocation of actin that is dependent on cofilin [89]. In addition to 
chaperoning actin to the nucleus, cofilin has been implicated in RNA polymerase 
II transcription activity [90]. 
A second role of cofilin that is independent of actin is the induction of cell death 
by apoptosis and necrotic-like programmed cell death. Under conditions of 
oxidative stress, either directly from oxidants or through compounds that 
increase oxidant levels in cells, cofilin translocates to the mitochondria [91-93]. 
Here it mediates the opening of the permeability transition pore which enables 
the release of cytochrome c and consequently apoptosis [94]. 
A further actin independent cofilin function is the regulation of lipid 
metabolism. Cofilin can directly interact with and activate phospholipase D1 
(PLD1), which hydrolyses phosphatidylcholine (PC) in cell membranes to 
phosphatidic acid (PA) [95]. PA is involved in a large number of cellular 
processes, suggesting that cofilin could therefore be involved in their regulation 
indirectly. [96, 97].  
1.7 Regulation of cofilin activity 
1.7.1 Phosphorylation of serine 3 
The main way by which cofilin activity is regulated is through the 
phosphorylation status of its serine 3 residue (Figures 1-5 and 1-6). When 
phosphorylated on serine 3, cofilin is inactivated with respect to its actin 
modulating activities [98]. This phosphorylation prevents cofilin from binding to 
both G-actin and F-actin due to the negatively charged phosphate forming an 
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electrostatic interaction with two lysine residues (lysine 126 and lysine 127). 
These lysines are normally involved in cofilin binding to actin so when they 
interact with phosphorylated serine 3, binding is prevented [99, 100]. Cofilin 
also needs to be dephosphorylated to translocate to the mitochondria and 
induce apoptosis [93]. In contrast to this, phosphorylation of cofilin is required 
for it to activate PLD1 [95].  
There are five kinases reported to phosphorylate and regulate the activity of 
cofilin; LIM domain kinases 1 and 2 (LIMK1 and LIMK2), testis-specific kinases 1 
and 2 (TESK1 and TESK2) and Nck-interacting kinase-like embryo-specific kinase 
(NESK) (Figure 1-5) [101-106]. LIMK1 and 2 are activated by phosphorylation 
predominantly downstream of the Rho GTPases Rho, Rac and Cdc42. Rho and 
Cdc42 induce the phosphorylation of both LIMK1 and 2 through ROCK and 
myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) respectively 
[107-109]. Rac has been reported to induce the phosphorylation of LIMK1 
downstream of p21-activated kinase (PAK) 1 and 4 [110, 111]. Furthermore 
LIMK1 can be phosphorylated and activated by kinases activated by adhesion to 
fibronectin and vascular endothelial growth factor (VEGF) signalling [112, 113]. 
LIMK1 can be dephosphorylated and inactivated by the phosphatase slingshot 
(SSH) [114]. 
In contrast to LIMK1 and 2, relatively little is known about the upstream 
regulators of TESK1 and 2, but their regulation is understood to mainly occur 
through integrin dependent adhesion. TESK1 is inhibited by binding to actopaxin 
and 14-3-3β but these interactions are dissociated by integrin binding to 
fibronectin [115, 116]. TESK1 is also inhibited by binding to sprouty-4 and spred1 
[117, 118].  
In addition to cellular kinases that phosphorylate cofilin, there are phosphatases 
that dephosphorylate it (Figure 1-5). Members of the SSH family, chronophin and 
the serine/threonine phosphatases protein phosphatase 1 (PP1) and protein 
phosphatase 2A (PP2A) are such enzymes [119-121]. As for the TESKs, little is 
known about the upstream regulators of these phosphatases. Association of the 
SSH family member SSH1L with F-actin enhances its activity [122]. SSH1L is also 
dephosphorylated and activated by increases in intracellular calcium (Ca2+) 
through the phosphatase calcineurin [123]. Conversely SSH1L is inactivated by 
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PAK4 and protein kinase D (PKD) mediated phosphorylation [114, 124]. 
Phosphorylation of SSH1L by these enzymes results in it binding to the 
scaffolding protein 14-3-3 and consequently prevents it from binding to and 
being activated by F-actin [114, 122, 124]. Inhibition of SSH1L by 14-3-3 can be 
released by the oxidation of the cysteine residues of 14-3-3 [125]. The 
phosphatase chronophin is inhibited through its interaction with heat shock 
protein 90 (hsp90) but when ATP is depleted this interaction is disrupted, 
releasing chronophin and enabling it to dephosphorylate cofilin [126]. 
The many kinases and phosphatases that alter the phosphorylation status and 
activity of cofilin and the array of upstream signalling pathways that regulate 
these proteins highlights the central importance of cofilin phosphorylation as a 
mechanism of its regulation (Figure 1-5). 
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Figure 1-5 Regulation of cofilin phosphorylation status 
Diagram showing the many kinases and phosphatases that can change the phosphorylation status 
and therefore activity of cofilin. Signalling pathways that are known to result in the activation of 
these enzymes are also shown.  
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1.7.2 pH and phosphatidylinositol (4,5) bisphosphate 
It has been known for a number of years that phosphatidylinositol (4,5) 
bisphosphate (PIP2) can bind to cofilin and prevent it from interacting with G-
actin [127]. This is due to the fact that the PIP2 and actin binding sites on cofilin 
overlap and therefore PIP2 bound cofilin cannot interact simultaneously with 
actin [128, 129]. The hydrolysis of PIP2 by phospholipase C (PLC) after epidermal 
growth factor (EGF) stimulation releases cofilin from its interaction with PIP2 
and allows it to bind to actin. Altering the kinetics of this process interferes with 
cofilin function [130, 131]. pH has also been shown to regulate cofilin activity 
both in vitro and in vivo with a higher pH increasing cofilin activity [132, 133]. 
Recent studies have highlighted that the pH and PIP2 control of cofilin function 
are in fact not separate mechanisms but part of the same regulatory pathway, 
since PIP2 binding to cofilin appears to be pH dependent with decreased binding 
at higher pH (Figure 1-6). It is suggested that the protonation of histidine 133 in 
cofilin is required for PIP2 to bind and therefore at a higher pH this protonation 
is lost leading to a decrease in PIP2 binding and consequent increase in cofilin 
activity [134]. 
1.7.3 Oxidation 
The first evidence indicating that cofilin could be regulated by oxidation came 
from in vitro studies showing that cofilin formed dimers and oligomers, and that 
these multimers exhibited actin bundling rather than severing activity. The data 
suggested that oligomers are formed by disulphide bonds between cysteines 39 
and 147 [135]. Shortly after this discovery, cell culture studies identified cofilin 
as one of the proteins that is glutathionylated (a product of oxidation) in 
oxidatively stressed T cells [136]. Furthermore, oxidation of cofilin is required 
for it to translocate to the mitochondria and mediate oxidant-induced apoptosis 
and necrotic-like programmed cell death. Both of these responses are suggested 
to be due to the formation of intramolecular disulphide bonds between cysteines 
39 and 80 and cysteines 139 and 147 or just cysteines 39 and 80 respectively [91, 
94]. Additionally, the altered actin dynamics observed in T cells during 
conditions of oxidative stress is attributed to oxidation of cofilin and the 
formation of an intramolecular disulphide bond between cysteines 39 and 80  
(Figure 1-6) [137]. 
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1.7.4 Regulation by other proteins 
Tropomyosins are a large family of proteins consisting of more than 40 isoforms 
that bind to and stabilise actin filaments, preventing cofilin from disassembling 
them [68, 138, 139]. Due to the competitive binding of these proteins, it was 
thought that all tropomyosins would inhibit cofilin activity; however, one of the 
isoforms has now been found to associate with cofilin on the same actin filament 
(Figure 1-6) [140]. It is possible that with such a large number of tropomyosin 
isoforms, this is not the only one with a cooperative rather than competitive 
role. Actin interacting protein 1 (Aip1) is another actin binding protein that can 
modulate cofilin activity (Figure 1-6). Aip1 collaborates with cofilin to enhance 
its actin disassembling function by binding to barbed ends of filaments and 
blocking polymerisation [141, 142]. CAP/Srv2 is another protein that can 
enhance the filament disassembling function of cofilin by accelerating the 
release of cofilin from ADP-actin subunits allowing it to continue to sever more 
filaments (Figure 1-6) [143, 144]. Coronin can also alter cofilin activity 
depending on the nucleotide state and age of the F-actin. In new filaments, that 
are loaded with ATP or ADP+Pi, coronin blocks cofilin from severing them but in 
older, ADP loaded filaments, coronin amplifies cofilin severing (Figure 1-6) 
[145]. Finally cortactin can bind to cofilin and inhibit its actin severing function 
(Figure 1-6) [146]. 
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Figure 1-6 Regulation of cofilin activity 
Diagram summarising the many ways in which cofilin activity can be activated and inhibited. Cofilin 
can be regulated by post translational modifications (phosphorylation and oxidation), proteins that 
compete with cofilin for actin binding (many tropomyosins and coronin), proteins that collaborate 
with cofilin to enhance actin filament severing and depolymerisation (Aip1, CAP/Srv2, tropomyosin 
isoform TmBr3 and coronin), phospholipids and pH. 
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1.8 Cofilin cellular functions 
The number of mechanisms that exist to regulate cofilin activity, and the even 
greater diversity of signalling pathways that feed into these, highlights the 
central importance of cofilin in modulating cellular processes. As the 
predominant role of cofilin is in remodelling the actin cytoskeleton, cellular 
processes that require dynamic changes in actin structure are likely to involve 
cofilin. Indeed cofilin has been implicated in cell migration, cytokinesis, 
endocytosis, apoptosis and cell specific functions (Figure 1-7). 
1.8.1 Cell migration  
In order for cells to migrate they must first extend membrane protrusions, such 
as lamellipodia, filopodia, invadopodia and blebs at the leading edge of the cell. 
All these protrusions depend on dynamic changes in the actin cytoskeleton and 
both lamellipodia and invadopodia have been directly shown to require cofilin. 
Development of lamellipodia depends on the activity of cofilin as inhibition of 
cofilin prevents lamellipod extension (Figure 1-7) [147, 148]. It was originally 
proposed that cofilin acted at the rear of the lamellipodia to disassemble actin, 
replenishing the pool of actin monomers required for polymerisation. This was 
based on the observation that cofilin preferentially bound to and disassembled 
filaments at the rear of the lamellipodia [149, 150]. Later studies supported this 
model, showing that cofilin promotes lamellipodium formation by depolymerising 
filaments and increasing G-actin levels [151, 152]. However, it has also been 
suggested that cofilin severs filaments generating additional barbed ends from 
which polymerisation can occur [130, 153, 154]. Furthermore, cofilin has been 
implicated in determining the direction of lamellipod growth by providing an 
initial burst of free barbed ends [155, 156]. Two models have been described 
that could explain these different roles of cofilin. In one, where cells are in 
continuous movement and availability of actin monomers is a limiting factor, 
cofilin disassembles filaments at the rear of protrusions to supply new monomers 
for polymerisation. In the other model, migration is stimulated for example by a 
chemoattractant such as EGF. In this situation cofilin enhances polymerisation 
and sets the direction of movement by severing actin filaments and generating a 
rapid increase in the available barbed ends for polymerisation [157]. In reality it 
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is possible that these two outcomes are not mutually exclusive and that a cell 
uses both at different stages of lamellipodia growth depending on local signalling 
and the presence of other actin remodelling proteins. 
Cofilin has also been implicated in the maturation but not the initial assembly of 
invadopodia (Figure 1-7) [37]. The activity of cofilin is restricted to the core of 
the invadopodia by the RhoC GTPase which specifically induces the 
phosphorylation and inactivation of cofilin around the periphery of the 
invadopodia while leaving cofilin in the core active [158]. This results in 
filaments in the centre of the invadopodia being severed, creating new barbed 
ends and increasing G-actin levels for the polymerisation of new filaments 
resulting in the elongation of invadopodia [146, 159].  
As cofilin was identified as one of the components required to recreate actin 
based motility in vitro, it is likely to be involved in the migration of all cells 
[160]. However, there are some specific cell types that have been proven 
directly to require cofilin for their migration. During development in mice, 
cofilin is essential for the polarisation and migration of neural crest cells to close 
the neural tube. This is the reason that cofilin knockout mice embryos do not 
survive past gastrulation [65]. Three different types of immune cells; 
macrophages, neutrophils and T cells, also depend on cofilin for migration [161-
163]. Interestingly T cells require cofilin for migration in 3D but not in two-
dimensional (2D) environments [162]. 
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Figure 1-7 Cellular functions of cofilin 
Diagram illustrating the many cellular functions of cofilin including those that involve dynamic 
changes in the actin cytoskeleton and those that are unrelated to actin dynamics. Figure adapted 
from  [164]. 
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1.8.2 Cytokinesis 
Cofilin contributes to cytokinesis in several organisms including fission yeast, 
fruit flies, nematodes and frogs (Figure 1-7) [165-168]. It concentrates at the 
cleavage furrow in dividing cells and is required for the correct assembly of the 
contractile ring which constricts to separate the two daughter cells [169, 170]. 
1.8.3 Endocytosis 
Cofilin is required for the disassembly of endocytic vesicles but not their 
assembly. It is proposed that cofilin binds to mature ADP loaded filaments at the 
membranes of internalised endocytic vesicles and depolymerises them thereby 
recycling actin monomers for the formation of other vesicles (Figure 1-7) [171]. 
1.8.4 Apoptosis 
As has already been mentioned, cofilin is necessary for the induction of 
apoptosis under conditions of oxidative stress. During this process, cofilin 
translocates from the cytoplasm to the mitochondria where it causes 
mitochondrial swelling, opening of the permeability transition pore and release 
of cytochrome c (Figure 1-7) [93, 94] 
1.8.5 Cell specific cofilin functions 
In addition to being involved in processes common to all cells, cofilin is required 
for functions that are specific to certain cell types. Costimulation of T 
lymphocytes through accessory receptors such as CD2 and CD28 but not 
signalling through the T cell receptor alone results in the dephosphorylation of 
cofilin which subsequently interacts with actin and this is essential for T cell 
activation [172-174]. Presentation of antigens to T cells by macrophages is also 
dependent on cofilin [163]. The excitation and directional growth of neurites is 
an essential process for the development of the nervous system and depends on 
the remodelling of the actin cytoskeleton. Cofilin has recently been shown to be 
one of the actin regulatory proteins required for this process [175]. Myelination 
of neurons by Schwann cells is also dependent on cofilin activity [176]. 
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1.9  Cofilin in disease 
1.9.1 Cancer 
Considering the many cellular processes that cofilin is involved in, it is not 
surprising that the cofilin pathway is implicated in cancer, predominantly in 
invasion and metastasis that depends heavily on cell migration. Cofilin 
expression is found altered in several cancer cell lines, being overexpressed in 
C6 rat glioblastoma, A549 human lung cancer and human pancreatic cancer cell 
lines and down-regulated in MHCC97-H hepatocellular carcinoma and ovarian 
surface epithelium cells from women with a family history of cancer and 
mutations in the BRCA1 gene [177-181]. The phosphorylation status of cofilin has 
also been observed to be decreased in cell lines from T cell lymphomas and 
carcinomas from the cervix, colon, liver and kidney [182]. Furthermore, 
elevated cofilin expression is seen in clinical samples from ovarian cancer, oral 
squamous cell carcinoma and renal cell carcinoma [183-185].  
In addition to cofilin expression being altered, changes in the levels of proteins 
that modulate cofilin activity and therefore the outcome of the cofilin pathway 
have also been detected. LIMK1 is highly expressed in many cancer cell lines 
including those derived from breast, prostate, skin and ovarian cancers and SSH 
is upregulated in mouse mammary tumour cells [186-188].  
Altering the expression of cofilin in cancer cell lines has also been shown to alter 
their invasiveness. Overexpression of cofilin in the H1299 human lung cancer cell 
line disrupted the actin cytoskeleton at the leading edge of the cells and 
inhibited their invasiveness [189]. Conversely, overexpression of wild type (WT) 
or non-phosphorylatable cofilin increased the migration and invasiveness of the 
K1735 melanoma cell line [190]. Additionally, the overexpression of cofilin and 
proteins that are part of pathways that regulate its activity was identified in an 
invasive subpopulation of cells from a mammary tumour [56]. Another study that 
regulated the output of the cofilin pathway by altering LIMK expression 
discovered that increasing or decreasing the activity of the cofilin pathway 
resulted in a respective increase or decrease in intravasation and metastasis of 
mammary tumours [191]. Furthermore, cofilin phosphorylation decreases with 
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colorectal cancer progression with the lowest levels observed in the most 
advanced primary tumours and lymph node metastases [192]. 
Although these studies do not agree on whether cofilin up- or down-regulation 
promotes cancer and most do not report on overall cofilin activity, it is clear 
that perturbations in the cofilin pathway and activity are commonly found in and 
enhance the progression of cancer. The involvement of cofilin in the invasion 
and metastasis of cancer is likely due to its central role in regulating the actin 
cytoskeleton and the formation of membrane protrusions required for cell 
migration that were described previously. Cofilin may also increase the 
chemotaxis of cancer cells towards a chemoattractant such as EGF. EGF 
signalling has been shown to positively correlate with the metastatic potential of 
cancer cells and tumour associated macrophages promote the invasion of 
carcinoma cells by expressing EGF [193-195]. Furthermore, the directional 
movement of carcinoma cells to EGF has been demonstrated to depend on 
cofilin [156]. Remodelling of the extracellular matrix may be an additional role 
of cofilin in the invasion of cancer cells. As was previously described, cofilin is 
involved in the maturation of invadopodia, which are often formed by invasive 
cancer cells [196]. Down-regulation of cofilin results in less stable invadopodia 
with reduced matrix degrading activity, while the expression of constitutively 
active cofilin leads to increased expression of matrix metalloproteinase (MMP) 2 
and 14 that can degrade the extracellular matrix [37, 190]. 
1.9.2 Neurodegenerative diseases 
Cofilin-actin rods are found in the hippocampal and cortical neurons in brains 
from Alzheimer’s disease patients. Further to this, many signalling molecules 
that are known to induce neurodegeneration lead to the formation of cofilin-
actin rods [84]. These aggregates of cofilin and actin contribute to the loss of 
synapses by blocking intracellular trafficking [197]. Accumulation of amyloid β 
peptide is a distinctive feature of Alzheimer’s disease, and amyloid β dimers and 
trimers can directly induce the formation of cofilin-actin rods [198]. It has been 
suggested that these rods could promote the formation of larger amyloid β 
plaques by blocking vesicles containing amyloid precursor protein and enzymes 
that process this to amyloid β [199]. The development of cofilin-actin rods have 
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also been implicated in the progression of Huntington’s disease, another 
neurodegenerative condition [200]. 
1.9.3 Other diseases 
Actin rod-like structures containing cofilin and spherical aggregates of cofilin 
and actin were identified in the brains of twins with dystonia for which a genetic 
basis could not be found [201]. Cofilin is also found overexpressed in the 
endometria of patients with endometriosis and is linked to the malignant-like 
cell behaviours associated with this disease [202]. In human immunodeficiency 
virus (HIV), both the viral Nef and gp120 proteins inhibit the migration of 
infected T cells through pathways involving cofilin allowing the virus to evade 
the immune system and replicate [203, 204]. 
1.10 Reactive oxygen species 
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen 
(O2). They can be divided into two groups; free radical ROS which have one or 
more unpaired electrons in their outer electron layer and non-radical ROS which 
have no unpaired electrons in their outer electron layer but can be converted 
into free radical ROS. Examples of free radical ROS are superoxide (O2
-) and 
hydroxyl radicals (-OH). Non-radical ROS include hydrogen peroxide (H2O2), 
ozone (O3) and singlet oxygen (
1O2). Oxidants that contain nitrogen such as nitric 
oxide (NO) and peroxynitrate (HNO4) are called reactive nitrogen species [205, 
206].  
There are two major sources of ROS in cells; the mitochondria and nicotinamide 
adenine dinucleotide phosphate oxidase (NOX) enzymes. During oxidative 
phosphorylation in the mitochondria, electrons are transferred through a series 
of protein complexes known collectively as the electron transfer chain. This 
generates a proton gradient that then powers the ATP synthetase to produce 
ATP for the cell [207]. However, this process is not always perfect as electrons 
can sometimes ‘leak’ out of the system leading to the incomplete reduction of 
O2 to O2
-. This ‘leaking’ can happen at complex I and complex III in the electron 
transfer chain [208]. In addition to ROS production during oxidative 
phosphorylation, there are seven other sites in the mitochondria where ROS are 
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produced, however less is known about these contributors than complex I and III 
[209].  
The second major sources of ROS in cells are the NOX enzymes. Although NOX 
enzymes were originally identified in and thought to be restricted to phagocytic 
cells, it is now appreciated that they are expressed in many cells [210-212]. The 
NOX family of enzymes is currently known to consist of seven members NOX1-5 
and dual oxidase (DUOX) 1 and 2. All isoforms are membrane bound and have a 
conserved function, which is to transfer electrons across membranes from 
nicotinamide adenine dinucleotide phosphate (NADPH), through flavin adenine 
dinucleotide (FAD) and haem groups, to O2 creating O2
-. In line with this, they 
have a core common structure of six transmembrane domains that can bind to 
two haem groups, and carboxy terminal NADPH and FAD binding sites [206]. 
Although they have a common function, the isoforms have different cellular 
localisations and regulatory subunits. NOX1 has been identified at the plasma 
membrane but also specifically at caveolae [213, 214]. Generation of O2
- by 
NOX1 depends on the cytosolic regulatory subunits NOXO1 and NOXA1 and the 
membrane protein p22phox [215, 216]. There is also evidence that the GTPase 
Rac can regulate NOX1 activity [217, 218]. NOX2 localises to intracellular and 
plasma membranes and its activation requires the membrane protein p22phox, 
cytosolic proteins p47phox, p67phox and p40phox as well as Rac [219, 220]. At 
present, nothing is known about the subcellular localisation of NOX3 but its 
regulation is dependent on p22phox and NOXO1 [221, 222]. The involvement of 
NOXA1, p47phox, p67phox and Rac are under debate as contradictory studies 
have been published [221-223]. NOX4 has been detected at a number of 
subcellular localisations including the plasma membrane, endoplasmic reticulum 
and mitochondrial membranes as well as at focal adhesions and invadopodia 
[213, 224-227]. The activity of NOX4 requires p22phox but, unlike the other NOX 
enzymes, it does not depend on other cytosolic proteins or Rac [216, 228]. NOX5 
is located at the plasma membrane and is activated through Ca2+ but not 
membrane or cytosolic regulatory subunits [229, 230]. DUOX1 and 2 have been 
identified in the apical membrane of certain epithelial cells and their activation, 
like NOX5, is regulated by Ca2+ and is independent of cytosolic or membrane 
factors [231-233]. 
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In addition to mitochondrial and NOX enzyme produced ROS, there are other 
cellular enzymes that produce ROS as a by-product of their normal reactions. 
Cyclooxygenases that catalyse the formation of prostaglandins generate O2
- 
during this process [234]. Endothelial nitric oxide synthetase that forms NO from 
L-arginine can also generate ROS in certain circumstances; for example when 
cofactors or substrate are in limited supply [235, 236]. Xanthine oxidase 
catalyses the oxidation of purines to urate and produces O2
- as a by-product 
[237]. These are just a few examples of the many enzymes that produce ROS as 
a result of their normal chemical reaction or under certain circumstances. 
It is clear that ROS are produced during normal cellular processes that are 
essential for cell survival, with ATP production in the mitochondria being the 
most obvious example. However, the highly reactive nature of some of the ROS 
means they readily react with and can damage proteins, DNA and lipids, and at 
very high levels can induce cell death [205]. The cell therefore has a range of 
protective mechanisms that maintain ROS homeostasis and avoid cell damage 
and death. Enzymatic antioxidants include superoxide dismutase (SOD), catalase 
and glutathione peroxidase (GPX). In humans there are three SOD enzymes; 
cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD and extracellular SOD (EC-SOD) that 
all destroy O2
- by converting it to H2O2 or O2. Catalase converts H2O2 to H2O + O2 
very efficiently. GPX, of which there are five isoforms that differ in tissue 
expression, reduces H2O2 by catalysing the reaction with glutathione (GSH) to 
form H2O and oxidised GSH [238]. GSH on its own is also a major cellular 
antioxidant as it directly reduces free radicals such as O2
- and –OH [239]. 
Additionally, GSH can reduce vitamin C and vitamin E back to their active forms 
which also act as cellular antioxidants [239-241]. The thioredoxin system consists 
of two enzymes, thioredoxin and thioredoxin reductase, which act together to 
reduce protein disulphide bonds formed by oxidation. Thioredoxin reduces the 
protein disulphide and becomes oxidised itself, while thioredoxin reductase 
reduces the oxidised thioredoxin so it can continue functioning. Thioredoxin 
reductase can also reduce other compounds and disulphide bonds in proteins 
other than thioredoxin [242]. Another family of antioxidant proteins are the 
peroxiredoxins. There are six mammalian isoforms that differ in subcellular 
localisation and the mechanism by which they are reduced. However, they all 
have the same basic catalytic mechanism whereby an active site cysteine 
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residue is oxidised while the substrate such as H2O2 or peroxynitrite are reduced 
[243]. 
1.11 Cell signalling by ROS 
Although ROS were originally thought to only be detrimental to cells, there is 
now growing evidence that they are important for normal cellular functions due 
to their involvement in the regulation of a number of signalling pathways. This 
first came to light after the observation that both platelet-derived growth factor 
(PDGF) and EGF signalling were dependent on the production of H2O2 [244, 245]. 
The main way in which ROS exert their downstream effects is through the 
oxidation of proteins which consequently alters their activity. 
1.11.1 Protein oxidation 
The regulation of proteins by oxidation occurs through the oxidation of specific 
cysteine residues by H2O2 (Figure 1-8). Cysteine residues contain a thiol (R-SH) 
group which in free cysteine residues has a pKa between 8 and 9, however 
sometimes when incorporated into a protein the pKa drops to between 4 and 5. 
This means the hydrogen of the thiol group is more easily lost leaving an 
oxidation sensitive cysteine residue [246]. The first intermediate to form when a 
cysteine residue is oxidised is a sulfenic acid (R-SOH) that contains one oxygen 
atom. This is very unstable and so rapidly undergoes further oxidation and 
reactions to stabilise it. In high oxidation conditions, the sulfenic acid can go on 
to form sulfinic acid (R-SO2H) that contains two oxygen atoms, or sulfonic acid 
(R-SO3H) that contains three oxygen atoms (Figure 1-8). Both of these oxidised 
states have been observed in peroxiredoxin enzymes [247, 248]. Cysteine thiol 
groups in the sulfenic acid state can also be stabilised by the formation of a 
intramolecular disulphide bond as seen in the chemokine CCL18 or an 
intermolecular disulphide as with protein kinase G isoform 1α where a disulphide 
bond forms between its two identical subunits (Figure 1-8) [249, 250]. Disulphide 
bonds can also form between the sulfenic acid and glutathione to form a 
glutathionylated protein as is seen in p21Ras (Figure 1-8) [251]. The final 
modification that can stabilise a thiol oxidised to the sulfenic acid state is 
nitrosylation, which occurs following reaction with reactive nitrogen species and 
is demonstrated in the protein parkin [252]. Although only a few examples of 
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oxidised proteins have been given here, many other proteins have been proven 
to be modified by oxidation and computational analysis of protein sequences and 
large scale proteomic studies predict that more than 500 individual proteins 
have reactive cysteine residues that could potentially be modified by oxidation 
[253, 254]. Therefore, it is highly likely that there are a number of signalling 
pathways involving proteins that can be regulated by oxidation. 
1.12 ROS and cell migration 
1.12.1 Regulation of cell migration by ROS 
One cellular function that is understood to be regulated by ROS is cell migration 
and there are several lines of evidence to support this. Treatment of vascular 
smooth muscle cells with antioxidants and ROS scavenging enzymes inhibited 
VEGF and PDGF stimulated migration [244, 255]. Furthermore, the migration of 
mouse and human endothelial cells and the chemotaxis of neutrophils was 
impaired by expressing antioxidant enzymes [256-258]. Conversely, the PDGF 
induced migration of mouse embryonic fibroblasts (MEFs) was increased when 
the antioxidant peroxiredoxin was removed from cells [259]. In addition to this 
in vitro evidence, in vivo studies have also confirmed an involvement of ROS in 
cell migration. Mice lacking both EC-SOD and Cu/Zn SOD showed decreased 
neovascularisation following ischemia, which was shown to be directly due, in 
part, to a decrease in migratory ability of cells in the Cu/Zn SOD knockout mice 
[260, 261]. The reverse of this has also been shown as the overexpression of EC-
SOD by gene transfer resulted in increased angiogenesis, which is another 
process known to require cell migration [262]. In addition to endogenous ROS 
production being required for cell migration, exogenous H2O2 has also been 
shown to act as a chemoattractant. Mouse neutrophils in vitro migrated directly 
towards low levels of H2O2 [263]. The recruitment of leukocytes and hemocytes 
to wounds in zebrafish larvae and Drosophila embryos, respectively, also 
required H2O2 which acted as the chemoattractant [264, 265].  
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Figure 1-8 Potential protein products resulting from cysteine oxidation by ROS 
A) Structure of the amino acid cysteine with oxidation sensitive thiol group highlighted. B) 
Schematic diagram showing the different stages and final protein products resulting from cysteine 
oxidation by ROS. 
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1.12.2 Sources of ROS in migrating cells 
The predominant sources of ROS that induce the migration of cells are the NOX 
enzymes. This has been shown through a number of studies that either inhibit 
NOX enzymes or alter the expression of one or more of the NOX enzyme catalytic 
or regulatory subunits. The migration of human and mouse endothelial cells in 
response to VEGF, angiopoietin-1 and wounding was suppressed by the inhibition 
of NOX enzymes [257, 266, 267]. Directional migration of colon epithelial cells 
also depends on NOX1 generated ROS as knockdown of NOX1 inhibited migration 
[268]. Stimulation of vascular smooth muscle cell migration to PDGF is inhibited 
by a decrease in the levels of NOX1 and NOX4 and migration to fibroblast growth 
factor (FGF) by a decrease in NOX1 levels [269-271]. Conversely, vascular 
smooth muscle cell migration increases in response to PDGF when NOX1 is 
overexpressed [271]. Furthermore, a small molecule inhibitor screen to find 
regulators of neutrophil chemotaxis identified ROS produced by NOX enzymes as 
one such factor [272]. This study also confirmed the requirement of NOX in 
neutrophil migration in vivo by showing that neutrophils from mice with deleted 
NOX2 displayed impaired recruitment to sites of inflammation compared to WT 
mice. Another in vivo study highlighted the requirement of NOX2 in VEGF 
induced angiogenesis [273]. It is not surprising that NOX enzymes are activated 
and required for cell migration considering the small GTPase Rac that is often 
activated in migrating cells is also one of the regulatory subunits of some of the 
NOX enzymes. 
Although NOX enzymes are the main source of ROS in migrating cells, recent 
studies have also implicated mitochondrial generated ROS. Induction of 
migration by MMP3 is mediated by ROS which was identified to originate from 
the mitochondria [274]. VEGF stimulation of human endothelial cells results in 
an increase in mitochondrial ROS production and cell migration which can be 
blocked by targeting the antioxidants vitamin E or catalase to the mitochondria 
[275]. 
1.12.3 Localisation of ROS in migrating cells 
In order for cells to promote directional cell movement with ROS as a mediator 
of the signalling pathway, they need to spatially regulate ROS production and 
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evidence for how they do this is now growing. p47phox, the regulatory subunit of 
NOX2 is localised to the leading edge in migrating cells and both it and NOX 
translocate to the leading edge in VEGF-induced endothelial cell migration [276-
279]. SOD that converts O2
- to H2O2, the ROS responsible for protein oxidation, is 
also localised to lipid rafts in VEGF stimulated endothelial cells [262]. Membrane 
associated peroxiredoxin 1, an antioxidant that could potentially reduce ROS 
levels and block ROS signalling, is phosphorylated and inactivated in response to 
growth factor and immune receptor activation and at the edges of healing 
wounds in mice [280]. This could allow a local increase in ROS for the purpose of 
promoting cell migration through ROS mediated signalling pathways. 
1.12.4 Targets of ROS in migrating cells 
Although the involvement and sources of ROS in cell migration are well 
established, very little is known about the downstream targets. Treatment of 
cells with H2O2 resulted in an increase in F-actin levels and establishment of 
stress fibres [281, 282]. This suggests that protein targets of ROS in migrating 
cells may be involved in rearranging the actin cytoskeleton as this is an 
important process for cell migration. Actin itself has been identified in an 
oxidised and glutathionylated state in oxidatively stressed T-lymphocytes, 
fibroblasts and gastric mucosal cells [136, 283, 284]. Actin is predominantly 
oxidised on cysteine 374 and when oxidised has a reduced stability and ability to 
polymerise, and increased ATPase activity [285, 286]. As was described 
previously, the actin binding protein cofilin is also a target of oxidation. 
Additionally, the actin cross-linking protein filamin translocates from the 
membrane to the cytosol when cells are treated with H2O2, however the direct 
oxidation of filamin has not been shown [287, 288]. Although there is evidence 
that these proteins are targeted and regulated by ROS, there is no evidence that 
this has any involvement in cell migration.  
The main class of proteins that have been proven to be directly oxidised by ROS 
in migrating cells are protein tyrosine phosphatases (PTPs). PTPs have a cysteine 
residue at their active site which is susceptible to oxidation and results in the 
reversible inhibition of these enzymes [289]. Phosphatases PTP1B and DEP1 were 
oxidised and inactivated in response to VEGF, which resulted in VEGF receptor 
phosphorylation that was shown to be required for endothelial cell migration 
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[262]. PTP-PEST was also oxidised and inhibited by NOX generated ROS and was 
necessary for endothelial cell migration [276]. Furthermore, Rac induced ROS 
production in migrating cells lead to the oxidation and inhibition of LMW-PTP. 
Consequently p190RhoGAP was phosphorylated, Rho activity decreased and 
lamellipodia were formed [290]. LMW-PTP was also inhibited by oxidation 
following the activation of integrin receptors, which resulted in focal adhesion 
kinase (FAK) phosphorylation and activation and the formation of focal adhesions 
and cell spreading [291]. 
It has yet to be determined if ROS produced in migrating cells mediate their 
effect entirely by the inhibition of PTPs, which can have a number of 
downstream targets, or if the activity of other proteins is also regulated by 
oxidation and contributes to cell migration. Recently a study reported that there 
were increased levels of protein oxidation at the leading edge of migrating cells 
and this colocalised with p47phox, a regulatory subunit of NOX2 and possibly 
NOX3. One of these proteins was identified as IQGAP1 but whether this oxidation 
alters its function is still unknown [278]. 
1.13 ROS and cancer 
1.13.1 ROS levels in cancer 
Cancer cell lines and tumour samples frequently exhibit higher levels of ROS 
compared to normal cells and tissues and this contributes to disease 
development and progression. ROS production was shown to be higher in 
prostate cancer cell lines compared to normal prostate cell lines [292]. A 
number of cancer cell lines derived from different tumour types including 
melanomas and ovarian tumours produced large amounts of H2O2 [293]. O2
- levels 
were also elevated in melanoma cells and in the leukocytes from leukaemia 
patients compared to healthy individuals [294, 295]. The number of free, non-
oxidised thiol groups was lower in oral squamous cell carcinoma compared to 
surrounding tissue indicating higher ROS levels were present in the cancerous 
tissue [296]. In renal cell carcinoma, mammary invasive ductal carcinoma, lung 
cancer and gliomas, levels of oxidised DNA, which result from damage by ROS, 
were also elevated [297-299]. Furthermore, lipid oxidation, another ROS induced 
damage, was increased in non-small cell lung cancer [300]. Not only are ROS 
  51 
 
levels increased in cancer cells and tissues but they also correlate with disease 
aggressiveness and overall prognosis [292, 296, 299]. 
1.13.2 Sources of increased ROS in cancer 
These increased ROS levels in cancer can originate from mitochondrial sources, 
NOX enzymes and from the altered expression of cellular antioxidants. 
Mitochondrial DNA, which codes for components of the electron transfer chain, 
is often found mutated in cancer resulting in an increase in ROS [301, 302]. 
Additionally, c-Myc, whose expression is associated with cell transformation, 
increases ROS production most likely due to an increase in oxidative 
phosphorylation in the mitochondria [303, 304]. Ras and p53, which are both 
frequently mutated in cancer, are involved in the expression of antioxidants, 
therefore loss of their function could result in increased ROS levels [305-307]. 
Furthermore, the expression of various NOX enzymes is elevated in cancer cell 
lines and tumour samples compared to the normal equivalents. NOX1 is 
increased in adenocarcinoma and prostate cancer cell lines and tumour samples, 
NOX2 in melanoma, NOX4 in thyroid cancer and NOX5 in malignant B cells [308-
312]. 
1.13.3 ROS in cancer invasion and metastasis 
ROS contribute to many stages of cancer development and progression through 
their ability to cause DNA damage and genetic instability, and their involvement 
in cell signalling pathways important in cancer. One of these areas is in 
promoting the invasion and metastasis of tumours. ROS generation is critical for 
the migratory and invasive phenotype of prostate cancer cells and conversely 
inhibition of NOX4 decreased the migration and metastasis of breast cancer cells 
[292, 313]. Altering cellular antioxidant levels had a similar effect, as a decrease 
in glutathione peroxidase increased lymph node metastasis of gastric carcinoma 
and injecting mice with catalase along with colon cancer cells, decreased the 
number of lung metastases [314, 315]. Mutations in mitochondrial DNA that are 
known to increase ROS levels also enhanced the metastatic potential of breast 
cancer cells [301, 316]. Furthermore, activation of the c-Met hepatocyte growth 
factor (HGF) and BLT2 leukotriene receptors and hypoxia promoted invasion and 
metastasis through ROS dependent signalling pathways [317-319]. These are just 
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a few examples of the signalling pathways and alterations in protein levels that 
have been shown to increase the migration, invasion and metastasis of cancer 
cells through ROS dependent processes. The involvement of ROS in this aspect of 
cancer progression is not surprising considering the participation of ROS in 
mediating cell migration, a key requirement for invasion and metastasis. 
1.14 Project aims 
Considering that cancer metastasis is so frequently the fatal stage in cancer 
progression, increasing our understanding of the underlying molecular 
mechanisms is key in developing successful therapeutic strategies to target it. It 
has become increasingly apparent, over the past decade in particular, that ROS 
have central roles in migration, invasion and metastasis. In addition to this, the 
involvement of ROS in cell signalling pathways, mediating its effects through the 
oxidation of target proteins has also become very clear. Despite this, surprisingly 
little is known about the direct protein targets of ROS in cells normally and more 
importantly in processes that contribute to cancer progression. Therefore, the 
aim of this project was to deepen our understanding in this area by, firstly, 
investigating the exact type and location of ROS produced in migrating cells and, 
secondly, identifying protein targets of this ROS that are oxidised and 
subsequently contribute to cell migration. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents and chemicals 
Table 2-1 List of reagents and chemicals 
Reagent/Chemical Supplier 
Albumin standard (2 mg/ml) Thermo Scientific 
Ampicillin sodium salt Sigma 
Bam HI Invitrogen 
β-mercaptoethanol Sigma 
Bicinchoninic acid solution Sigma 
Biotin-iodoacetamide Invitrogen 
Catalase Sigma 
Copper (II) sulphate solution Sigma 
DCFDA (2’,7’-dichlorofluorescin diacetate) Sigma 
Dimedone (5,5-dimethyl-1,3-cyclohexanedione) Sigma 
DMEM (Dulbecco’s Modified Eagle Medium) Gibco 
DMEM (phenol red free) Gibco 
DMSO (dimethyl sulfoxide) Sigma 
dNTPs Invitrogen 
E. coli BL21 (DE3) pLyss cells Agilent Technologies 
E. coli DH5α cells Invitrogen 
Ethidium bromide Sigma 
Fetal bovine serum PAA 
FuGENE transfection reagent Promega 
G418 Formedium 
Glutathione Sepharose 4B GE Healthcare 
Hin dIII Invitrogen 
Hydrogen peroxide (30%, w/w) Sigma 
HyPerLadder I Bioline 
IPTG (Isopropyl β-D-1-thiogalactopyranoside) Melford 
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L15 medium Gibco 
L-glutamine (200 mM) Gibco 
Lipofectamine LTX reagent Invitrogen 
Matrigel basement membrane matrix BD Biosciences 
NAC (N-acetly-L-cysteine) Sigma 
NuPAGE 4-12% Bis-Tris gels Invitrogen 
NuPAGE LDS sample buffer (4x) Invitrogen 
NuPAGE MES SDS running buffer (20x) Invitrogen 
NuPAGE sample reducing agent (10x) Invitrogen 
NuPAGE transfer buffer (20x) Invitrogen 
One-Phor-All buffer Amersham 
Optimem I reduced serum medium Gibco 
p-aminobenzamidine Sigma 
PenStrep (penicillin and streptomycin) Gibco 
PfuUltra II Fusion HS DNA polymerase Agilent Technologies 
Precision Plus ProteinTM all blue standards Bio-Rad 
Protein A Dynabeads Invitrogen 
Protein G Sepharose beads Sigma 
ProtranTM nitrocellulose membrane GE Healthcare 
Pyrene labelled G-actin Laura Machesky Lab 
SimplyBlueTM SafeStain Invitrogen 
S.O.C. medium (Super Optimal broth with Catabolite 
repression) 
Invitrogen 
Streptavidin Alexa Fluor 680 conjugated Invitrogen 
T4 DNA ligase Roche 
T4 DNA ligase buffer (10x) Roche 
Thrombin Sigma 
Trypsin-EDTA (0.05%) Gibco 
Xho I Roche 
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2.1.2 Kits 
Table 2-2 List of kits 
Kit Supplier 
CellTiter-Glo Luminescent Cell Viability Assay Promega 
Purelink HiPure Plasmid Filter Purification Kit Invitrogen 
QIAquick PCR Purification Kit QIAGEN 
QuikChange II XL Site-Directed Mutagenesis Kit Agilent Technologies 
 
2.1.3 Solutions 
Table 2-3 List of solutions and their recipes 
Solutions Recipe 
Agar plates 
85 mM NaCl, 1% (w/v) bacto trypton, 0.5% (w/v) yeast 
extract, 1.5% (w/v) agarose, antibiotic (100 µg/ml 
ampicillin or 50 µg/ml kanamycin) 
Annealing buffer 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 50 mM NaCl 
Bacterial lysis buffer 
1x TBS, 2x complete protease inhibitor, 3 mM DTT, 1 
mg/ml lysozyme 
DNA loading buffer 
20 mM EDTA, 0.05% (w/v) bromophenol blue, 50% (v/v) 
glycerol 
F-buffer (10x) 
20 mM Tris–HCl pH 8.0, 2 mM ATP, 5 mM DTT and 2 mM 
CaCl2, 500 mM KCl, 20 mM MgCl2, 1 mM EGTA 
G-buffer 
2 mM Tris–HCl pH 8.0, 0.2 mM ATP, 0.5 mM DTT, 0.2 mM 
CaCl2 
IP lysis buffer 
TBS, 1% Triton X-100, 1 mM EDTA, 0.2 mM Na3VO4, 20 
mM NaF, 1x complete protease inhibitor, 1% (v/v) 
phenylmethylsulfonyl fluoride (PMSF) 
L-broth 
85 mM NaCl, 1% (w/v) bacto trypton, 0.5% (w/v) yeast 
extract 
PBS 
170 mM NaCl, 3.3 mM KCl, 1.8 mM Na2HPO4, 10.6 mM 
H2PO4 
PBS-T PBS, 0.1% Triton X-100 
RIPA lysis buffer 
10 mM Tris-HCl pH 7.5, 5 mM EDTA, 150 mM NaCl, 40 
mM NaPPi, 1 mM Na3VO4, 50 mM NaF, 1% NP40, 0.5% Na 
deoxycholate, 0.025% SDS, 1 mM PMSF, 1X complete 
protease inhibitor 
SDS running buffer 25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS 
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SDS sample buffer 
125 mM Tris-HCl pH 6.8, 6% (w/v) SDS, 30% glycerol, 225 
mM DTT, 0.05% (w/v) bromophenol blue 
SDS transfer buffer 
192 mM glycine, 25 mM Tris base, 20% 
(v/v) methanol, 0.036% (w/v) SDS 
TBE 89 mM Tris base, 89 mM boric acid, 2.5 mM EDTA 
TBS 20 mM Tris-HCl pH 7.5, 136 mM NaCl 
TBS-T 20 mM Tris-HCl pH 7.5, 136 mM NaCl, 0.1% Tween 20 
Wash buffer 1  1x TBS, 3 mM DTT, 1 mM EDTA 
Wash buffer 2 1x TBS, 1 mM MgCl2, 1 mM CaCl2, 3 mM DTT 
 
2.1.4 Antibodies 
Table 2-4 List of primary antibodies 
Antigen Species Supplier Catalogue no. 
Cofilin Mouse Abcam Ab75510 
Cofilin Rabbit Abcam Ab42824 
Cofilin Rabbit Cytoskeleton ACFL02-A 
Dimedone (cysteine 
sulfenic acid) 
Rabbit Millipore 07-2139 
DsRed (mCherry) Rabbit Clontech 632496 
ERK2 Rabbit Cell Signalling 91085 
GFP Mouse Clontech 632380 
Mouse IgG Mouse 
Jackson Immune 
Research 
015-000-120 
 
 
Table 2-5 List of secondary antibodies 
Antibody Supplier Catalogue no. 
Alexa Fluor 680 goat anti-mouse IgG Invitrogen A21076 
DyLight 800 goat anti-mouse IgG Perbio Science UK  35521 
DyLight 800 goat anti-rabbit IgG Perbio Science UK 35571 
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2.1.5 Plasticware 
Table 2-6 List of plasticware 
Plasticware Supplier 
35 mm glass bottom dishes Mat Tek 
96-well ImageLockTM plates Essen Bioscience 
96-well plates (black/clear bottom/sterile) BD Falcon 
96-well plates (clear/non-sterile) Greiner Bio-One 
96-well plates (white/non-sterile) Fisher Scientific 
Amicon Ultra 0.5 ml 10k centrifugal filters Millipore 
Cell strainers BD Falcon 
Cryogenic vials Thermo Scientific 
E plate 16 ACEA Biosciences 
FACS tubes BD Falcon 
Falcon tubes for bacterial transformation (352059) BD Falcon 
Syringe filters Gilson 
Tissue culture flasks Nunclon 
Tissue culture dishes (10 cm and 6-well) Corning 
Tissue culture dishes (96-well) Falcon 
 
2.2 Molecular cloning 
2.2.1 Plasmids 
A list of plasmids and their sources or how they were made is detailed below 
(Table 2-7). 
Table 2-7 List of plasmids and their sources 
Plasmid Source 
pGEX-KG-hCofilin WT Previously made in research group 
pGEX-KG-hCofilin C39A 
Made during this project by site-directed 
mutagenesis (SDM) from pGEX-KG-hCofilin WT 
pGEX-KG-hCofilin C80A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
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pGEX-KG-hCofilin C139A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C147A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C39/80A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C39/139A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C39/147A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C80/139A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C80/147A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pGEX-KG-hCofilin C139/147A 
Made during this project by SDM from pGEX-KG-
hCofilin WT 
pmCherry C1 Provided by Kurt Anderson’s research group 
pmCherry N1 Provided by Kurt Anderson’s research group 
pmCherry Cofilin WT 
Made during this project by amplifying cofilin 
gene from pGEX-KG-hCofilin WT and inserting 
this into pmCherry C1 
pmCherry Cofilin C139/147A 
Made during this project by SDM from pmCherry 
Cofilin WT 
pHyPer-cyto Purchased from Evrogen 
pHyPer-PM 
Made during this project by annealing 
oligonucleotides for a CAAX motif and inserting 
this into pHyPer-cyto after removing the stop 
codon by SDM 
 
2.2.2 Oligonucleotides and primers 
Oligonucleotides and primers used in this project are listed below (Table 2-8). 
Table 2-8 List of primers, their applications and sequences 
Oligonucleotide Application Sequence (5’-3’) 
pGEX F 
Sequencing pGEX 
plasmids 
CTTTGCAGGGCTGGCAAG 
pGEX R 
Sequencing pGEX 
plasmids 
GAGCTGCATGTGTCAGAGG 
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pGEX N 
Sequencing pGEX 
plasmids 
CACAAATTGATAAGTACTTG 
Cofilin C39A F 
SDM to make cofilin 
mutants 
CGCAAGAAGGCGGTGCTCTTCGCG
CTGAGTGAGGACAAG 
Cofilin C39A R 
SDM to make cofilin 
mutants 
CTTGTCCTCACTCAGCGCGAAGAGC
ACCGCCTTCTTGCG 
Cofilin C80A F 
SDM to make cofilin 
mutants 
GCTGCCAGATAAGGACGCGCGCTAT
GCCCTCTATGATGCAACC 
Cofilin C80A R 
SDM to make cofilin 
mutants 
GGTTGCATCATAGAGGGCATAGCG
CGCGTCCTTATCTGGCAGC 
Cofilin C139A F 
SDM to make cofilin 
mutants 
GAATTGCAAGCAAACGCGTACGAGG
AGGTCAAGGACCGC 
Cofilin C139A R 
SDM to make cofilin 
mutants 
GCGGTCCTTGACCTCCTCGTACGCG
TTTGCTTGCAATTC 
Cofilin C147A F 
SDM to make cofilin 
mutants 
GAGGAGGTCAAGGACCGCGCGACC
CTGGCAGAGAAG 
Cofilin C147A R 
SDM to make cofilin 
mutants 
CTTCTCTGCCAGGGTCGCGCGGTCC
TTGACCTCCTC 
CMV-F 
Sequencing pmCherry 
plasmids 
CGCAAATGGGCGGTAGGCGTG 
EGFP-C1-R 
Sequencing pmCherry 
plasmids 
AACCATTATAAGCTGCAATAAAC 
mCh SEQ F 
Sequencing pmCherry 
plasmids 
CCCCGTAATGCAGAAGAAGA 
mCh SEQ R3 
Sequencing pmCherry 
plasmids 
CCTTATCTGGCAGCATCTTGAC 
Xho I Cofilin 
Amplifying cofilin gene 
from pGEX-KG-hCofilin 
WT 
TCTCGAGCTATGGCCTCCGGTGTG
GCTGTC 
Cofilin Bam HI 
Amplifying cofilin gene 
from pGEX-KG-hCofilin 
WT 
GCTGGATCCTCACAAAGGCTTGCCC
TCCAG 
pHyPer SEQ F 
Sequencing pHyPer 
plasmids 
CATTGACGTCAATGGGAGTTTG 
pHyPer SEQ F2 
Sequencing pHyPer 
plasmids 
CAACCACTACCTGAGCTTCC 
pHyPer SEQ F3 
Sequencing pHyPer 
plasmids 
CAAGGACGACGGCAACTACAAGAC 
pHyPer SEQ F4 
Sequencing pHyPer 
plasmids 
CTGGTTTATCGTCCTGGCTCAC 
pHyPer SEQ R1b 
Sequencing pHyPer 
plasmids 
CAACCCTATCTCGGTCTATTC 
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pHyPer SEQ R2 
Sequencing pHyPer 
plasmids 
GCTCCTGGACGTAGCCTTCG 
pHyPer anti-TAA F 
SDM to remove pHyPer-
cyto stop codon 
CAGGCGGTTGCAAAGCTTCGAATTC
TGCAG 
pHyPer anti-TAA R 
SDM to remove pHyPer-
cyto stop codon 
CTGCAGAATTCGAAGCTTTGCAACC
GCCTG   
CAAX motif F 
Oligonucleotides for 
annealing to generate 
CAAX insert 
AGCTTAAAAAGATGAGCAAGGACGG
CAAGAAGAAGAAGAAGAAGAGCAAG
ACAAAGTGTGTAATTATGTAAG 
CAAX motif R 
Oligonucleotides for 
annealing to generate 
CAAX insert 
GATCCTTACATAATTACACACTTTGT
CTTGCTCTTCTTCTTCTTCTTCTTGC
CGTCCTTGCTCATCTTTTTA 
 
2.2.3 Annealing oligonucleotides 
3 µg each of CAAX forward and reverse oligonucleotides were diluted in 
annealing buffer to a total volume of 50 µl in a polymerase chain reaction (PCR) 
tube. This was placed in a MJ Research PTC-200 PCR machine that was set to 
heat the sample at 94oC for 4 minutes and then gradually reduce the 
temperature to 4oC over 1.5 hours.  
2.2.4 PCR 
50 µl PCR mix was set up in a PCR tube as detailed below: 
Reagent Volume (µl) 
Nuclease free H2O 
10x PfuUltra buffer 
dNTPs (2.5 mM) 
Template DNA (100 ng/µl) 
Primer 1 (Xho I Cofilin) (10 µM) 
Primer 2 (Cofilin Bam HI) (10 µM) 
PfuUltra 
36 
5 
5 
1 
1 
1 
1 
Total Volume 50 
 
PCR mix was placed in a MJ Research PTC-200 PCR machine and the PCR 
programme was set up as detailed below: 
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Temperature  Time 
95oC 7 minutes 
30 cycles of: 
95oC 
60oC 
72oC 
 
40 seconds 
30 seconds 
2 minutes 
72oC 7 minutes 
4oC ∞ 
 
Amplification of PCR product was confirmed by agarose gel electrophoresis and 
purified as described below. 
2.2.5 Restriction enzyme digestion 
Digestion of DNA with restriction enzymes was carried out in One-Phor-All Buffer 
at 37oC for 2 hours (Xho I and Hin dIII) or 3 hours (Bam HI). 10 U of restriction 
enzyme was added per 1 µg of DNA and reactions were adjusted to a total 
volume of 30 µl for single digests and 50 µl for double digests. Digestion of DNA 
was confirmed by agarose gel electrophoresis and purified as described below. 
2.2.6 DNA purification 
DNA from restriction digests and PCR products was purified using the QIAquick 
PCR Purification Kit following the manufacturer’s instructions. Briefly, 5 volumes 
of Buffer PB was added to 1 volume of PCR or restriction digest product in a 
QIAquick column. This was centrifuged in a collection tube in an Eppendorf 
5417R centrifuge at 13,000 rpm for 1 minute at room temperature. The flow 
through was discarded, 750 µl Buffer PE added to the QIAquick column and 
centrifuged at 13,000 rpm for 1 minute at room temperature. Flow through was 
discarded and the QIAquick column centrifuged one more time at 13,000 rpm for 
1 minute at room temperature. DNA was eluted by adding 50 µl Buffer EB to the 
middle of the QIAquick membrane and centrifuging at 13,000 rpm for 1 minute 
at room temperature in a new microfuge tube.  
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2.2.7 Determination of DNA concentration 
Concentration of double stranded DNA was determined using an Eppendorf 
BioSpectrometer. DNA was diluted in nuclease free H2O and absorbance at 260 
nm measured. 
2.2.8 Ligation of DNA 
Ligation reactions were performed using T4 DNA ligase. The ligation reaction was 
prepared by adding a 1:3 molar ratio of restriction digested vector:insert and 1 
µl of T4 DNA ligase to 1x T4 DNA ligase buffer. This was incubated at room 
temperature for 16 hours.  
2.2.9 Agarose gel electrophoresis 
1% agarose gels were prepared by adding 1 g agarose to 100 ml 1x TBE in a 
conical flask and heating in a microwave until all the agarose had dissolved. 
After the solution had cooled slightly, 2 µg/ml ethidium bromide was added and 
the gel poured into the gel caster. Once the gel had set it was placed into a Bio-
Rad gel tank containing 1x TBE buffer. DNA samples were prepared by adding 
DNA loading buffer and then loaded on the gel alongside the DNA ladder, 
HyPerLadder I. Gels were run at 80-100 V and the DNA bands visualised using a 
Syngene Genius Bio Imaging System. 
2.2.10 Bacterial transformation 
An aliquot of E. coli DH5α competent cells was thawed on ice. 50 µl was then 
transferred to a pre-cooled Falcon tube (Falcon 352059) along with 2 µl plasmid 
DNA and incubated for 30 minutes on ice. Bacteria were heat shocked by placing 
the tubes in a 42oC water bath for 45 seconds followed by incubation on ice for 2 
minutes. 200 µl S.O.C. medium was added and the cultures were incubated at 
37oC for 1 hour in a shaking incubator. The transformation mixture was then 
spread on an agar plate containing the appropriate antibiotic for selection. After 
the liquid had been absorbed the plates were placed inverted in a 37oC 
incubator for at least 16 hours. 
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2.2.11 Site-directed mutagenesis 
Site-directed mutagenesis was carried out using the QuikChange II XL Site-
Directed Mutagenesis Kit following the manufacturer’s instructions. Details of 
the oligonucleotide primers used for these experiments can be found in the table 
of oligonucleotides and primers (Table 2-8). Briefly, mutagenesis reactions were 
set up in PCR tubes as follows: 
Reagent Volume (µl) 
10x reaction buffer 
Template DNA (2 ng/µl) 
Primer 1 (125 ng/µl) 
Primer 2 (125 ng/µl) 
dNTP mix 
QuikSolution 
Nuclease free H2O 
PfuUltra HF DNA polymerase (2.5 U/µl) 
5 
5 
1 
1 
1 
3 
33 
1 
Total volume 50 
 
The mutagenesis mix was placed in a MJ Research PTC-200 PCR machine and the 
PCR programme was set up as detailed below: 
Temperature Time 
95oC 1 minute 
18 cycles of: 
95oC 
60oC 
68oC 
 
50 seconds 
50 seconds 
1 minute/kb of plasmid 
68oC 7 minutes 
4oC ∞ 
 
Parental DNA was digested by adding 10 U Dpn I restriction enzyme and 
incubating at 37oC for 1 hour. The remaining mutated plasmid DNA was 
transformed into E. coli XL10-Gold ultracompetent cells by adding 2 µl to 45 µl 
of the bacterial cells in a pre-cooled Falcon tube (Falcon 352059). The bacteria 
were then incubated on ice for 30 minutes before heat shocking at 42oC for 30 
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seconds. After incubating on ice for 2 minutes, 500 µl S.O.C. medium was added 
and the cultures were incubated at 37oC for 1 hour in a shaking incubator. The 
transformation mixture was spread across two agar plates containing the 
appropriate antibiotic for selection. Once the liquid was absorbed, the plates 
were placed inverted in a 37oC incubator for at least 16 hours. Eight colonies 
were selected and successful mutagenesis confirmed by DNA sequencing of the 
insert region. 
2.2.12 Plasmid preparation 
2.2.12.1 Small scale plasmid preparation 
5 ml cultures of E. coli DH5α cells that had been transformed with the required 
plasmid were grown overnight at 37oC in a shaking incubator. Cultures were then 
centrifuged in a Beckman Coulter J6-M1 centrifuge at 2,000 rpm for 15 minutes 
and DNA isolated from the cell pellet using a Qiagen 8000 Robot. DNA isolation 
was carried out by the Beatson Molecular Technology Services. 
2.2.12.2 Large scale plasmid preparation 
250-500 ml cultures of E. coli DH5α cells that had been transformed with the 
required plasmid were grown overnight at 37oC in a shaking incubator. Cells 
were then centrifuged in a Beckman Coulter J6-M1 centrifuge at 4,000 rpm for 
20 minutes and DNA isolated from the cell pellet using the Invitrogen Purelink 
HiPure Plasmid Filter Purification Kit following the manufacturer’s instructions. 
DNA isolation was carried out by the Beatson Molecular Technology Services. 
2.2.13 DNA Sequencing 
DNA sequencing of plasmids was performed on an Applied Biosystems 3130x1 (16 
capillary) sequencer. DNA sequencing reactions were set up, prepared for 
loading into the sequencer and sequenced DNA precipitated following the 
Applied Biosystems (BigDye 3.1) DNA sequencing protocol. DNA sequencing was 
carried out by the Beatson Molecular Technology Services. 
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2.3 Recombinant proteins and in vitro assays 
2.3.1 Recombinant protein production 
For large scale protein production, six bacterial culture flasks containing 100 ml 
of L-broth with 150 µg/ml ampicillin were inoculated with E. coli BL21 (DE3) 
pLyss cells containing the desired plasmid and grown overnight in a shaking 
incubator at 37oC. These starter cultures were transferred to larger flasks 
holding 1 l of L-broth, with 150 µg/ml ampicillin, and returned to the shaking 
incubator for ~1 hour until the OD600 was between 0.6 and 1.0. Cultures were 
then induced with 100 µM IPTG and grown for a further 3 hours in the shaking 
incubator at 37oC. Bacterial cells were pelleted by centrifuging in a Beckman 
Coulter J6-M1 centrifuge at 4,000 rpm for 20 minutes at 4oC and then 
resuspended in 3 ml bacterial lysis buffer. Samples were incubated on ice for 30 
minutes before being sonicated and then centrifuged in a Beckman Coulter 
Avanti J-25 centrifuge at 14,000 rpm for 30 minutes at 4oC. Meanwhile 10 ml 
glutathione Sepharose beads were washed twice in 50 ml TBS. The supernatant 
from the bacterial sample was transferred to the washed glutathione beads and 
incubated overnight at 4oC while rotating to allow the expressed GST tagged 
proteins to bind to the beads. Beads were washed with 500 ml wash buffer 1 
followed by 500 ml wash buffer 2 and left resuspended in 15 ml of wash buffer 2 
to which 50 U of thrombin was added. This was left to incubate overnight at 4oC 
while rotating to release the desired protein from the GST tag.  The flow 
through was collected and incubated with 100 µl of pre-washed p-
aminobenzamidine bead solution (50% v/v), for 30 minutes at 4oC while rotating. 
After allowing the p-aminobenzamidine beads to settle, the supernatant was 
collected and concentrated to around 1 ml in a Millipore Amicon Ultra 0.5 ml 10k 
centrifugal filter. The protein concentration was then determined and aliquots 
stored at -80oC. The purity of the expressed protein was assessed by SDS-PAGE 
and gel staining. 
2.3.2 Oxidation of recombinant cofilin 
50 µl recombinant cofilin and 450 µl TBS were added to a Millipore Amicon Ultra 
0.5 ml 10K centrifugal filter unit and centrifuged in an Eppendorf 5417R 
centrifuge at 14,000 rpm for 8 minutes at 4oC. The flow through was removed 
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and an additional 450 µl TBS added to the top of the filter unit and centrifuged 
as before. This was repeated three times. The filter unit was then placed 
inverted into a new tube and centrifuged in an Eppendorf 5417R centrifuge at 
1,000 rpm for 2 minutes at 4oC to collect the dialysed and concentrated protein. 
50 µg of protein in a total volume of 4 µl was transferred to a 1.5 ml microfuge 
tube. 20 µl of H2O2 at the indicated concentration was then added and incubated 
for 1 hour on ice and in the dark. Any remaining H2O2 was quenched by the 
addition of 4 µl catalase (2,000 U). 
2.3.3 Biotin-iodoacetamide labelling of recombinant cofilin 
Following oxidation of recombinant cofilin as described above, levels of 
oxidation could be monitored by labelling with biotin-iodoacetamide (IAA) as 
follows. 1 nmole of biotin-IAA was added to the recombinant cofilin and 
incubated for 20 minutes in the dark at room temperature. Following this β-
mercaptoethanol was added to a final concentration of 30 mM to quench any 
remaining biotin-IAA. Biotin-IAA labelling of cofilin was assessed by SDS-PAGE 
and western blotting using Alexa Fluor 680 conjugated streptavidin. 
2.3.4 Preparation of G-actin 
20 ml G-buffer was mixed with each gram of muscle acetone powder (kindly 
provided by Laura Machesky) by stirring on ice for 30 mins in a fume hood. 
Insoluble material was pelleted by centrifugation in a Beckman Coulter Avanti J-
25 centrifuge at 16,000 rpm for 30 minutes at 2oC. The supernatant was kept 
while the pellet was used to repeat the extraction in G-buffer step. The 
combined supernatants were stirred while KCl and MgCl2 were added to final 
concentrations of 50 mM KCl and 2 mM MgCl2. This was stirred gently at room 
temperature for 30 minutes and then on ice for 30 minutes. More KCl was added, 
while still stirring on ice, to reach a final concentration of 0.8 M and then stirred 
for a further 30 minutes. This was centrifuged in a Beckman Coulter Optima L-
90k Ultracentrifuge at 35,000 rpm for 2 hours at 4oC. Pellets were resuspended 
in G-buffer, homogenized in a Dounce homogenizer and dialysed in G-buffer for 
2 days. G-buffer was changed twice during dialysis and concentration was kept 
below 6 mg/ml. The dialysed material was then centrifuged for another 2 hours 
in a Beckman Coulter Optima L-90k Ultracentrifuge at 35,000 rpm at 4oC. The 
  67 
 
top 2/3 of the supernatant was removed, concentration determined by 
measuring absorbance at 290 nm and aliquots stored at -80oC. 
2.3.5 Actin depolymerisation assay 
2 µM F-actin was prepared by adding 100 µl 10x F-buffer to 900 µl 2 µM G-actin 
(5% labelled with pyrene) (pyrene labelled actin kindly provided by Laura 
Machesky). This was left at room temperature to polymerise for 2-3 hours. 
Polymerisation was monitored by adding 50 µl of the polymerising actin to a 
glass cuvette and measuring the fluorescence (excitation wavelength = 339 nm; 
emission wavelength = 384 nm) on a spectrofluorimeter. 50 µl of the polymerised 
F-actin was then added to a glass cuvette, with or without 10 µM WT or mutant 
cofilin, and fluorescence measured for 300 seconds. Data were presented as 
change in fluorescence over time. 
2.4 Cell culture techniques 
2.4.1 Origin, maintenance and storage of cell lines 
MDAMB231 and MCF7 cells are both adherent, epithelial cell lines that were 
originally extracted from human breast cancer metastases. MDAMB231 cells were 
used for the majority of experiments, however occasionally MCF7 cells were 
used. Both cell lines were grown in DMEM medium supplemented with 10% fetal 
bovine serum (FBS), 2 mM L-glutamine, 10 U/ml penicillin and 10 µg/ml 
streptomycin. Cells were kept at 37oC with 5% CO2 in a humidified incubator and 
passaged every 3-4 days as follows. Culture medium was removed, cells were 
washed once with PBS and then incubated in 0.05% trypsin for a short time. Cells 
were then resuspended in fresh culture medium and an aliquot was transferred 
to a new tissue culture flask or dish. 
MDAMB231 cell lines stably expressing HyPer-cyto, HyPer-PM, mCherry (mCh), 
mCh cofilin WT or mCh cofilin C139/147A were grown and maintained as 
described above with the exception that the culture medium was also 
supplemented with 400 µg/ml G418 to ensure the continued expression of the 
plasmids. 
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For long term storage, all cell lines were kept frozen in liquid nitrogen vapour 
phase tanks. To freeze cells down, a flask of healthy cells was harvested by 
trypsinisation as described above for the general passaging of cells. They were 
then centrifuged in an Eppendorf 5804R centrifuge at 1,200 rpm for 5 minutes, 
the cell pellet resuspended in FBS supplemented with 10% DMSO and aliquots 
transferred to cryogenic vials. Cells were stored in a polystyrene box at -80oC for 
24 hours before being placed in the liquid nitrogen tank. To thaw cells, 
cryogenic vials containing cells were transferred directly from the liquid 
nitrogen tank to a 37oC water bath. As soon as they were thawed, cells were 
transferred to culture medium and centrifuged in an Eppendorf 5804R centrifuge 
at 1,200 rpm for 5 minutes. The cell pellet was then resuspended in fresh 
culture medium and transferred to a new tissue culture flask or plate.  
2.4.2 Tissue culture treatments 
Treatment of cells with N-acetylcysteine (NAC) was carried out as follows. Fresh 
culture medium containing NAC at the indicated concentration (0, 2.5, 5, 10, 25, 
50 or 75 mM) was prepared and then filtered through a 0.2 µm syringe filter. pH 
of the culture medium was adjusted by adding sodium hydroxide (NaOH) until 
the phenol red in the medium indicated that the pH was equivalent across all 
samples. Culture medium on the cells was removed and the fresh, pH adjusted 
medium containing NAC was added. Cells were incubated for up to 72 hours 
depending on the experiment. 
Treatment of cells with H2O2 was carried out as follows. Fresh culture medium 
without FBS (serum free (SF) culture medium) containing H2O2 at the indicated 
concentration (0, 1, 3 or 10 µM) was prepared. Culture medium on cells was 
removed and cells were washed twice with SF culture medium before the fresh 
medium containing H2O2 was added. Cells were incubated for 5 hours before 
continuing with the remainder of the experiment. 
2.4.3 Transfection of plasmid DNA 
FuGENE HD transfection reagent was used to transfect MDAMB231 cells with 
pHyPer-cyto and pHyPer-PM plasmids as follows. MDAMB231 cells were seeded at 
2x105 cells per well in 6-well plates 24 hours before transfection. FuGENE HD 
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transfection reagent, plasmid DNA and Optimem I Reduced Serum Medium 
(Optimem) were allowed to reach room temperature before starting 
transfections. pHyPer-cyto plasmid DNA (2 µg) or pHyPer-PM plasmid DNA (0.75 
µg) was diluted in 100 µl of Optimem. 7 µl of FuGENE HD transfection reagent 
was then added to the diluted DNA and the contents mixed by vortexing before 
being incubated at room temperature for 15 minutes to allow transfection 
reagent:DNA complexes to form. Meanwhile culture medium on the cells was 
removed, cells were washed twice with antibiotic free culture medium and then 
2 ml of fresh antibiotic free culture medium was added. The full volume of the 
transfection reagent:DNA complex solution was added to one well of a 6-well 
plate and mixed by rocking the plate back and forth to ensure the complexes 
were evenly distributed. This medium containing transfection complexes was 
removed after 24 hours and replaced with fresh culture medium with antibiotics. 
Lipofectamine LTX transfection reagent was used to transfect MDAMB231 cells 
with pmCherry, pmCherry cofilin WT or pmCherry cofilin C139/147A plasmids as 
follows. MDAMB231 cells were seeded at 5x105 cells per well in 6-well plates 24 
hours before transfection. Lipofectamine LTX transfection reagent, plasmid DNA 
and Optimem medium were allowed to reach room temperature before starting 
transfections. 2.5 µg of each plasmid DNA was diluted in 500 µl Optimem 
medium, mixed gently by vortexing and then incubated for 5 minutes at room 
temperature. 11.25 µl Lipofectamine LTX transfection reagent was then added 
to the diluted DNA and mixed gently by vortexing before incubating at room 
temperature for 30 minutes. Meanwhile culture medium on the cells was 
removed, cells were washed twice with antibiotic free culture medium and then 
2 ml of fresh antibiotic free culture medium was added. The full volume of the 
transfection reagent:DNA complex solution was added to one well of a 6-well 
plate and mixed by rocking the plate back and forth to ensure the complexes 
were evenly distributed. This medium containing transfection complexes was 
removed after 24 hours and replaced with fresh culture medium with antibiotics. 
2.4.4 Establishment of stable cell lines 
MDAMB231 cells were transfected with pHyPer-cyto, pHyPer-PM, pmCherry, 
pmCherry cofilin WT or pmCherry cofilin C139/147A plasmids as described 
above. 48 hours after transfection cells were transferred to a 10 cm tissue 
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culture dish and 400 µg/ml G418 was added to the culture medium. Cells were 
cultured until all control cells were dead and cells expressing the plasmids were 
identified and selected for by FACS. From then on, cells were maintained in the 
presence of 400 µg/ml G418. 
2.4.5 Fluorescence activated cell sorting (FACS) 
Cells stably expressing HyPer-cyto, HyPer-PM, mCh, mCh cofilin WT or mCh 
cofilin C139/147A were identified and selected for by FACS on a FACSaria cell 
sorter. Cells were harvested by trypsinisation as described for the general 
passaging of cells. Cells were centrifuged in an Eppendorf 5804R centrifuge at 
1,200 rpm for 5 minutes and then resuspended in serum free culture medium to 
a concentration of 4x106 cells/ml before being strained through a 40 µm cell 
strainer. Appropriate gates were set on the FACSaria cell sorter to ensure only 
cells expressing the required protein were selected. Cells were then transferred 
to a new tissue culture dish and maintained as normal. 
2.4.6 Labelling and detection of oxidised proteins 
Oxidised proteins in cells were labelled and detected using the chemical 5,5-
dimethyl-1,3-cyclohexanedione (dimedone). 5 mM dimedone was prepared 
directly in serum free culture medium and was filtered through a 0.2 µm syringe 
filter before use. After the required treatment, cell culture medium was 
removed and cells washed twice with serum free culture medium. Culture 
medium containing 5 mM dimedone was then added and cells incubated at 37oC 
for between 1 and 3 hours depending on the experiment and cell type. Cells 
were then harvested and dimedone labelling of oxidised proteins determined by 
western blot analysis. The specific experiments carried out are detailed below. 
2.4.6.1 Dimedone labelling following NAC treatment 
Cells were treated with NAC at the indicated concentrations for 72 hours, as 
described in the tissue culture treatment section, and 5mM dimedone was added 
for the final 3 hours. 
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2.4.6.2 Dimedone labelling following H2O2 treatment 
Cells were treated with H2O2 at the indicated concentrations for 6 hours, as 
described in the tissue culture treatment section, and 5mM dimedone was added 
for the final 1 hour. 
2.4.6.3 Dimedone labelling following wounding 
Between 20 and 30 wounds, depending on the experiment, were created through 
a confluent cell monolayer with a P10 pipette tip. Cells were washed gently 
twice with culture medium before fresh medium was added. After 3 hours to 
allow the cells to start migrating to close the wounds, 5 mM dimedone was 
added for 1 hour. 
2.4.7 Measurement of ROS production 
The production of ROS in cells was measured using the fluorescent probe 2’,7’-
dichlorofluorescin diacetate (DCFDA). MDAMB231 cells were seeded at 40,000 
cells per well in a BD Falcon 96-well plate (black/clear bottom, sterile). After 24 
hours cells were treated with NAC at the indicated concentrations for 6 hours. 
Cells were washed once with PBS before 100 µl of 5 µM DCFDA in serum and 
phenol red free DMEM was added. After incubation at 37oC for 30 minutes, cells 
were washed once with PBS and 100 ul serum and phenol red free medium added 
to each well. DCFDA fluorescence was measured on a Tecan Safire II microplate 
reader (excitation wavelength = 485 nm; emission wavelength = 528 nm; 
bandwidth = 5 nm). 
2.4.8 Cell proliferation assay 
Cells were seeded in a 96-well tissue culture plate at 5,000 cells per well. 
Number of cells at 24, 48, 72 and 96 hours was measured using the CellTiter-Glo 
Luminescent Cell Viability Assay as follows. CellTiter-Glo reagent and cells were 
left at room temperature for 30 minutes to equilibrate. 100 µl of CellTiter-Glo 
reagent was added to each well including control wells containing culture 
medium only and the plate placed on an orbital shaker for 2 minutes. After 
incubation at room temperature for 10 minutes, the contents of each well were 
transferred to a Fisherbrand white 96-well plate. Luminescence readings were 
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made on a Glomax 96 Microplate Luminometer. Relative cell numbers were 
reported using 24 hours as the reference point.  
2.4.9 Cell adhesion/spreading assay 
Cell adhesion/spreading was measured on the xCelligence Real-Time Cell 
Analyzer (RTCA) system. 50 µl culture medium was added to each well of an E-
plate 16 and left to equilibrate in the RTCA analyser, which is situated in a 
standard tissue culture incubator, for 1 hour before the background 
measurement was taken. 10,000 cells in 100 µl culture medium were added to 
each well of the E-plate 16, the plate placed back in the RTCA analyser and 
measurements taken every 10 minutes for 3 hours. The RTCA software 
automatically subtracted the background from each measurement taken. 
2.4.10 Cell adhesion assay 
50 µl of culture medium was added to each well of a 96-well tissue culture plate 
and placed in a tissue culture incubator for 1 hour. 40,000 cells in 100 µl culture 
medium were added to each well and left to adhere for 3 hours in standard 
culture conditions. Wells were washed 4 times with PBS to remove any cells that 
had not adhered before 100 µl culture medium was added. Number of adherent 
cells was measured using the CellTiter-Glo Luminescent Cell Viability Assay as 
described for the cell proliferation assay. 
2.4.11 Wound healing cell migration assay 
Migration of cells was assessed using the Essen Bioscience CellPlayerTM 96-well 
cell migration assay. Cells were seeded at 40,000 cells per well in a 96-well 
ImageLockTM plate and cultured overnight to form a confluent monolayer. 
Wounds were then created through the monolayers using a WoundMakerTM tool, 
cells washed twice with medium and then 100 µl fresh culture medium was 
added. The plate was placed in the IncucyteTM machine, which is situated in a 
standard tissue culture incubator, and left to equilibrate for 10 minutes before 
starting image acquisition. Brightfield images of the wounds were taken every 2 
hours for 24 hours and wound width at each time point measured by the 
IncucyteTM software. 
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2.4.12 Individual cell migration assay 
Cells were seeded at a subconfluent density in a 6-well tissue culture plate 
which was then placed on a Nikon TE 2000 Timelapse microscope fitted with an 
incubation chamber set at 37oC with 5% CO2. This was left for 1 hour to allow the 
cells to settle on the bottom of the dish and for the plastic to adjust to the 
conditions of the chamber. Brightfield images were then taken every 10 minutes 
for 4 hours with a 10x objective. Migration of individual cells was analysed using 
the manual tracking and chemotaxis tool plugins in Image J. 
2.4.13 Cell invasion assay 
Invasion of cells through a 3D matrix was assessed using the Essen Bioscience 
CellPlayerTM 96-well cell invasion assay. Cells were seeded at 40,000 cells per 
well in a 96-well ImageLockTM plate and cultured overnight to form a confluent 
monolayer. Wounds were created through the monolayers using a WoundmakerTM 
tool. Cells were washed twice with medium and overlaid with MatrigelTM (diluted 
1:1 with PBS) which was then left in the tissue culture incubator for 30 minutes 
to set. An additional 100 µl of culture medium was added to each well and the 
plate left in the IncucyteTM machine to equilibrate for 10 minutes before starting 
image acquisition. Brightfield images of the wounds were taken every 2 hours for 
10 hours and the relative wound density at each time point was measured by the 
IncucyteTM software. 
2.5 Microscopy 
2.5.1 Fluorescence lifetime imaging microscopy  
All fluorescence lifetime imaging microscopy (FLIM) of the HyPer-cyto and 
HyPer-PM cells was carried out on a Nikon TE 2000 inverted microscope fitted 
with a Lambert Instruments FLIM Attachment (LIFA) and a Yokogawa CSU22 
spinning disk unit using a x100 oil objective. The LIFA system was equipped with 
an Omicron 50 mW 445 nm laser for CFP lifetimes and a 60 mW 488 nm laser for 
GFP lifetimes. It is based on the frequency domain method for fluorescence 
lifetime imaging and allows the rapid acquisition and generation of lifetime 
images. Fluorescence lifetimes were measured using LI-FLIM software and the 
results presented in a box and whiskers plot where the box represents the upper 
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and lower quartiles and the middle line represents the median. The specific 
experiments carried out are described below. 
2.5.1.1 Baseline fluorescence lifetime imaging 
Cells were grown in 35 mm glass bottom dishes until 50% confluent. 24 hours 
before imaging, culture medium was changed to Optimem and 1 hour before 
imaging cells were transferred to L15 medium to help maintain physiological pH 
during imaging.  
2.5.1.2 Fluorescence lifetime imaging following H2O2 treatment 
Cells were grown in 35 mm glass bottom dishes until 50% confluent. 24 hours 
before imaging, culture medium was changed to Optimem and 1 hour before 
imaging cells were transferred to L15 medium to help maintain physiological pH 
during imaging. For experiments investigating a single dose of H2O2, the 
microscope software was set up to acquire images every 30 seconds for a total of 
15 minutes. After 2 minutes of imaging, 100 µl 3 mM H2O2 was added to the dish 
in the area being imaged. For experiments investigating two sequential doses of 
H2O2, the microscope software was set up to acquire images every 30 seconds for 
a total of 30 minutes. After 2 minutes of imaging, the first dose of 100 µl 3 mM 
H2O2 was added to dish in the area being imaged. After the fluorescence lifetime 
had recovered to starting levels, a second dose of 100 µl 3 mM H2O2 was added 
to the dish in the area being imaged. 
2.5.1.3 Fluorescence lifetime imaging of in vitro wound healing assay 
Cells were grown in 35 mm glass bottom dishes until 100% confluent. A wound 
was then created through the middle of the cell monolayer using a P10 pipette 
tip. Cells were left for 1 hour to allow the cells at the wound edge to start 
migrating and then transferred to L15 medium for 1 hour before imaging. Cells 
that were migrating at the wound edge and cells that were stationary in the 
confluent monolayer area of the dish were imaged. 
2.5.1.4 Fluorescence lifetime imaging of cell protrusions 
Cells were grown in 35 mm glass bottom dishes until 100% confluent. A wound 
was then created through the middle of the cell monolayer using a P10 pipette 
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tip. Cells were left for 1 hour to allow the cells at the wound edge to start 
migrating and then transferred to L15 medium for 1 hour before imaging. Cells 
that were actively migrating at the wound edge and at the time of imaging had 
clear cell protrusions were imaged. The z-position of the microscope was 
carefully set for each cell to ensure that the image taken captured the tips of 
cell protrusions and the cell body. 
2.6 Cellular protein extraction and analysis 
2.6.1 Cell lysate preparation 
After cells had been grown to the desired confluence or treated as required, 
they were lysed to extract proteins. Cell culture dishes were placed on ice, the 
culture medium removed and cells washed twice with ice cold PBS. RIPA lysis 
buffer was then added to the dish (100-150 µl per well of a 6-well dish, 
depending on confluence; 400 µl per 10 cm plate) and cell lysates collected by 
scraping. Lysates were then incubated on ice for 15 minutes before being 
centrifuged at 14,000 rpm for 15 minutes at 4oC. The supernatant was 
transferred to a new microfuge tube, protein concentration determined and 
samples stored at -20oC. 
2.6.2 Protein concentration determination 
Protein concentration of recombinant protein and cell lysates was determined 
using the bicinchoninic acid (BCA) assay. Protein standards (0.08, 0.1, 0.2, 0.4, 1 
and 2 mg/ml) were prepared in the appropriate buffer (recombinant protein 
wash buffer or RIPA buffer for cell lysates) using a 2 mg/ml albumin standard 
stock solution. 10 µl of blank (buffer alone), protein standards and samples were 
added to a Greiner Bio-One 96-well plate. 200 µl of developing solution (50:1, 
bicinchoninic acid:copper sulphate solution) was added to each well and 
incubated at 37oC for 30-60 minutes. Absorbance was measured using a 
Molecular Devices microplate reader and sample concentrations determined 
from the standard curve. 
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2.6.3 Immunoprecipitation 
For the immunoprecipitation of cofilin from MCF7 cells following NAC and 
dimedone treatment, the following method was used. Cells were lysed using 
RIPA buffer and protein concentration determined as described above. At every 
stage of this protocol, Dynabeads were separated from the supernatant using a 
magnetic tube rack. 50 µl of protein A Dynabead solution per 
immunoprecipitation was washed twice with PBS-T by rotating for 10 minutes at 
4oC. Beads were then resuspended in 200 µl PBS-T containing 2 µg anti-cofilin Ab 
(Abcam: ab42824) and incubated for 1 hour at 4oC while rotating. Bead-Ab 
complexes were washed 3 times in 1 ml PBS-T by rotating for 10 minutes at 4oC. 
These were then incubated with 500 µg lysate, in a total volume of 500 µl, at 
4oC while rotating. Beads were then washed 5 times with 1 ml PBS, as done 
previously, before being transferred in 100 µl PBS to a new microfuge tube and 
resuspended in 20 µl NuPAGE LDS sample buffer. Samples were stored at -20oC 
for further analysis by SDS-PAGE and western blot.  
For the immunoprecipitation of cofilin from MDAMB231 cells following wounding 
and dimedone treatment, the following method was used. At every stage of this 
protocol, protein G Sepharose beads were separated from the supernatant by 
centrifuging in an Eppendorf 5417R centrifuge at 3,600 rpm for 1 minute at 4oC. 
Cells were washed with ice cold PBS and then lysed in IP lysis buffer (1 ml per 6-
well or 10 cm plate) and harvested by scraping. Lysates were placed in 1.5 ml 
microfuge tubes and incubated at 4oC for 20-30 minutes while rotating. During 
this time 200 µl of protein G Sepharose bead solution was washed 3 times with 1 
ml TBS. Cell lysates were then centrifuged in an Eppendorf 5417R centrifuge at 
13,200 rpm for 10 minutes, the supernatant removed and protein concentration 
determined. Equivalent quantities of lysate from each condition were then 
incubated with 25 ul of protein G Sepharose beads for 30 minutes on a rotating 
wheel to remove proteins that bound non-specifically to the beads. After 
centrifuging to remove the beads, the lysates were incubated with anti-cofilin 
antibody or mouse IgG at a 1:25 dilution overnight at 4oC on a rotating wheel. 25 
µl of protein G Sepharose bead solution, which had been washed in the same 
way as before, was added to each tube and incubated for 1 hour at 4oC while 
rotating. Beads were washed three times in 1 ml TBS before being resuspended 
in 25 µl of prewarmed (95oC) 1% SDS and then heated at 95oC for 5 minutes. 
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Samples were centrifuged in an Eppendorf 5417R centrifuge at 3,600rpm for 2 
minutes after which the supernatant was removed and SDS sample buffer added. 
Samples were stored at -20oC until they were analysed by SDS-PAGE and western 
blot. 
2.6.4 SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (PAGE) was used to separate protein 
samples based on molecular weight. Protein samples were first prepared in 
sample buffer. For 15% Tris-glycine gels (recipe below), protein samples were 
prepared in SDS sample buffer and heated at 100oC for 3 minutes. For 4-12% 
NuPAGE Bis-tris gels, protein samples were prepared in NuPAGE LDS sample 
buffer with NuPAGE reducing agent for reducing gels or without for non-reducing 
gels. In both cases samples were heated at 70oC for 10 minutes. After heating, 
samples were briefly centrifuged and loaded on the gels alongside Precision Plus 
ProteinTM all blue molecular weight marker. In general, Tris-glycine gels were 
run in tanks containing 1x SDS running buffer at 120 V for approximately 2 hours. 
Both reducing and non-reducing NuPAGE Bis-tris gels were run in tanks 
containing 1x NuPAGE MES running buffer at 150 V for approximately 1 hour 15 
minutes. Afterwards, gels were either stained or used for western blotting. 
Reagent Separating Gel Stacking Gel 
30% Acrylamide mix 15 ml 1.7 ml 
1 M Tris pH 6.8 - 1.25 ml 
1 M Tris pH 8.8 7.5 ml - 
10% SDS 300 µl 100 µl 
H2O 6.9 ml 6.8 ml 
10% ammonium persulfate 300 µl 100 µl 
TEMED 24 µl 50 µl 
 
2.6.5 Gel staining 
Following protein separation by SDS-PAGE some gels were stained to detect 
protein bands as follows. Gels were washed in distilled water (dH2O) for 5 
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minutes and this was repeated three times. Gels were then incubated in 
SimplyBlueTM SafeStain for 1 hour at room temperature. Following this, gels were 
washed in dH2O for 1 hour and then overnight. Images of stained gels were 
acquired on a LI-COR Odyssey® system.  
2.6.6 Western blotting 
Following protein separation by SDS-PAGE some gels were used for western 
blotting. Proteins were transferred to ProtranTM nitrocellulose membrane using a 
Bio-Rad Mini Trans-Blot® Cell. Proteins from Tris-glycine gels were transferred in 
tanks containing 1x SDS transfer buffer while proteins from NuPAGE Bis-tris gels 
were transferred in tanks containing 1x NuPAGE transfer buffer. All transfers 
were run at 100 V for 1 hour. The nitrocellulose membrane was blocked with 5% 
(w/v) milk powder in TBS-T (TBS-TM) for 1 hour. Primary antibodies were diluted 
to the required concentration in TBS-TM and membranes incubated with these 
solutions for 1 hour at room temperature or 4oC overnight. This was followed by 
four washes in TBS-T for 5 minutes each. The membrane was then incubated 
with the secondary antibody that had been diluted to the required concentration 
in TBS-TM, for 30-60 minutes at room temperature. After the blot was washed in 
TBS-T three times for 5 minutes each, it was rinsed in dH2O and protein bands 
visualised on the LI-COR Odyssey® system. Protein bands were quantified using 
Image Studio Lite Version 3.1. Antibodies used for western blotting and the 
concentrations used are listed below. 
Antibody Concentration 
Cofilin (Ab75510) 1:2000 
Cofilin (Ab42824) 1:1000 
Cofilin (ACFL02-A) 1:2000 
Dimedone 1:5000 
DsRed 1:1000 
ERK2 1:2000 
GFP 1:2000 
All secondary antibodies 1:5000 
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3 Reactive Oxygen Species and Cell Migration 
3.1 Introduction 
There are a number of in vitro and in vivo studies demonstrating that ROS are 
required for cell migration. These have mainly involved increasing or decreasing 
antioxidant or ROS scavenging enzymes, which resulted in an inhibition or 
enhancement of cell migration respectively [255-259]. Increased ROS levels in 
migrating cells have also been shown directly through the use of fluorescent ROS 
sensors. Additionally, these studies identified an accumulation of ROS at the 
leading edge of migrating cells and at membrane ruffles which are the regions of 
the cell undergoing the most dynamic changes in the actin cytoskeleton [266, 
277]. However, which of the many ROS are specifically elevated in migrating 
cells has not yet been determined. Therefore, I set out to establish if the ROS, 
H2O2, was increased in migrating cells globally and within specific regions of the 
cell. The results from these investigations are presented in this chapter. 
3.2 Results 
3.2.1 NAC reduces cellular ROS levels in MDAMB231 cells 
To better understand the relationship between cellular ROS levels and migration 
I first wanted to find a method by which I could reliably reduce cellular ROS 
levels in the MDAMB231 cell line. I decided to treat cells with the ROS scavenger 
NAC and determine its effect on cellular ROS levels using the ROS sensitive 
chemical DCFDA. DCFDA is cell permeable and not fluorescent, however when it 
enters cells, it is deacetylated by cellular esterases to form DCF. When DCF is 
oxidised by ROS in cells, it becomes highly fluorescent with maximum excitation 
and emission wavelengths of 485 nm and 528 nm respectively, and therefore 
cellular ROS levels can be determined by measuring the fluorescence. 
MDAMB231 cells that had been seeded in a 96-well plate were treated with NAC 
at 0, 2.5, 5 or 10 mM for 3 hours followed by incubation with DCFDA. 
Fluorescence and therefore ROS levels were then measured using a fluorescence 
plate reader. These results revealed that, as expected, there was a 
concentration dependent decrease in relative ROS levels following NAC 
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treatment, with significantly lower levels observed with 10 mM NAC compared to 
control (0 mM NAC) (Figure 3-1). 
3.2.2 Reducing cellular ROS levels decreases cell migration 
Having confirmed that NAC was able to effectively reduce ROS levels in 
MDAMB231 cells, I next wanted to see if this had any effect on the ability of the 
cells to migrate. To address this I used the Essen Bioscience CellPlayerTM 96-well 
cell migration assay, which is based on a traditional wound healing assay. Wound 
healing assays are used as a simple way to measure cell migration and based on 
the finding that cells will migrate into the wound until new cell-cell contacts are 
made [320]. The benefits of the Essen Bioscience CellPlayerTM 96-well assay is 
that the wounds created are much more reproducible, as they are made using a 
device designed for this purpose rather than by hand, and it has a much higher 
throughput.  
MDAMB231 cells were seeded in a 96-well ImageLockTM plate, a specialised plate 
that allows wounds to be located by the IncucyteTM software, and cultured 
overnight to form a confluent monolayer. Wounds were then created through the 
middle of the monolayer using the WoundMakerTM, a device containing 96 pins 
that each produce a wound in the wells of a 96-well plate. After this, cells were 
treated with 0, 2.5, 5 or 10 mM NAC and the plate placed in the IncucyteTM 
machine, which was scheduled to acquire images of the wounds every 2 hours 
for a total of 24 hours. The IncucyteTM software automatically analyses the 
wound and reports three parameters for each time point; wound width (the 
average distance between the edges of the wound), wound confluence 
(percentage of initial wound area that is covered by cells) and relative wound 
density (a measure of the density of the wound region compared to the cell 
regions). As the edges of the wound with MDAMB231 cells remain relatively 
parallel to one another, I decided to use the wound width as a measure of cell 
migration. Treatment of cells with NAC resulted in a concentration dependent 
decrease in wound closure (Figure 3-2) that mirrored the decrease in ROS levels 
observed with the same concentrations of NAC (Figure 3-1).  
  81 
 
 
Figure 3-1 The antioxidant NAC reduces cellular ROS levels 
MDAMB231 cells were seeded in a 96-well plate and allowed to adhere overnight. Cells were then 
treated with NAC at the indicated concentrations for 3 hours followed by measurement of cellular 
ROS levels using the cell permeable, ROS sensitive probe DCFDA. Graph indicates the mean 
relative ROS levels +/- standard error of the mean (SEM) measured across 4 independent 
experiments. Statistical significance of differences was determined by a one-way ANOVA followed 
by a Tukey Kramer multiple comparison test (*=p<0.05, **=p<0.01, ***=p<0.001). 
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Figure 3-2 Decreasing cellular ROS levels with NAC reduces wound closure 
MDAMB231 cells were seeded in a 96-well ImageLock
TM
 plate and allowed to adhere overnight 
forming a confluent monolayer. Wounds were then created using a WoundMaker
TM
 and cells 
treated with NAC at the indicated concentrations. Wound width was measured every 2 hours for a 
total of 24 hours using the Incucyte
TM
 system. A) Representative images taken of the wounds at 0 
and 24 hours. Scale bars = 200 µm. B) Graph indicates the mean wound closure at 24 hours +/- 
SEM measured across 3 independent experiments. Statistical significance of differences was 
determined by a one-way ANOVA followed by a Tukey Kramer multiple comparison test (*=p<0.05, 
**=p<0.01, ***=p<0.001). 
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3.2.3 Establishment of MDAMB231 cell line stably expressing 
HyPer-cyto 
After finding that the presence of ROS was required for cell migration, I next 
wanted to know if I could directly see ROS being produced in migrating cells. To 
investigate this, I employed a fluorescent probe, HyPer, that can detect H2O2, 
one of the ROS, in live cells. This was an attractive tool as it would allow me to 
image the production of H2O2 in real time in migrating cells. Additionally it can 
specifically detect H2O2 which, as described in Chapter 1, is a well established 
second messenger in cells and therefore a possible mediator of downstream 
responses in migrating cells. HyPer is composed of circularly permuted yellow 
fluorescent protein (YFP) inserted into the regulatory domain of the E. coli 
transcription factor OxyR. HyPer has two excitation peaks with maximums at 420 
nm and 500 nm and one emission peak with a maximum of 516 nm. In the 
presence of H2O2 a disulphide bond forms between two cysteine residues 
(cysteine 199 and  cysteine 208) in the OxyR part of HyPer that results in a 
conformational change [321]. This change in structure alters the excitation and 
emission spectra with a decrease in the excitation peak at 420 nm and a 
proportional increase in the excitation peak at 500 nm (Figure 3-3) [322]. The 
presence of H2O2 can therefore be measured by ratiometric confocal microscopy 
comparing the emission after excitation at 500 nm to that at 420 nm. 
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Figure 3-3 Schematic diagram of H2O2 sensing HyPer-cyto probe activation 
HyPer is an H2O2 sensing fluorescent probe in which a derivative of YFP has been inserted into the 
regulatory domain of the bacterial OxyR protein. HyPer-cyto is a form of this probe that is 
expressed throughout the cell cytoplasm. In the presence of H2O2, there is a conformational 
change in the probe resulting from the formation of a disulphide bond which leads to a change in 
the spectral properties of the probe. 
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I decided that the most efficient way to conduct my experiments using the 
HyPer-cyto probe (form of HyPer that is expressed throughout the cytoplasm) 
was to create a MDAMB231 cell line stably expressing the probe. To do this I 
transfected parental MDAMB231 cells with a plasmid expressing HyPer-cyto and a 
gene conferring resistance to G418. 48 hours after transfection, cells were 
transferred to G418 containing medium and cultured until all control cells that 
had not been transfected with the plasmid had died. The surviving cells 
expressing HyPer-cyto were selected by cell sorting using a FACSaria cell sorter 
and subdivided into populations expressing the probe at low, medium and high 
levels (Figure 3-4 A). The cells expressing HyPer-cyto at a medium level were 
then used for further experiments after confirming that the probe was expressed 
in these cells by western blot analysis using anti-green fluorescent protein (GFP) 
Ab capable of detecting HyPer (Figure 3-4 B). This population of cells was chosen 
because, out of the three subpopulations, they had the lowest level of HyPer-
cyto expression that was still high enough for detection by microscopy. 
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Figure 3-4 Creation of MDAMB231 cell line stably expressing HyPer-cyto 
A) FACS plots confirming a population of cells which positively expressed the HyPer-cyto probe. B) 
Western blot confirming the stable expression of HyPer-cyto in the MDAMB231 cell line. Membrane 
probed using anti-GFP Ab capable of detecting HyPer. 
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3.2.4 Baseline fluorescence lifetime of MDAMB231 HyPer-cyto 
cells 
I wanted to extend the potential uses of HyPer-cyto by investigating if the 
presence of H2O2 could also be measured by fluorescence lifetime imaging 
microscopy (FLIM). The benefits of this are that only one wavelength image 
needs to be acquired allowing for faster data acquisition and less post 
acquisition analysis is required to determine H2O2 levels. The fluorescence 
lifetime measured is also independent of the concentration of the probe so slight 
cell to cell differences in expression will not affect the results. 
Before investigating if H2O2 production could be monitored using FLIM, I wanted 
to know the fluorescence lifetime of HyPer-cyto in cells with basal H2O2 levels. 
Therefore, I imaged MDAMB231 HyPer-cyto cells using a microscope fitted with a 
LIFA system and measured the fluorescence lifetime using LI-FLIM software. The 
average fluorescence lifetime of these cells was 1.463 ns (Figure 3-5). 
3.2.5 HyPer-cyto fluorescence lifetime decreases after the 
addition of H2O2 
The next step of the investigation was to see how the fluorescence lifetime of 
HyPer-cyto changed with the addition of exogenous H2O2. To test this, I cultured 
MDAMB231 HyPer-cyto cells in 35 mm glass bottom dishes to 50% confluence. 
Fields of view containing between one and four cells expressing HyPer-cyto were 
then imaged on a microscope fitted with a LIFA system every 30 seconds for a 
total of 15 minutes. After the 4th image had been acquired (around 2 minutes), 
100 µl of 3 mM H2O2 was added to the dish. I found that the addition of H2O2 
resulted in a significant decrease in HyPer-cyto fluorescence lifetime (Figure 3-
6). 
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Figure 3-5 Expression and average fluorescence lifetime of HyPer-cyto 
MDAMB231 HyPer-cyto cells were imaged on a microscope fitted with a LIFA system and 
fluorescence lifetime measured using LI-FLIM software. A) Representative fluorescence image and 
corresponding lifetime map of MDAMB231 HyPer-cyto cells. Scale bar = 20 µm. B) Box and 
whiskers plot (5-95 percentile) representing range of baseline fluorescence lifetimes observed in 
MDAMB231 HyPer-cyto cells with average fluorescence lifetime measured indicated. Results from 
55 cells. 
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Figure 3-6 HyPer-cyto fluorescence lifetime decreases after addition of H2O2 
MDAMB231 HyPer-cyto cells were grown in 35 mm glass bottom dishes until ~50% confluent. 
Fields of view containing between one and four cells expressing HyPer-cyto were imaged on a 
microscope fitted with a LIFA system every 30 seconds for a total of 15 minutes with 100 µl 3 mM 
H2O2 added at ~2 minutes. Fluorescence lifetime was measured in each cell over the time course 
using LI-FLIM software. A) Representative fluorescence images and corresponding lifetime maps 
of MDAMB231 HyPer-cyto cells before and after H2O2 treatment. Scale bar = 20 µm. B) Graph 
showing change in fluorescence lifetime over a 15 minute period with the point of H2O2 addition 
indicated. Results displayed are average of 32 cells. C) Box and whiskers plot (5-95 percentile) 
indicating range of changes in fluorescence lifetimes observed after H2O2 addition. D) Table 
showing average fluorescence lifetimes measured before and after H2O2 treatment. Results from 
32 cells. Statistical significance of differences determined by a paired t-test (****=p<0.0001). 
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3.2.6 Change in fluorescence lifetime of HyPer-cyto after the 
addition of H2O2 is reversible. 
As changes in H2O2 levels in cells are likely to be transient events, I wanted to 
assess if the fluorescence lifetime of HyPer-cyto would return to normal levels 
after it is decreased by the addition of H2O2, and if at this point HyPer-cyto 
could be reactivated by a further addition of H2O2. For this reason I repeated the 
previous experiment, but this time continued to measure the fluorescence 
lifetime every 30 seconds for a total of 30 minutes. After the addition of the 
first dose of H2O2, I waited for the fluorescence lifetime to return to starting 
levels and then added a second dose of 100 µl 3 mM H2O2. These experiments 
revealed that with time, the decrease in fluorescence lifetime observed when 
H2O2 was added returned to starting levels. In addition, HyPer-cyto could be 
restimulated by a second dose of H2O2 again significantly decreasing the 
fluorescence lifetime. It was noted that there was no significant difference in 
the fluorescence lifetimes measured before the first and second doses of H2O2 
nor between the fluorescence lifetimes after each H2O2 dose (Figure 3-7). This 
confirms that HyPer-cyto can fully recover after activation by H2O2 and is equally 
sensitive to a second increase in H2O2 of the same dose. These results are not 
unexpected as the change in lifetime occurs due to the formation of a disulphide 
bond which would be exposed to and reduced by the cells endogenous 
mechanisms to protect itself against oxidative damage. Consequently, the probe 
would be returned to its inactivated state and sensitive to subsequent 
activations. 
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Figure 3-7 HyPer-cyto fluorescence lifetime recovers to baseline levels following H2O2 
treatment and can be reactivated following further H2O2 addition 
MDAMB231 HyPer-cyto cells were grown in 35 mm glass bottom dishes until ~50% confluent. 
Fields of view containing between one and four cells expressing HyPer-cyto were imaged on a 
microscope fitted with a LIFA system every 30 seconds for a total of 30 minutes with 100 µl 3 mM 
H2O2 added after ~2 minutes and after fluorescence lifetime had returned to starting levels. 
Fluorescence lifetime was measured in each cell over the time course using LI-FLIM software. A) 
Representative fluorescence images and corresponding lifetime maps of MDAMB231 HyPer-cyto 
cells before and after first and second H2O2 treatments. Scale bar = 20 µm. B) Graph showing 
change in fluorescence lifetime over a 30 minute period with the points of first and second H2O2 
addition indicated. Results displayed are from a representative cell. C) Box and whiskers plot (5-95 
percentile) indicating range of changes in fluorescence lifetimes observed before and after each 
H2O2 treatment. D) Table showing average fluorescence lifetimes measured before and after each 
H2O2 treatment. Results from 18 cells. Statistical significance of differences determined by a one-
way ANOVA followed by a Tukey Kramer multiple comparison test (***=p<0.001). 
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3.2.7 H2O2 levels are higher in migrating cells than stationary 
cells 
Having validated the use of FLIM as a way to measure H2O2 levels with HyPer-
cyto, I now wanted to determine if I could detect the production of H2O2 in 
migrating cells. To do this, I cultured MDAMB231 HyPer-cyto cells in 35 mm glass 
bottom dishes until they formed a confluent monolayer. Wounds were then 
created through the middle of the monolayer using a P10 pipette tip. Cells were 
then left for 1 hour to allow time for cells to start migrating to close the wound. 
Cells at the edge of the wound (classified as migrating) and those in the 
confluent areas of the dish (classified as stationary) were then imaged on a 
microscope fitted with a LIFA system and fluorescence lifetime measured using 
LI-FLIM software. I discovered that there was a significantly lower fluorescence 
lifetime and therefore higher H2O2 levels in cells that were migrating (Figure 3-
8). 
3.2.8 Establishment of MDAMB231 cell line stably expressing   
HyPer-PM 
After finding that H2O2 levels were elevated globally in migrating compared to 
stationary cells, I next wanted to know if this was also the case at the plasma 
membrane of cells. My reason for asking this was due to the fact that the plasma 
membrane is where signals from outside the cell are received and processed and 
the area of the cell that undergoes the most dynamic changes when migrating 
[35, 55]. To address this, I modified the HyPer-cyto probe by the addition of a 
CAAX motif (full sequence can be found in Table 2-8) at the C terminus, 
localising it to cell membranes and called this version HyPer-PM (Figure 3-9). 
Proteins that have this motif at their C terminus are targeted by a series of 
enzymes that modify the protein to become hydrophobic and consequently 
integrated into cell membranes [323]. 
I made a MDAMB231 cell line stably expressing this probe by transfecting 
parental MDAMB231 cells with a plasmid expressing HyPer-PM and a gene 
conferring resistance to G418. 48 hours after transfection, cells were transferred 
to G418 containing medium and cultured until all control cells that had not been 
transfected with the plasmid died. Surviving cells expressing HyPer-PM were 
selected by cell sorting using a FACSaria cell sorter and subdivided into 
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populations expressing the probe to low, medium and high levels (Figure 3-10 A). 
In this case the cells expressing HyPer-PM to the highest level were used for 
further experiments after confirming that the probe was expressed in these cells 
by western blot analysis using anti-GFP Ab capable of detecting HyPer (Figure 3-
10 B). This population of cells was chosen as it was the only population that 
expressed HyPer-PM to a high enough level for detection by microscopy. 
3.2.9 Baseline fluorescence lifetime of MDAMB231 HyPer-PM 
cells 
Before investigating if HyPer-PM responded to H2O2 in the same way as HyPer-
cyto, I wanted to know the fluorescence lifetime of HyPer-PM in cells with basal 
H2O2 levels. I therefore imaged MDAMB231 HyPer-PM cells using a microscope 
fitted with a LIFA system and measured the fluorescence lifetime using LI-FLIM 
software. The average fluorescence lifetime of these cells was 1.404 ns (Figure 
3-11). This is slightly, but significantly, lower than was observed for HyPer-cyto 
(Figure 3-5) which could mean that the areas at cell membranes have higher 
levels of H2O2 than the cell as a whole or that the integration of the probe into 
the cell membrane slightly alters its fluorescence lifetime. 
3.2.10 HyPer-PM fluorescence lifetime decreases upon the 
addition of H2O2 
I next wanted to test whether HyPer-PM responded to the addition of H2O2 in the 
same way as HyPer-cyto to ensure that adding the CAAX motif and targeting the 
probe to the membrane had not changed its sensitivity. In the same way as I did 
for HyPer-cyto cells, I cultured MDAMB231 HyPer-PM cells in 35 mm glass bottom 
dishes until around 50% confluent. Fields of view containing between one and 
four cells expressing HyPer-PM were then imaged on a microscope fitted with a 
LIFA system every 30 seconds for a total of 15 minutes. After the 4th image had 
been acquired (around 2 minutes) 100 µl of 3 mM H2O2 was added to the dish. As 
with HyPer-cyto, addition of H2O2 to the MDAMB2321 HyPer-PM cells resulted in a 
significant decrease in the fluorescence lifetime of HyPer-PM (Figure 3-12). 
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Figure 3-8 H2O2 levels elevated in migrating compared to stationary cells 
MDAMB231 HyPer-cyto cells were grown in 35 mm glass bottom dishes until they formed a 
confluent monolayer. A wound was then created through the middle of the monolayer and after 1 
hour cells still in a confluent area of the dish (stationary cells) and those at the edge of the wound 
(migrating cells) were imaged on a microscope fitted with a LIFA system. Fluorescence lifetime was 
measured in each cell imaged using LI-FLIM software. A) Box and whiskers plot (5-95 percentile) 
showing the range of changes in fluorescence lifetimes observed in migrating cells compared to 
stationary cells. B) Table showing average lifetimes measured in stationary and migrating cells. 
Results from >102 cells. Statistical significance of differences determined by an unpaired t-test 
(***=p<0.001). 
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Figure 3-9 Schematic diagram of H2O2 sensing HyPer-PM probe activation 
HyPer is an H2O2 sensing fluorescent probe in which a derivative of YFP has been inserted into the 
regulatory domain of the bacterial OxyR protein. HyPer-PM is a form of this probe that has been 
modified from the HyPer-cyto version by the addition of a CAAX motif (full sequence can be found 
in Table 2-8) (PM – green), localising it to the plasma membrane. In the presence of H2O2 there is 
a conformational change resulting from a disulphide bond being formed which leads to a change in 
the spectral properties of the probe. 
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Figure 3-10 Creation of MDAMB231 cell line stably expressing HyPer-PM 
A) FACS plots confirming a population of cells that positively expressed the HyPer-PM probe. B) 
Western blot confirming the stable expression of HyPer-PM and HyPer-cyto in MDAMB231 cell 
lines. Membrane was probed using anti-GFP Ab capable of detecting HyPer.  
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Figure 3-11 Expression and average fluorescence lifetime of HyPer-PM 
MDAMB231 HyPer-PM cells were imaged on a microscope fitted with a LIFA system and 
fluorescence lifetime measured using LI-FLIM software. A) Representative fluorescence image and 
corresponding lifetime map of MDAMB231 HyPer-PM cell. Scale bar = 20 µm. B) Box and whiskers 
plot (5-95 percentile) representing range of baseline fluorescence lifetimes observed in 
MDAMB231 HyPer-PM cells with average fluorescence lifetime measured indicated. Results from 
42 cells. 
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Figure 3-12 HyPer-PM fluorescence lifetime decreases after addition of H2O2 
MDAMB231 HyPer-PM cells were grown in 35 mm glass bottom dishes until ~50% confluent. 
Fields of view containing between one and four cells expressing HyPer-PM were imaged on a 
microscope fitted with a LIFA system every 30 seconds for a total of 15 minutes with 100 µl 3 mM 
H2O2 added at ~2 minutes. Fluorescence lifetime was measured in each cell over the time course 
using LI-FLIM software. A) Representative fluorescence images and corresponding lifetime maps 
of MDAMB231 HyPer-PM cells before and after H2O2 treatment. Scale bar = 20 µm. B) Graph 
showing change in fluorescence lifetime over a 15 minute period with the point of H2O2 addition 
indicated. Results displayed are average of 5 cells. C) Box and whiskers plot (5-95 percentile) 
indicating range of changes in fluorescence lifetimes observed after H2O2 addition. D) Table 
showing average fluorescence lifetimes measured before and after H2O2 treatment. Results from 
32 cells. Statistical significance of differences determined by a paired t-test (****=p<0.0001). 
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3.2.11 Change in fluorescence lifetime of HyPer-PM upon H2O2 
addition is reversible 
Along the same lines, I wanted to check if the fluorescence lifetime of HyPer-PM 
would return to starting levels after it was decreased by the addition of H2O2, 
and if the probe could then be reactivated by a further addition of H2O2. As for 
the HyPer-cyto probe, I repeated the previous experiment but this time 
continued to measure the fluorescence lifetime every 30 seconds for a total of 
30 minutes. After addition of the first dose of H2O2, I waited for the fluorescence 
lifetime to return to starting levels and then added a second dose of 100 µl 3 mM 
H2O2. In a similar way to HyPer-cyto, with time the decrease in fluorescence 
lifetime of HyPer-PM observed when H2O2 is added recovers to starting levels. 
Additionally, HyPer-PM can be restimulated by a second dose of H2O2 exhibiting 
a significant decrease in fluorescence lifetime, although the decrease observed 
with the second H2O2 dose was not as large as that seen with the first H2O2 dose 
(Figure 3-13). As the decrease in fluorescence lifetime was still significant, this 
difference would not prevent HyPer-PM from detecting transient and repeated 
changes in H2O2 levels. 
3.2.12 H2O2 levels are higher at the plasma membrane in 
migrating cells than stationary cells 
After confirming that adding a CAAX motif to target HyPer-PM to the plasma 
membrane did not adversely affect the functioning of the probe, I then wanted 
to determine if H2O2 levels were higher at the plasma membrane in migrating 
cells compared to stationary cells. Therefore, I cultured MDAMB231 HyPer-PM 
cells in 35 mm glass bottom dishes until they formed a confluent monolayer. 
Wounds were then created through the middle of the monolayer using a P10 
pipette tip and cells were left for 1 hour to allow cells to start migrating to close 
the wound. Cells that were at the edge of the wound (classified as migrating) 
and those still in confluent areas of the dish (classified as stationary) were then 
imaged on a microscope fitted with a LIFA system and fluorescence lifetime 
measured using LI-FLIM software. When all cells had been analysed there was a 
significantly lower fluorescence lifetime and therefore higher H2O2 levels at the 
plasma membrane in the migrating cells compared to the stationary cells (Figure 
3-14). 
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Figure 3-13 HyPer-PM lifetime recovers to baseline levels following H2O2 treatment and can 
be reactivated following further H2O2 addition 
MDAMB231 HyPer-PM cells were grown in 35 mm glass bottom dishes until ~50% confluent. 
Fields of view containing between one and four cells expressing HyPer-PM were imaged on a 
microscope fitted with a LIFA system every 30 seconds for a total of 30 minutes with 100 µl 3 mM 
H2O2 added after ~2 minutes and after fluorescence lifetime had returned to starting levels. 
Fluorescence lifetime was measured in each cell over the time course using LI-FLIM software. A) 
Representative fluorescence images and corresponding lifetime maps of MDAMB231 HyPer-PM 
cells before and after first and second H2O2 treatments. Scale bar = 20 µm. B) Graph showing 
change in fluorescence lifetime over a 30 minute period with the points of first and second H2O2 
addition indicated. Results displayed are from a representative cell. C) Box and whiskers plot (5-95 
percentile) indicating range of changes in fluorescence lifetimes observed before and after each 
H2O2 treatment. D) Table showing average fluorescence lifetimes measured before and after each 
H2O2 treatment. Results from 21 cells. Statistical significance of differences determined by a one-
way ANOVA followed by a Tukey Kramer multiple comparison test (***=p<0.001). 
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Figure 3-14 H2O2 levels elevated at plasma membrane in migrating compared to stationary 
cells 
MDAMB231 HyPer-PM cells were grown in 35 mm glass bottom dishes until they formed a 
confluent monolayer. A wound was then created through the middle of the monolayer and after 1 
hour cells still in a confluent area of the dish (stationary cells) and those at the edge of the wound 
(migrating cells) were imaged on a microscope fitted with a LIFA system. Fluorescence lifetime was 
measured in each cell imaged using LI-FLIM software. A) Box and whiskers plot (5-95 percentile) 
showing the range of changes in fluorescence lifetimes observed at the plasma membrane in 
migrating cells compared to stationary cells. B) Table showing average fluorescence lifetimes 
measured in stationary and migrating cells. Results from 83 cells. Statistical significance of 
differences determined by an unpaired t-test (****=p<0.0001). 
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3.2.13 H2O2 levels are elevated at the tips of cell protrusions 
While analysing data from the experiments investigating if there were increased 
H2O2 levels in migrating cells, I made an interesting observation. In some cells 
where cell protrusions had been captured in the image acquired, the tip of the 
protrusion was much more blue in the lifetime map, indicating higher H2O2 levels 
compared to the rest of the cell. I therefore decided to investigate this further 
by repeating the experiment undertaken to compare H2O2 levels in MDAMB231 
HyPer-cyto cells that were stationary or migrating. However, this time the focus 
was on imaging migrating cells at the edge of the wound that at the time of 
image acquisition had obvious cell protrusions. The z-position of the microscope 
was carefully set for each cell to ensure that the image taken captured the tip 
of the cell protrusions and the cell body. Fluorescence lifetime of HyPer-cyto 
was then measured at the tip of the cell protrusion and in the cell body using LI-
FLIM software. This confirmed my initial observations were correct, as I found 
there was a significantly lower fluorescence lifetime, indicating higher H2O2 
levels, at the tips of cell protrusions compared to the cell body (Figure 3-15). 
3.3 Conclusions 
In this chapter I have presented results showing that the ROS scavenger, NAC, 
reduced ROS levels in MDAMB231 cells and that reducing ROS levels with NAC 
resulted in a corresponding decrease in cell migration. Not only are ROS required 
for migration but I also provided evidence that the ROS, H2O2, was present at 
higher levels in migrating cells than in stationary cells both throughout the cell 
and specifically at the cell membrane, an area that undergoes massive dynamic 
changes during cell migration. Further to this, I revealed that H2O2 levels were 
not uniform throughout a migrating cell with increased levels found at the tip of 
cell protrusions compared to the cell body.  
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Figure 3-15 H2O2 levels elevated at tips of protrusions compared to cell bodies 
MDAMB231 HyPer-cyto cells were grown in 35 mm glass bottom dishes until they formed a 
confluent monolayer. A wound was then created through the middle of the monolayer and after 1 
hour cells at the edge of the wound which had well defined protrusions were imaged on a 
microscope fitted with a LIFA system ensuring that the z-position set captured the protrusion tip 
and cell body. Fluorescence lifetime in the protrusion tip and cell body were measured in each cell 
using LI-FLIM software. A) Representative fluorescence image and corresponding lifetime map of 
MDAMB231 HyPer-cyto cell with enlarged images of protrusion tips and selected area of cell body 
displayed. Scale bar = 20 µm. B) Box and whiskers plot (5-95 percentile) showing the range of 
changes in the fluorescence lifetimes observed in the tips of cell protrusions compared to the cell 
body. C) Table showing average fluorescence lifetimes measured in the cell body and tips of cell 
protrusions. Results from >29 cells. Statistical significance of differences determined by a paired t-
test(****=p<0.0001). 
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4 Protein Oxidation and Cell Migration 
4.1 Introduction 
After finding that H2O2 levels were elevated in migrating cells, in particular at 
the tips of cell protrusions, and knowing that H2O2 can regulate cellular 
signalling pathways through the oxidation of proteins, I wanted to investigate if 
protein oxidation was also increased in migrating cells [244-246]. Global protein 
oxidation has been shown previously to be increased in cells stimulated with 
VEGF, a growth factor known to induce the migration of endothelial cells. In 
addition, a population of oxidised proteins was located at the leading edge in 
migrating cells in the presence of VEGF [278]. However, the direct oxidation of 
proteins in migrating cells has not yet been demonstrated. Moreover, there are 
only a few proteins, mainly protein tyrosine phosphatases, that have been found 
to be oxidised and to contribute to cell migration [262, 276, 290, 291]. 
Therefore, I set out to identify the direct oxidation of specific proteins in 
migrating cells. In this chapter I have presented results from my investigations 
into the global oxidation of proteins in migrating cells and the identification of a 
specific protein that is oxidised. 
4.2 Results 
4.2.1 Cellular protein oxidation increases with H2O2 treatment 
In order to determine if the oxidation of proteins is increased in migrating cells, 
I needed to identify a reliable method to monitor levels of protein oxidation in 
cells. There are several commercially available options for this however, they 
each can have a number of drawbacks. Many are not completely specific for 
cysteine sulfenic acids and will cross-react with other cellular molecules and 
amino acids. Some also label oxidised proteins during cell lysis since the probes 
are unable to or inefficiently enter cells. As proteins can be easily oxidised 
during cell lysis and sample preparation steps, this may lead to an inaccurate 
representation of the actual oxidation state of proteins within cells. 
Additionally, some of the probes form modifications on the oxidised cysteine 
that are reversible and may be lost before they are detected and measured 
[324]. For these reasons I decided to use the chemical dimedone. Dimedone is a 
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cell permeable chemical that forms a covalent bond with the sulfenic acid form 
of an oxidised protein (Figure 4-1) [325]. It therefore has the benefits that it 
monitors protein oxidation levels as they are in the cell and results are not 
affected by protein oxidation that could occur during cell lysis or sample 
preparation. Equally as important, since it forms an irreversible covalent bond 
with oxidised proteins, it will not be lost or reduced during cell lysis or sample 
preparation. A further advantage of dimedone is it can detect all proteins 
undergoing oxidation regardless of the final oxidation product as it reacts with 
sulfenic acid, the very first intermediate formed when a protein is oxidised 
(Figure 1-8). 
Firstly, I wanted to validate the probe functioned correctly. To test this I 
treated MCF7 cells with 0, 1, 3 or 10 µM H2O2 for 6 hours. For the final 1 hour 
cells were also incubated with 5 mM dimedone and then harvested. The levels of 
protein oxidation, as indicated by dimedone labelling, were analysed by western 
blot. The membrane was probed with anti-dimedone Ab to detect oxidised 
proteins and anti-ERK2 Ab as a loading control. This confirmed the probe was 
behaving as expected as when cells were treated with H2O2, I saw increased 
dimedone labelling and therefore oxidised protein levels (Figure 4-2). 
4.2.2 Cellular protein oxidation decreases with NAC treatment 
In a similar way, I wanted to investigate if dimedone was also sufficiently 
sensitive to detect decreased oxidation. For this I treated MDAMB231 cells with 
0, 10, 25, 50 and 75 mM of the ROS scavenger NAC for 72 hours, again incubating 
them with 5 mM dimedone for the final 3 hours before harvesting. Protein 
oxidation was analysed by western blot with the membrane being probed with 
anti-dimedone Ab to detect oxidised proteins and anti-ERK2 Ab as a loading 
control. Again dimedone acted as expected with decreased levels of dimedone 
labelling of proteins, and therefore oxidised protein levels, when cells were 
treated with NAC (Figure 4-3). 
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Figure 4-1 Dimedone irreversibly reacts with oxidised cysteine in its sulfenic acid state 
A) Structure of chemical probe dimedone. B) Schematic diagram of the reaction of dimedone with 
oxidised cysteine residues. 
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Figure 4-2 Cellular protein oxidation increases with H2O2 treatment 
MCF7 cells were treated with H2O2 for 6 hours at the indicated concentrations and incubated with 5 
mM dimedone for the final 1 hour before harvesting. Dimedone labelling of oxidised proteins was 
then assessed by western blot analysis. Membranes were probed with anti-dimedone Ab to detect 
oxidised proteins and anti-ERK2 Ab as a loading control. Western blot showing levels of protein 
oxidation present following treatment with indicated concentrations of H2O2. 
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Figure 4-3 Cellular protein oxidation decreases with NAC treatment 
MDAMB231 cells were treated with NAC for 72 hours at the indicated concentrations and 
incubated with 5 mM dimedone for the final 3 hours before harvesting. Dimedone labelling of 
oxidised proteins was then assessed by western blot analysis. Membranes were probed with anti-
dimedone Ab to detect oxidised proteins and anti-ERK2 Ab as a loading control. A) Western blot 
showing levels of protein oxidation present following treatment with indicated concentrations of 
NAC. 
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4.2.3 Cellular protein oxidation is higher in migrating than 
stationary cells 
After validating that dimedone could detect both increases and decreases in 
protein oxidation, I could continue with experiments to determine if oxidation of 
proteins was increased in cells that were migrating compared to those that were 
stationary. This was investigated by culturing MDAMB231 cells in a 6-well dish 
until they formed a confluent monolayer. Half of the wells were then wounded 
20 times using a P10 pipette tip and the other half were left as a confluent 
monolayer. Cells were then left for 3 hours to allow those cells at the edge of 
the wounds to begin migrating to close the wounds. After a further 1 hour during 
which cells were incubated with 5 mM dimedone, cells were harvested. Levels of 
protein oxidation were then analysed by western blot with the membrane being 
probed with anti-dimedone Ab to detect oxidised proteins. A second set of 
samples from each condition was separated on a protein gel and stained to 
check for equal loading. From this it was discovered that oxidation of proteins is 
indeed increased in migrating compared to stationary cells (Figure 4-4). This was 
not unexpected as I had seen in the previous chapter that H2O2 is elevated in 
migrating cells and one of the downstream targets of H2O2, as explained in the 
introduction, are proteins which become oxidised. Therefore in a situation 
where increased H2O2 is observed, you would also expect to see increased 
protein oxidation. 
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Figure 4-4 Protein oxidation is increased in migrating cells compared to stationary cells 
MDAMB231 cells were cultured in a 6-well dish until they formed a confluent monolayer and then 
wounded 20 times (migrating) or left unwounded (stationary). After 3 hours cells were incubated 
with 5 mM dimedone for 1 hour before harvesting. Dimedone labelling of oxidised proteins was 
then assessed by western blot analysis. A) Representative western blot from 3 independent 
experiments showing levels of protein oxidation in migrating cells compared to stationary cells. 
Membrane probed with anti-dimedone Ab to detect oxidised proteins. B) Protein gel stained to 
confirm equal loading of samples. 
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4.2.4 Cofilin is identified as a protein oxidised in cells 
Having found that overall protein oxidation was increased in migrating cells, I 
started to speculate about which proteins could be targets of this oxidation. 
Additionally, which of these proteins would have an altered activity as a result 
of this oxidation and could therefore be contributing to remodelling of the actin 
cytoskeleton to aid migration. As cofilin is a key regulator of actin cytoskeleton 
dynamics and its involvement in the induction of cell death and the reduced 
response of T cells under conditions of oxidative stress have recently been shown 
to be regulated by oxidation, it came up as an attractive candidate to 
investigate further [91, 94, 137]. 
I therefore set out to determine if I could detect oxidised cofilin in cells using 
dimedone. To do this I cultured MCF7 cells in the presence or absence of NAC for 
72 hours with cells being incubated with 5 mM dimedone for the final 3 hours 
before harvesting. Cofilin was then immunoprecipitated from the cell lysates 
and analysed for dimedone labelling by western blot. Membranes were probed 
with anti-cofilin Ab to check total cofilin levels and anti-dimedone Ab to 
determine oxidised cofilin levels. From this I found that cofilin was indeed 
present in an oxidised form in cells as indicated by dimedone labelling. This was 
confirmed to be oxidised cofilin as in the presence of NAC, the level of 
dimedone labelling on cofilin decreased (Figure 4-5). 
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Figure 4-5 Cofilin identified in oxidised state in cells 
MCF 7 cells treated with or without 25 mM NAC for 72 hours and with 5 mM dimedone for the final 
3 hours before harvesting. Cofilin was then immunoprecipitated and dimedone incorporation 
assessed by western blot analysis. A) Western blot from preliminary experiment showing levels of 
oxidised cofilin and total cofilin in cells with and without NAC treatment. Membrane probed with 
anti-cofilin Ab and anti-dimedone Ab to detect oxidised cofilin. 
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4.2.5 Cofilin oxidation is higher in migrating than stationary cells 
After establishing that cofilin was oxidised in cells, I next wanted to determine if 
cofilin was one of the proteins that exhibited increased oxidation in migrating 
cells compared to stationary cells.  This was investigated by culturing MDAMB231 
cells in a 6-well dish until they formed a confluent monolayer. Cell monolayers 
were then wounded 30 times using a P10 pipette tip or left unwounded. After 3 
hours to allow those cells at the edge of the wounds to begin migrating to close 
the wounds, cells were incubated with 5 mM dimedone for 1 hour. Cells were 
then harvested, cofilin immunoprecipitated from lysates and levels of cofilin 
oxidation were analysed by western blot with the membrane being probed with 
anti-dimedone Ab to detected oxidised protein. From this it was established that 
cofilin oxidation was indeed increased in migrating cells compared to stationary 
cells (Figure 4-6). 
4.3 Conclusions 
In this chapter I have presented results confirming that the chemical dimedone 
can be used to reliably monitor levels of protein oxidation in cells, as shown by 
increases and decreases in dimedone labelling with H2O2 and NAC treatment 
respectively. Dimedone was then used to reveal that the oxidation of proteins 
was increased in migrating cells compared to stationary cells. Additionally, 
cofilin was identified in an oxidised state in cells and the level of cofilin 
oxidation was increased in migrating cells compared to stationary cells. 
Therefore, cofilin oxidation could alter its activity and contribute to the 
remodelling of the actin cytoskeleton required for cell migration.   
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Figure 4-6 Cofilin oxidation increased in migrating cells compared to stationary cells 
MDAMB231 cells were cultured until they formed a confluent monolayer and then wounded 30 
times (migrating) or left unwounded (stationary). After 3 hours cells were incubated with 5 mM 
dimedone for 1 hour before harvesting. Cofilin was immunoprecipitated from lysates and dimedone 
labelling was then assessed by western blot analysis. Representative western blot from 3 
independent experiments showing levels of cofilin oxidation in migrating cells compared to 
stationary cells. Membrane probed with anti-cofilin Ab and anti-dimedone Ab to detect oxidised 
protein. Figure courtesy of June Munro. 
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5 Cofilin Oxidation and Actin Dynamics 
5.1 Introduction 
The oxidation of cofilin has previously been reported to be required for some 
cellular processes. The induction of apoptosis and necrotic-like programmed cell 
death in response to oxidants is dependent on the oxidation of cofilin [91, 94]. 
Furthermore, cofilin oxidation has been implicated in the reduced response of T 
cells under conditions of oxidative stress [137]. Having established that cofilin 
was one of the proteins oxidised in migrating cells, I next wanted to determine if 
this oxidation was altering its activity and consequently contributing to cell 
migration. As cofilin has a central role in remodelling the actin cytoskeleton and 
this is essential for cell migration, I set out to identify if the oxidation of cofilin 
altered its ability to sever and depolymerise F-actin in vitro. In addition to this, 
as proteins are oxidised on cysteine residues, I wanted to establish which of the 
cysteine residues in cofilin were oxidised and contributing to any observed 
change in activity [246]. The results from these in vitro studies are presented in 
this chapter. 
5.2 Results 
5.2.1 Purification of actin and cofilin for in vitro actin 
depolymerisation assay 
Having identified oxidised cofilin in cells I wanted to know if the oxidation of 
cofilin affected its ability to depolymerise F-actin. To assess this, I used an in 
vitro actin depolymerisation assay that used pyrene conjugated actin [326]. 
When pyrene conjugated actin is in a G-actin state, it has a low fluorescence; 
however, when it is incorporated into F-actin, its fluorescence increases. 
Changes in F-actin levels over time can therefore be monitored by measuring the 
change in pyrene actin fluorescence. To assess the ability of a protein of interest 
to depolymerise F-actin, a solution of G-actin is prepared in which 5% is 
conjugated to pyrene. Upon the addition of a high salt solution (polymerisation 
buffer), F-actin begins to form and eventually equilibrium between G-actin and 
F-actin levels is reached. The point at which equilibrium has been reached can 
be determined by measuring the fluorescence throughout the polymerisation; 
when fluorescence stops increasing and remains constant, equilibrium has been 
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achieved. A protein of interest can then be added and if it depolymerises F-actin 
a decrease in fluorescence will be observed due to a shifting of the equilibrium 
towards G-actin. In contrast, if the protein promotes further polymerisation 
there will be an increase in fluorescence due to a shifting of the equilibrium 
towards F-actin (Figure 5-1). In order to test the effect of cofilin oxidation on its 
actin depolymerisation activity in this assay, I purified bacterially expressed 
recombinant cofilin. The actin used for this assay was extracted and purified 
from rabbit skeletal muscle (Figure 5-2).  
5.2.2 Oxidation of recombinant cofilin 
Before investigating the effect of cofilin oxidation on its actin depolymerising 
activity, I wished to confirm that I could oxidise the recombinant cofilin. I 
decided to do this by incubating the recombinant cofilin with H2O2 of increasing 
concentrations between 0 and 10 mM for 1 hour. Residual H2O2 left at the end of 
the incubation time was quenched with catalase and then levels of cofilin 
oxidation measured using biotin conjugated iodoacetamide (biotin-IAA). IAA is a 
chemical that attaches to free, non-oxidised thiol groups on protein cysteine 
residues. It therefore binds to proteins that are not oxidised and the presence of 
the biotin tag on IAA allows its incorporation into non-oxidised proteins to be 
measured. I analysed the levels of non-oxidised cofilin in these samples by 
western blot, probing the membrane using Alexa Fluor 680 conjugated 
streptavidin. As streptavidin has a high affinity for biotin, this will detect biotin-
IAA incorporation in proteins and therefore measure non-oxidised protein levels. 
I found that I could effectively oxidise recombinant cofilin by incubating it with 
H2O2 at concentrations greater than 1 mM as I observed a dose dependent 
decrease in non-oxidised cofilin with 1, 3, and 10 mM H2O2 (Figure 5-3). 
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Figure 5-1 Schematic diagram of in vitro actin depolymerisation assay 
A) Schematic diagram illustrating change in fluorescence seen when pyrene labelled G-actin is 
incorporated into F-actin. B) Graph illustrating potential changes in G-actin and F-actin levels and 
consequently the fluorescence that could result from the addition of a protein of interest. 
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Figure 5-2 Purification of cofilin and actin for in vitro assay 
A) Protein gel of purified recombinant cofilin expressed in bacteria. B) Protein gel of purified actin 
extracted from rabbit skeletal muscle. 
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Figure 5-3 Oxidation of recombinant cofilin with H2O2 
Recombinant cofilin was treated with H2O2 at the concentrations indicated. After quenching of 
residual H2O2, cofilin was incubated with biotin-IAA to detect non-oxidised cofilin. Biotin-IAA 
incorporation and therefore non-oxidised cofilin was assessed by western blot analysis. 
Membranes were probed with anti-cofilin Ab to detect total cofilin levels and Alexa Fluor 680 
conjugated streptavidin to detect biotin-IAA and therefore non-oxidised cofilin. A) Western blot 
showing total cofilin and non-oxidised cofilin levels (as indicated by biotin-IAA) at the H2O2 
concentrations indicated. 
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5.2.3 Oxidation of recombinant cofilin reduces its ability to 
decrease F-actin levels 
Having established that I could oxidise recombinant cofilin in vitro I was then 
able to assess the ability of oxidised cofilin to decrease F-actin levels in the 
assay described at the start of this chapter. I incubated the recombinant cofilin 
with 0, 3, 5, 7 or 10 mM H2O2 for 1 hour as these concentrations were within the 
range in which I observed oxidation previously. Remaining H2O2 was quenched 
with catalase to prevent any further oxidation. These cofilin samples were then 
added to pyrene labelled actin that had reached a steady state level of F-actin 
following addition of polymerisation buffer to a G-actin solution. Fluorescence 
was measured over 5 minutes to monitor F-actin levels.  
The results showed that the percentage fluorescence and therefore the F-actin 
levels at the endpoint of the assay were significantly higher when cofilin was 
treated with 5, 7 or 10 mM H2O2 compared to untreated cofilin. This 
demonstrates that the oxidation of cofilin inhibits it from decreasing F-actin 
levels in the depolymerisation assay and the degree of inhibition observed is 
dependent on the concentration of H2O2 with which the cofilin was oxidised 
(Figure 5-4). 
5.2.4 Generation of cofilin cysteine to alanine mutants 
As it was explained in the introduction, it is the cysteine residues in proteins 
that are targeted and oxidised by H2O2. As cofilin has four cysteine residues 
(Figure 5-5), I wanted to know which of these residues, when oxidised, was 
inhibiting cofilin from reducing F-actin levels. To do this I generated four cofilin 
mutants by site-directed mutagenesis in which each cysteine residue was 
independently mutated to alanine and therefore unable to be oxidised. These 
cofilin mutants were designated C39A, C80A, C139A and C147A depending on the 
position of the cysteine residue that had been mutated to alanine. These mutant 
cofilin proteins, as with the WT cofilin, were bacterially expressed and purified 
(Figure 5-6). 
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Figure 5-4 Oxidation of cofilin reduces its ability to decrease F-actin levels 
Recombinant cofilin was oxidised with H2O2 at the concentrations indicated. Oxidised cofilin was 
then added to pyrene labelled actin which had already reached a steady state level of F-actin. 
Fluorescence was measured over 5 minutes to monitor changes in F-actin levels. A) Graph 
showing average changes in fluorescence over 5 minutes after addition of cofilin treated with 
indicated concentrations of H2O2. B) Graph showing mean percentage fluorescence +/- standard 
deviation (SD) at endpoint compared to start of experiment after addition of cofilin treated with 
indicated concentrations of H2O2. Statistical significance of differences determined by a one-way 
ANOVA followed by a Tukey Kramer multiple comparison test (ns=not significant, *=p<0.05, 
**=p<0.01, ***=p<0.001), n=9. 
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Figure 5-5 Cofilin has four cysteine residues 
Cysteine 39 (red), cysteine 80 (blue), cysteine 139 (pink), cysteine 147 (orange). A) Position of 
cysteine residues in cofilin amino acid sequence. B) Position of cysteine residues in cofilin 3D 
structure. Model created in PyMol using NMR structure data (PDB ID: 1Q8G) [327]. 
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Figure 5-6 Purification of cofilin cysteine to alanine mutants used for in vitro assay 
A) Protein gel of purified recombinant cofilin cysteine to alanine mutants expressed in bacteria. 
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5.2.5 Cofilin cysteine residues 139 and 147 are responsible for 
the reduced ability of cofilin to decrease F-actin levels 
when oxidised 
Having generated these cofilin cysteine to alanine mutants, I wanted to test 
their ability to decrease F-actin levels in the actin depolymerisation assay when 
non-oxidised and oxidised. To do this, I incubated each of the cofilin mutants or 
WT protein with 10 mM H2O2 for 1 hour or left them untreated. 10 mM H2O2 was 
chosen as this was the concentration of H2O2 that showed the greatest inhibition 
of cofilin activity in the previous experiment. Any remaining H2O2 was quenched 
with catalase to prevent further oxidation. The cofilin WT and mutant samples 
were then added to pyrene labelled actin that had reached a steady state level 
of F-actin following addition of polymerisation buffer to a G-actin solution. 
Fluorescence was measured over 5 minutes to monitor F-actin levels. 
These results indicated that in the absence of oxidation the cofilin cysteine to 
alanine mutants were able to decrease F-actin levels to the same degree as WT 
cofilin. However, when these mutants were oxidised, the C139A and C147A 
mutants were still able to decrease F-actin levels unlike oxidised WT cofilin. In 
fact when looking at the percentage fluorescence and therefore F-actin levels at 
the endpoint of this experiment, there was no significant difference seen 
between the non-oxidised and oxidised C139A and C147A mutants. This 
demonstrates that both cysteines 139 and 147 must be oxidised and contribute 
to the inhibition of cofilin activity observed in the actin depolymerisation assay 
when it was oxidised. Interestingly I also noticed that when the C39A and C80A 
mutants were oxidised they led to an increase in the F-actin levels at the 
endpoint of the assay compared to oxidised WT cofilin (Figure 5-7). It could be 
that when oxidised these mutants are causing F-actin filaments already present 
to bundle together forming actin rods and this is leading to an increased 
fluorescence. Alternatively, as the actin the proteins are added to is in a state 
of equilibrium where the rate of polymerisation and depolymerisation of F-actin 
are equal; these mutants when oxidised could be blocking or at least slowing the 
rate of depolymerisation while polymerisation continues at an unaltered rate 
and consequently causing a shift in the equilibrium towards F-actin, again 
explaining the increased fluorescence I observed. Although this was an 
interesting phenomenon, it was not within the scope of my study to investigate 
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this further as my primary interest was in which of the cysteine residues was 
inhibiting the ability of cofilin to decrease F-actin levels when oxidised. 
5.2.6 Generation of cofilin double cysteine to alanine mutants 
After discovering that cofilin cysteine residues 139 and 147 appeared to be the 
ones responsible for the inhibition of cofilin activity when oxidised, I next 
wanted to know if mutating either of these residues in combination with each of 
the other cysteine residues would also be able to rescue the inhibition of cofilin 
activity seen when it was oxidised. For this reason I generated cofilin mutants by 
site-directed mutagenesis in which every combination of two cysteine residues 
were mutated to alanine therefore creating cofilin proteins that could not be 
oxidised on two of the cysteine residues. These were named C39/80A, 
C39/139A, C39/147A, C80/139A, C80/147A and C139/147A depending on which 
two of the cysteine residues had been mutated to alanine. These cofilin double 
cysteine to alanine mutants, as with the WT and single cysteine to alanine 
mutants, were bacterially expressed and purified (Figure 5-8). 
5.2.7 Cofilin cysteine residue 147 appears to be the cysteine 
residue predominantly responsible for the reduced ability 
of cofilin to decrease F-actin levels when oxidised 
Having generated cofilin double cysteine to alanine mutants, I wanted to test 
their ability to reduce F-actin levels in the actin depolymerisation assay when 
non-oxidised and oxidised. To do this I incubated each of the cofilin mutants and 
WT protein with 10 mM H2O2 for 1 hour or left them untreated as was done with 
the cofilin single cysteine to alanine mutants. Remaining H2O2 was then 
quenched with catalase to prevent further oxidation. Cofilin WT and mutant 
proteins were then added to pyrene labelled actin that had reached a steady 
state level of F-actin following the addition of polymerisation buffer to a G-actin 
solution. Fluorescence was measured over 5 minutes to monitor F-actin levels. 
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Figure 5-7 Cofilin cysteine residues 139 and 147 are responsible for the reduced ability of 
cofilin to decrease F-actin levels when oxidised 
Recombinant cofilin cysteine to alanine mutants were oxidised with 10 mM H2O2 or left untreated. 
Non-oxidised and oxidised cofilin mutants were then added to pyrene labelled actin which had 
already reached a steady state level of F-actin. Fluorescence was measured over 5 minutes to 
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monitor changes in F-actin levels. A) Graph showing average changes in fluorescence over 5 
minutes after addition of non-oxidised cofilin mutants. B) Graph showing average changes in 
fluorescence over 5 minutes after addition of oxidised cofilin mutants. C) Graph showing mean 
percentage fluorescence +/- SD at endpoint compared to start of experiment after addition of non-
oxidised and oxidised cofilin mutants. Statistical significance of differences determined by a one-
way ANOVA followed by a Tukey Kramer multiple comparison test (ns=not significant, 
***=p<0.001), n>12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  132 
 
 
 
Figure 5-8 Purification of cofilin double cysteine to alanine mutants used for in vitro assay 
Protein gel of purified recombinant cofilin double cysteine to alanine mutants expressed in bacteria. 
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By comparing results across all the mutants that contain cysteine 39 mutated to 
alanine (C39A, C39/80A, C39/139A and C39/147A), I determined that when 
these mutants were not oxidised, they were able to decrease F-actin levels to 
the same degree as WT as there was no significant difference between the 
percentage fluorescence and therefore F-actin levels at the endpoint of the 
assay. As I saw in the previous experiment, the C39A mutant was not able to 
rescue the inhibition of cofilin activity seen when WT cofilin was oxidised. 
Similarly with the double C39/80A and C39/139A mutants, there was no rescue 
in activity seen upon oxidation. However, when the C39/147A mutant was 
oxidised it was still able to decrease F-actin levels and no significant difference 
was observed between the percentage fluorescence and therefore F-actin levels 
at the endpoint of this assay between the non-oxidised and oxidised protein 
(Figure 5-9). 
By comparing results across all mutants that contain cysteine 80 mutated to 
alanine (C80A, C39/80A, C80/139A and C80/147A) I saw that when these cofilin 
mutants were not oxidised, they were able to decrease F-actin levels to the 
same degree as WT as there was no significant difference between the 
percentage fluorescence and therefore F-actin levels at the endpoint of the 
assay. As I saw before, the C80A mutant was not able to rescue the inhibition of 
cofilin activity seen when WT cofilin was oxidised. I also found that none of the 
cofilin double cysteine to alanine mutants, namely C39/80A, C80/139A and 
C80/147A, were able to rescue cofilin activity when oxidised. Interestingly 
though, I observed a partial restoration of cofilin activity in the C80/147A 
mutant when it was oxidised as it was able to cause a decrease in the 
percentage fluorescence and therefore F-actin levels at the endpoint of the 
assay compared to all the other cofilin mutants involving the mutation of 
cysteine 80 which resulted in an increase in percentage fluorescence and F-actin 
levels (Figure 5-10). 
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Figure 5-9 Cofilin C39/147A mutant can rescue the inhibition in the ability of cofilin to 
decrease F-actin levels when oxidised 
Recombinant cofilin single and double cysteine to alanine mutants containing mutated cysteine 39 
were oxidised with 10 mM H2O2 or left untreated. Non-oxidised and oxidised cofilin mutants were 
then added to pyrene labelled actin which had already reached a steady state level of F-actin. 
Fluorescence was measured over 5 minutes to monitor changes in F-actin levels. A) Graph 
showing average changes in fluorescence over 5 minutes after addition of non-oxidised cofilin 
mutants containing mutated cysteine 39. B) Graph showing average changes in fluorescence over 
5 minutes after addition of oxidised cofilin mutants containing mutated cysteine 39. C) Graph 
showing mean percentage fluorescence +/- SD at endpoint compared to start of experiment after 
addition of non-oxidised or oxidised cofilin mutants containing mutated cysteine 39. Statistical 
significance of differences determined by a one-way ANOVA followed by a Tukey Kramer multiple 
comparison test (ns=not significant, ***=p<0.001), n>7. 
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Figure 5-10 No cofilin cysteine to alanine mutants containing mutated cysteine 80 can 
rescue the inhibition in the ability of cofilin to decrease F-actin levels when oxidised 
Recombinant cofilin single and double cysteine to alanine mutants containing mutated cysteine 80 
were oxidised with 10 mM H2O2 or left untreated. Non-oxidised and oxidised cofilin mutants were 
then added to pyrene labelled actin which had already reached a steady state level of F-actin. 
Fluorescence was measured over 5 minutes to monitor changes in F-actin levels. A) Graph 
showing average changes in fluorescence over 5 minutes after addition of non-oxidised cofilin 
mutants containing mutated cysteine 80. B) Graph showing average changes in fluorescence over 
5 minutes after addition of oxidised cofilin mutants containing mutated cysteine 80. C) Graph 
showing mean percentage fluorescence +/- SD at endpoint compared to start of experiment after 
addition of non-oxidised or oxidised cofilin mutants containing mutated cysteine 80. Statistical 
significance of differences determined by a one-way ANOVA followed by a Tukey Kramer multiple 
comparison test (**=p<0.01, ***=p<0.001), n>9. 
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By comparing results across all the mutants that contain cysteine 139 mutated to 
alanine (C139A, C39/139A, C80/139A and C139/147A) I saw that when these 
cofilin mutants were not oxidised, they were able to decrease F-actin levels to 
the same degree as WT as there was no significant difference between the 
percentage fluorescence and therefore F-actin levels at the endpoint of the 
assay. As seen previously, the C139A mutant was able to decrease F-actin levels 
when oxidised unlike WT cofilin. With the C39/139A and C80/139A mutants 
there was actually a loss of this effect as these mutants were unable to decrease 
F-actin levels. Although the mutation of cysteine 139 to alanine on its own was 
sufficient to rescue cofilin activity when oxidised, this was clearly not a strong 
enough effect to overcome the increase in F-actin levels observed when cysteine 
39 or 80 were mutated independently. In contrast, the C139/147A mutant, when 
oxidised, could still decrease F-actin levels and to an even greater extent than 
C139A (Figure 5-11). 
By comparing the results across all the mutants that contain cysteine 147 
mutated to alanine (C147A, C39/147A, C80/147A and C139/147A) I saw that 
when these cofilin mutants were not oxidised, they were able to decrease F-
actin levels to the same degree as WT as there is no significant difference 
between the percentage fluorescence and therefore F-actin levels at the 
endpoint of the assay. As was presented before, the C147A mutant when 
oxidised was able to decrease F-actin levels, rescuing the inhibition of activity 
seen when WT cofilin was oxidised. Indeed all cofilin single and double cysteine 
to alanine mutants that have cysteine 147 mutated to alanine, except C80/147A, 
were able to restore cofilin activity with no significant differences observed in 
the F-actin levels at the endpoint of the assay between the non-oxidised and 
oxidised forms of these mutants. Although the C80/147A mutant was not able to 
completely rescue cofilin activity when oxidised, it did result in a decrease in F-
actin levels unlike the C80A mutant where an increase was seen (Figure 5-12). 
All these results suggest that cysteine 147 appears to be the key cysteine residue 
that inhibits WT cofilin activity when oxidised. This is evident from the fact that 
all the cofilin single and double mutants containing cysteine 147 mutated were 
able to decrease F-actin levels to some degree when oxidised, with three out of 
the four being able to completely rescue the inhibition in the ability of cofilin to 
decrease F-actin levels that was seen with oxidised WT cofilin. 
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Figure 5-11 Cofilin C139A and C139/147A mutants can rescue the inhibition in the ability of 
cofilin to decrease F-actin levels when oxidised 
Recombinant cofilin single and double cysteine to alanine mutants containing mutated cysteine 139 
were oxidised with 10 mM H2O2 or left untreated. Non-oxidised and oxidised cofilin mutants were 
then added to pyrene labelled actin which had already reached a steady state level of F-actin. 
Fluorescence was measured over 5 minutes to monitor changes in F-actin levels. A) Graph 
showing average changes in fluorescence over 5 minutes after addition of non-oxidised cofilin 
mutants containing mutated cysteine 139. B) Graph showing average changes in fluorescence over 
5 minutes after addition of oxidised cofilin mutants containing mutated cysteine 139. C) Graph 
showing mean percentage fluorescence +/- SD at endpoint compared to start of experiment after 
addition of non-oxidised or oxidised cofilin mutants containing mutated cysteine 139. Statistical 
significance of differences determined by a one-way ANOVA followed by a Tukey Kramer multiple 
comparison test (ns=not significant, ***=p<0.001), n>7. 
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Figure 5-12 Cofilin C147A, C39/147A and C139/147A mutants can rescue the inhibition in the 
ability of cofilin to decrease F-actin levels when oxidised 
Recombinant cofilin single and double cysteine to alanine mutants containing mutated cysteine 147 
were oxidised with 10 mM H2O2 or left untreated. Non-oxidised and oxidised cofilin mutants were 
then added to pyrene labelled actin which had already reached a steady state level of F-actin. 
Fluorescence was measured over 5 minutes to monitor changes in F-actin levels. A) Graph 
showing average changes in fluorescence over 5 minutes after addition of non-oxidised cofilin 
mutants containing mutated cysteine 147. B) Graph showing average changes in fluorescence over 
5 minutes after addition of oxidised cofilin mutants containing mutated cysteine 147. C) Graph 
showing mean percentage fluorescence +/- SD at endpoint compared to start of experiment after 
addition of non-oxidised or oxidised cofilin mutants containing mutated cysteine 147. Statistical 
significance of differences determined by a one-way ANOVA followed by a Tukey Kramer multiple 
comparison test (ns=not significant, **=p<0.01, ***=p<0.001), n>7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  143 
 
5.2.8 Oxidation of recombinant cofilin results in a reduction in 
monomer levels and the formation of oligomers 
As was detailed in the introduction, there are a number of different products 
that can form when a protein is oxidised (Figure 1-8). Since I was able to show 
that the oxidation of cofilin had an effect on its ability to reduce F-actin levels 
in the actin depolymerisation assay, I next wanted to establish if I could 
determine which oxidised cofilin product was being formed in the context of this 
assay. My first approach to address this was to separate the oxidised cofilin 
samples by non-reducing SDS-PAGE. The theory behind this was if any disulphide 
bonds were being formed within cofilin, a possibility considering the presence of 
more than one cysteine residue, a shift in the cofilin band may be observed as 
non-reducing gels preserve the integrity of disulphide bonds. I therefore 
incubated recombinant cofilin with 0, 3, 5, 7 or 10 mM H2O2 for 1 hour as I had 
done for the actin depolymerisation assay, quenching residual H2O2 at the end by 
the addition of catalase. Cofilin samples were then separated by non-reducing 
SDS-PAGE and cofilin assessed by western blot analysis with the membrane being 
probed with anti-cofilin Ab. Surprisingly and very interestingly what I observed 
was that when recombinant cofilin was treated with H2O2 there was a 
concentration dependent decrease in the levels of cofilin monomer and the 
appearance of a distinctive banding pattern in which each band corresponded to 
the expected molecular weight of cofilin oligomers. This trend observed was 
confirmed when the levels of cofilin monomer present at each concentration of 
H2O2 was quantified across four independent experiments (Figure 5-13). 
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Figure 5-13 Oxidation of recombinant cofilin results in a reduction in cofilin monomer levels 
and the formation of oligomers 
Recombinant cofilin was oxidised with H2O2 at the concentrations stated. Samples were then 
separated by non-reducing SDS-PAGE and cofilin levels assessed by western blot analysis. 
Membrane probed with anti-cofilin Ab. A) Representative western blot showing cofilin monomer 
levels and oligomerisation. B) Graph showing mean cofilin monomer levels +/- SEM measured 
from 4 independent experiments. Statistical significance of differences determined by a one-way 
ANOVA followed by a Tukey Kramer multiple comparison test (***=p<0.001). 
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5.2.9 Cofilin cysteine residue 147 is predominantly responsible 
for the reduction in monomer levels and oligomerisation 
of oxidised recombinant cofilin 
After discovering that the oxidation of recombinant cofilin was leading to its 
oligomerisation and a decrease in monomer levels, I wanted to know what 
happened in the case of the cofilin single cysteine to alanine mutants I had 
generated. I therefore incubated cofilin WT, C39A, C80A, C139A and C147A with 
10 mM H2O2 for 1 hour, as this was the concentration I used when testing these 
mutant cofilin proteins in the actin depolymerisation assay, or left them 
untreated. Residual H2O2 present at the end of the incubation time was 
quenched by catalase. Cofilin samples were then separated by non-reducing SDS-
PAGE and cofilin assessed by western blot analysis with the membrane being 
probed with anti-cofilin Ab. The results from this experiment revealed that the 
levels of cofilin monomer present after oxidation of C39A and C80A was lower 
although not significantly than WT cofilin when oxidised. In contrast when C139A 
and C147A were oxidised, higher levels of cofilin monomer remained compared 
to oxidised WT cofilin. This increase in cofilin monomer levels was not classified 
as significant for the C139A mutant but was for the C147A cofilin mutant when 
quantified and analysed across three independent experiments (Figure 5-14). 
These results suggest that both cysteine 139 and 147 contribute to the formation 
of oligomers in oxidised cofilin but cysteine 147 has a greater and more 
important role than cysteine 139. 
 
 
 
 
 
 
 
  146 
 
 
 
Figure 5-14 Monomer levels and oligomerisation before and following oxidation of cofilin 
cysteine to alanine mutants 
Recombinant cofilin cysteine to alanine mutants were oxidised with 10 mM H2O2 or left untreated. 
Non-oxidised and oxidised cofilin mutant samples were then separated by non-reducing SDS-
PAGE and cofilin levels assessed by western blot analysis. Membrane probed with anti-cofilin Ab. 
A) Representative western blot showing monomer levels and oligomerisation of cofilin mutants. B) 
Graph showing mean monomer levels +/- SEM of cofilin mutants measured from 3 independent 
experiments. Statistical significance of differences determined by a one-way ANOVA followed by a 
Tukey Kramer multiple comparison test (ns=not significant, **=p<0.01). 
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5.2.10 Cofilin cysteine residues 139 and 147 are almost 
completely responsible for the reduction in monomer 
levels and oligomerisation of oxidised recombinant cofilin 
I also decided to investigate how cofilin monomer levels and oligomerisation 
were affected in the cofilin double cysteine to alanine mutants to see if I could 
learn any more about the oligomerisation of recombinant cofilin. I therefore 
incubated the cofilin double cysteine to alanine mutants (C39/80A, C39/139A, 
C39/147A, C80/139A, C80/147A and C139/147A) with 10 mM H2O2 for 1 hour, 
again as this was the concentration used for the actin depolymerisation assay, or 
left them untreated followed by quenching remaining H2O2 with catalase. Cofilin 
samples were then separated by non-reducing SDS-PAGE and cofilin assessed by 
western blot analysis with the membrane being probed with anti-cofilin Ab. 
Comparing the levels of cofilin monomer quantified across four independent 
experiments I found that of the cofilin cysteine to alanine mutants containing 
mutant cysteine 39, only cofilin C39/147A exhibited significantly increased 
levels of monomer compared to WT when oxidised (Figure 5-15 B). There was no 
significant difference identified between the cofilin monomer levels in any of 
the oxidised cofilin cysteine to alanine mutants containing cysteine 80 (Figure 5-
15 C). Cofilin mutants which had cysteine 139 mutated to alanine showed a 
similar trend to those involving mutant cysteine 39 in that only the double 
mutant involving C147 (C139/147A) showed significantly increased monomer 
levels compared to WT when oxidised (Figure 5-15 D). Of the four cofilin 
cysteine to alanine mutants containing cysteine 147 mutated, three showed 
increased monomer levels when oxidised compared to WT (Figure 5-15 E). The 
greatest increase in cofilin monomer levels was seen in the C139/147A mutant; 
western blot of this sample revealed that virtually all oligomerisation of cofilin 
was prevented (Figure 5-15 A). These results indicate that cofilin cysteine 
residues 139 and 147 are responsible almost exclusively for the formation of 
intermolecular disulphide bonds and subsequent oligomerisation of cofilin. 
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Figure 5-15 Monomer levels and oligomerisation before and following oxidation of cofilin 
double cysteine to alanine mutants 
Recombinant cofilin double cysteine to alanine mutants were oxidised with 10 mM H2O2 or left 
untreated. Non-oxidised and oxidised cofilin mutant samples were then separated by non-reducing 
SDS-PAGE and cofilin levels assessed by western blot analysis. Membrane probed with anti-cofilin 
Ab. A) Representative western blot showing monomer levels and oligomerisation of cofilin mutants. 
B) Graph showing mean monomer levels of cofilin mutants containing cysteine 39 mutated +/- SEM 
measured from >3 independent experiments. C) Graph showing mean monomer levels of cofilin 
mutants containing cysteine 80 mutated +/- SEM measured from >3 independent experiments. D) 
Graph showing mean monomer levels of cofilin mutants containing cysteine 139 mutated +/- SEM 
measured from >3 independent experiments. E) Graph showing mean monomer levels of cofilin 
mutants containing cysteine 147 mutated +/- SEM measured from >3 independent experiments. 
Statistical significance of differences in B) - E) determined by a one-way ANOVA followed by a 
Tukey Kramer multiple comparison test (ns=not significant, *=p<0.05, ***=p<0.001). 
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5.3 Conclusions 
In this chapter I have presented data showing that the oxidation of recombinant 
cofilin inhibited its activity as it had a reduced ability to decrease F-actin levels. 
Cofilin cysteine residues 139 and 147, but more notably cysteine 147, were the 
key cysteine residues responsible for this inhibition of activity observed with 
oxidised cofilin. Oxidation of recombinant cofilin also resulted in its 
oligomerisation and a corresponding reduction in monomer levels. Cofilin 
cysteine residues 139 and 147 were almost entirely responsible for this 
oligomerisation and reduction in monomer levels again with cysteine 147 having 
the predominant role. 
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6 Cofilin Oxidation and Cell Migration and Invasion 
6.1 Introduction 
Cofilin has been well documented to be involved in cell migration and invasion. 
Reports have been published highlighting that cofilin is required for the 
migration of neural crest cells, macrophages, neutrophils and T cells [65, 161-
163]. Moreover, the overexpression of cofilin increased the migration and 
invasion of melanoma cells, while cofilin was identified to be overexpressed in 
an invasive subpopulation of mammary tumour cells [56, 190]. In addition to 
this, increasing or decreasing the activity of cofilin resulted in an increase or 
decrease in the invasiveness of mammary tumour cells, respectively [191]. Since 
I demonstrated that oxidation of cofilin inhibited its ability to reduce F-actin 
levels and that this was dependent on cysteine residues 139 and 147, I wanted to 
establish if the oxidation of cofilin on these residues was also required for cell 
migration and invasion, cellular processes that require dynamic changes in the 
actin cytoskeleton. In this chapter, the results from my investigations into the 
involvement of cofilin oxidation in cell migration and invasion are presented. 
6.2 Results 
6.2.1 Establishment of MDAMB231 cell lines stably expressing 
mCh, mCh cofilin WT or mCh cofilin C139/147A 
After discovering through my in vitro studies that the oxidation of cofilin 
inhibited its ability to decrease F-actin levels and resulted in its oligomerisation 
and a reduction in monomer levels, I wanted to investigate how the oxidation of 
cofilin could affect its functioning in cells. To do this I created MDAMB231 cell 
lines stably expressing either mCh cofilin WT or mCh cofilin C139/147A which 
would be insensitive to oxidation on cysteine residues 139 and 147. I chose the 
cofilin C139/147A mutant as it was the one that was able to reduce F-actin 
levels to the same degree when oxidised and non-oxidised, and showed the 
greatest inhibition of oligomerisation in vitro. In addition to the cofilin 
expressing cell lines I also generated a mCh expressing cell line as a control. To 
create these cell lines, I transfected parental MDAMB231 cells with plasmids 
expressing mCh, mCh cofilin WT or mCh cofilin C139/147A and a gene conferring 
resistance to G418. 48 hours after transfection, cells were transferred to G418 
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containing medium and cultured until all control cells that had not been 
transfected with any of the plasmids had died. Surviving cells expressing mCh, 
mCh cofilin WT or mCh cofilin C139/147A were selected by cell sorting using a 
FACSaria cell sorter (Figure 6-1 A). These cells were then used for subsequent 
experiments after confirmation by western blot analysis that they were 
expressing the mCh control or cofilin proteins. Membranes were probed using 
both anti-cofilin Ab and anti-dsRed Ab capable of detecting mCh (Figure 6-1 B). 
6.2.2 No difference in proliferation of MDAMB231 cell lines 
expressing mCh, mCh cofilin WT or mCh cofilin C139/147A 
Before undertaking any further experiments with the newly generated cell lines, 
I wanted to check that their proliferation rates had not been affected by the 
expression of these proteins. To do this I seeded each cell line at 5,000 cells per 
well in a 96-well plate and then counted the cells at 24, 48, 72 and 96 hours 
using the CellTiter-Glo assay. From this I was able to confirm that there was no 
difference in the proliferation of the cell lines expressing mCh, mCh cofilin WT 
or mCh cofilin C139/147A compared to the parental MDAMB231 cells (Figure 6-
2). 
6.2.3 mCh cofilin WT and mCh cofilin C139/147A cells show 
slight decrease in migration 
After establishing that; i) H2O2 levels were increased in migrating cells and ROS 
are necessary for migration, ii) cofilin oxidation was found increased in 
migrating cells and iii) that the oxidation of cofilin inhibits its activity, I wanted 
to know if the mCh cofilin C139/147A cells exhibited an altered ability to 
migrate compared to the mCh cofilin WT cells. To address this I again used the 
Essen Bioscience CellPlayerTM 96-well cell migration assay as described in 
chapter 3.  
Cells were seeded in a 96-well ImageLockTM plate and cultured overnight to form 
a confluent monolayer. Wounds were then created through the monolayer using 
the WoundMakerTM after which the plate was placed in the IncucyteTM machine 
which was scheduled to acquire images of the wounds every 2 hours for 24 
hours. Again as in chapter 3, wound width was used as a measure of cell 
migration. The results from this experiment showed that both the MDAMB231 
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cell lines expressing mCh cofilin WT and mCh cofilin C139/147A had a slightly 
reduced migration compared to the parental and mCh expressing cell lines but 
no difference was observed between the WT and C139/147A cofilin expressing 
cells (Figure 6-3). This was not unexpected as it has been reported that 
overexpressing cofilin within cells disrupts the actin cytoskeleton at the leading 
edge and this inhibits their invasiveness [189]. 
6.2.4 mCh cofilin C139/147A cells have reduced directionality 
Having seen no difference in the migration between mCh cofilin WT and mCh 
cofilin C139/147A cells, I next wanted to investigate if cofilin oxidation was 
involved in particular aspects of cell migration. Such factors might not be 
detected in an assay that just measures overall migration, such as the one used 
previously, due to the fact that cells have a remarkable ability to switch the way 
in which they migrate as discussed in the introduction. One aspect of cell 
migration that cofilin has been implicated in is directionality, therefore it was 
decided to determine if cofilin oxidation was required for cell directionality 
[155, 156]. To investigate this, cells were seeded at a subconfluent density in a 
6-well plate, allowed to settle to the bottom and then imaged on a timelapse 
microscope for 4 hours. Paths taken by individual cells were tracked and 
directionality determined using ImageJ. This revealed that the MDAMB231 cells 
expressing mCh cofilin C139/147A had a significantly lower directionality 
compared to the mCh and mCh cofilin WT expressing cells (Figure 6-4). 
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Figure 6-1 Creation of MDAMB231 cell lines stably expressing mCh, mCh cofilin WT or mCh 
cofilin C139/147A 
A) FACS plots confirming a population of cells which positively expressed either mCh, mCh cofilin 
WT or mCh cofilin C139/147A. B) Western blot confirming the stable expression of mCh, mCh 
cofilin WT or mCh cofilin C139/147A in the MDAMB231 cell line. Membranes were probed using  
anti-cofilin Ab and anti-dsRed Ab capable of detecting mCh. 
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Figure 6-2 No difference in proliferation rate of stable cell lines expressing mCh, mCh cofilin 
WT or mCh cofilin C139/147A 
Cells were seeded in a 96-well plate at 5,000 cells per well and at the time points indicated cells 
were counted using the CellTiter-Glo assay. A) Graph showing mean cell number +/- SEM relative 
to 24 hours measured across 3 independent experiments. Statistical significance of differences 
determined by a one-way ANOVA followed by a Tukey Kramer multiple comparison test (ns=not 
significant). 
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Figure 6-3 Expression of mCh cofilin WT or mCh cofilin C139/147A results in a small 
decrease in wound closure 
Cells were cultured in ImageLock
TM
 96-well plates to form a confluent monolayer. Wounds were 
created using a WoundMaker
TM
 and wound closure measured over 24 hours using the Incucyte
TM
 
system. A) Representative images of wounds at 0 and 24 hours. B) Graph showing wound closure 
over 24 hours. C) Graph showing mean wound closure at 24 hours +/- SEM measured across 3 
independent experiments. Statistical significance of differences determined by a one-way ANOVA 
followed by a Tukey Kramer multiple comparison test (ns=not significant, *=p<0.05). 
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Figure 6-4 Cells expressing mCh cofilin C139/147A have reduced directionality 
Cells were seeded subconfluently in 6-well dishes and images taken on a timelapse microscope 
every 10 minutes for 4 hours. Paths taken by individual cells were tracked and directionality 
determined using ImageJ. Graph shows mean relative directionality +/- SEM, n=12. Statistical 
significance of differences determined by a one-way ANOVA followed by a Tukey Kramer multiple 
comparison test (**=p<0.01). Figure courtesy of Mike Olson. 
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6.2.5 mCh cofilin C139/147A cells have reduced 
spreading/adhesion as measured by xCelligence system 
Having identified a difference in the directionality of the mCh cofilin C139/147A 
expressing cells, I next wanted to investigate if these cells exhibited any 
difference in adhesion and/or spreading. To address this I used the xCelligence 
system which can monitor changes in a number of different cell properties using 
special plates, called E-plates, which have electrodes at the base of the wells. 
When cells adhere to and spread on these plates there is a change in the 
electrical impedance measured and a read out of this called cell index is 
reported. This system can therefore be used to measure differences in the 
adhesion and spreading of cells. 
I seeded cells in the E-plates at 10,000 per well and scheduled the xCelligence 
software to measure the electrical impedance every 10 minutes for 3 hours. I 
found that the spreading/adhesion of mCh cofilin C139/147A cells increased at a 
slower rate and was significantly lower at the end of the 3 hours compared to 
the mCh cofilin WT, mCh or parental cell lines (Figure 6-5). 
6.2.6 mCh cofilin C139/147A cells have reduced adhesion 
As the lower cell index measured in the mCh cofilin C139/147A cells could be 
the result of reduced cell adhesion and/or cell spreading, I decided to carry out 
experiments to investigate this finding further. Initially I wanted to know if the 
difference in cell index observed was due to adhesion. I therefore seeded cells 
in a 96-well plate at 40,000 cells per well. After 3 hours, I washed the wells 
multiple times to remove cells that had not fully adhered to the plate and 
counted the number of adherent cells using the CellTiter-Glo Assay. I discovered 
that the mCh cofilin C139/147A cells had significantly reduced cell adhesion 
compared to mCh cofilin WT and mCh cells (Figure 6-6). The reduction in 
relative adhesion measured was similar to the decrease in relative 
spreading/adhesion reported in the previous experiment. Reduced adhesion 
could therefore account in full or in part for the decreased cell index seen. 
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Figure 6-5 Cells expressing mCh cofilin C139/147A have reduced spreading/adhesion as 
measured by the xCelligence system 
Cells were seeded in E-plates at 10,000 per well and spreading/adhesion (as indicated by cell 
index) measured over 3 hours on the xCelligence system. A) Graph showing spreading/adhesion 
relative to parental cell line measured over 3 hours from time of seeding. B) Graph showing mean 
spreading/adhesion +/- SEM relative to parental cell line at 3 hours measured across 3 
independent experiments. Statistical significance of differences determined by a one-way ANOVA 
followed by a Tukey Kramer multiple comparison test (ns=not significant, **=p<0.01, ***=p<0.001). 
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Figure 6-6 Cells expressing mCh cofilin C139/147A have reduced adhesion 
Cells were seeded in 96-well plates at 40,000 cells per well. After 3 hours non-adherent cells were 
washed off and adherent cells counted using CellTiter-Glo assay. A) Graph showing mean 
percentage adhesion +/- SEM relative to parental cell line after 3 hours measured across 3 
independent experiments. Statistical significance of differences determined by a one-way ANOVA 
followed by a Tukey Kramer multiple comparison test (ns=not significant, *=p<0.05). 
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6.2.7 mCh cofilin WT and mCh cofilin C139/147A cells show no 
difference in invasion 
Having seen a decrease in the directionality and adhesion of the mCh cofilin 
C139/147A cells, I wanted to know if there was any difference in their rate of 
invasion. To do this, I used the Essen Bioscience CellPlayerTM 96-well cell 
invasion assay which follows a similar format to the cell migration assay except 
the cells have to invade through a layer of Matrigel in order to close the wound. 
Cells were seeded in a 96-well ImageLockTM plate and cultured overnight to form 
a confluent monolayer and wounds then created through the monolayer using 
the WoundMakerTM. Cells were then overlaid with a layer of Matrigel and the 
plate placed in the IncucyteTM machine which was scheduled to acquire images 
of the wounds every 2 hours. In this case relative cell density was used as a 
measure of cell invasion. Neither wound width or wound confluence could be 
used as a measure of invasion as the presence of the Matrigel and the way in 
which cells invade interferes with the integrated metrics that measure these 
factors. From this I discovered that there was no difference in the rate of 
invasion between the mCh cofilin WT and mCh cofilin C139/147A cells even with 
respect to the parental and mCh cell lines (Figure 6-7). 
6.3 Conclusions 
In this chapter I have presented results showing that cells expressing mCh cofilin 
WT and mCh cofilin C139/147A have no difference in proliferation compared to 
control parental and mCh cells. Both mCh cofilin WT and mCh cofilin C139/147A 
cells exhibit a decrease in migration compared to parental and mCh cells. In 
contrast mCh cofilin C139/147A cells have a decreased directionality and 
adhesion, compared to mCh cofilin WT, mCh and parental cells. Although these 
differences were observed in migration, directionality and adhesion, there was 
no change in the invasion of either mCh cofilin WT or mCh cofilin C139/147A 
cells compared to parental or mCh cells. 
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Figure 6-7 No difference in invasion observed in cells expressing mCh cofilin WT or mCh 
cofilin C139/147A 
Cells were cultured in ImageLock
TM
 96-well plates to form a confluent monolayer. Wounds were 
created using a WoundMaker
TM
 then overlaid with Matrigel. Invasion was measured over 10 hours 
by measuring relative wound density using the Incucyte
TM
 system. A) Representative images of 
wounds at 0 and 10 hours. B) Graph showing relative wound density over 10 hours. C) Graph 
showing mean relative wound density at 10 hours +/- SEM measured across 3 independent 
experiments. Statistical significance of differences determined by a one-way ANOVA followed by a 
Tukey Kramer multiple comparison test (ns=not significant). 
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7 Discussion 
As described in the introduction, ROS are frequently elevated in cancer cell lines 
and tissue samples. Increased ROS levels are also associated with a more 
aggressive disease and poorer prognosis. One of the hallmarks of cancer and 
aspects of disease progression that is known to be promoted by ROS is invasion 
and metastasis. Cell migration is an essential component of invasion and 
metastasis, and is also understood to be regulated by ROS. Although it is known 
that ROS exert their downstream effects primarily through the oxidation of 
proteins on key cysteine residues, very few proteins have been identified as 
direct targets of this oxidation and found to be involved in ROS mediated 
signalling in migrating cells. Here I have presented data showing that the ROS, 
H2O2, is produced at increased levels in migrating cells, predominantly at the 
tips of protrusions. Additionally I have demonstrated that protein oxidation is 
increased in migrating cells and identified the actin binding protein cofilin as 
one of the oxidised proteins. Furthermore I established that, when oxidised, 
cofilin forms oligomers and has a reduced ability to decrease F-actin levels in 
vitro, which is dependent on the oxidation of cysteine residues 139 and 147. 
Moreover, the oxidation of these cysteine residues is required for directional cell 
migration and adhesion in cell culture. 
7.1 ROS and cell migration 
There is a wealth of in vitro and in vivo evidence demonstrating the involvement 
of ROS in cell migration. Most of these studies have shown this by increasing 
antioxidant or ROS scavenging enzyme levels, which results in a decrease in 
migration, or conversely reducing antioxidant levels which enhances cell 
migration [255-259]. These reports are supported by my own experiments 
showing that treatment of cells with the antioxidant NAC inhibits migration 
(Figure 3-2). Others have shown a direct increase in ROS levels in migrating cells 
using derivatives of the fluorescent ROS sensor, DCF. Some of these studies also 
identified an accumulation of ROS at membrane ruffles and the leading edge of 
migrating cells which are the areas undergoing the most dynamic changes in the 
actin cytoskeleton [266, 277]. However, the ROS sensors used in these 
experiments are not able to distinguish between different types of ROS. It would 
be of interest to know if H2O2 in particular was elevated as it is the ROS known 
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to act as a second messenger in signalling pathways and be responsible for 
protein oxidation [328]. To address this issue I employed a fluorescent probe, 
HyPer, that is sensitive specifically to H2O2 and can be used in live cell imaging 
[322]. Using this probe, I established that H2O2 levels are elevated in actively 
migrating cells (Figures 3-8 and 3-14). Moreover, this increase in H2O2 was 
particularly apparent at the tips of cell protrusions, which are the most motile 
areas of the cell (Figure 3-15). These results are consistent with the previously 
mentioned studies but, as far as I am aware, is the first time H2O2 levels have 
been specifically shown to be elevated in migrating cells and localised at the 
leading edge. As H2O2 is the ROS responsible for protein oxidation, this finding 
compliments and provides further insight into the observation that protein 
oxidation is increased at the leading edge of migrating cells [278]. 
Although my data clearly show that the concentration of H2O2 is higher in 
migrating cells, especially at the leading edge, one question still remains; what 
is the source of this H2O2? A possible answer to this question is the NOX enzymes. 
A number of studies where NOX enzymes were chemically inhibited reported a 
decrease in migration [257, 266, 267]. Similarly, knockdown of NOX1 and NOX4 
lead to impaired migration and conversely, overexpressing NOX1 increased 
migration [268-271]. Additionally, NOX2 and its regulatory subunit, p47phox, 
have been identified at the leading edge in VEGF-induced migrating cells and 
NOX4 in focal adhesions and invadopodia, both structures that are associated 
with the leading edge in migrating cells [213, 227, 277, 278]. Although the ROS 
produced by NOX enzymes is O2
-, this is very unstable and so will rapidly convert 
to H2O2 either spontaneously or by the action of enzymes such as SOD [206, 329]. 
Interestingly, SOD has also been found localised at specific regions of the 
membrane in VEGF stimulated cells but the colocalisation of SOD and NOX 
enzymes has yet to be shown [262]. In further support of this hypothesis is the 
fact that cells at wound margins in zebrafish larvae and Drosophila embryos 
produce H2O2 to attract leukocytes and hemocytes respectively to wounds, which 
is dependent on DUOX, a member of the NOX family of proteins [264, 265]. 
Nevertheless a direct involvement of NOX in the production of H2O2 at the 
leading edge of migrating cells remains to be confirmed by the use of NOX 
inhibitors or the knockdown of NOX in cells. 
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7.2 Protein oxidation and cell migration 
Global protein oxidation has previously been shown to be increased in human 
umbilical vein endothelial cells (HUVEC) stimulated with VEGF, a growth factor 
that is known to induce the migration of endothelial cells [278]. This study also 
reported that a population of oxidised proteins was located at the leading edge 
in migrating cells in the presence of VEGF. However, the results I have presented 
are the first directly demonstrating that protein oxidation is increased in 
migrating cells (Figure 4-4). Due to observations by myself and others that ROS 
are required for cell migration, it is likely that the oxidation of some of these 
proteins alters their activity in order to aid migration. In addition to showing 
that there was a population of oxidised proteins at the leading edge in migrating 
cells, Kaplan et al. also highlighted that this population colocalised with F-actin 
[278]. I therefore hypothesised that some of the proteins oxidised in migrating 
cells would be involved in remodelling the actin cytoskeleton at the leading edge 
where it is undergoing constant dynamic changes. 
With this in mind, I started to speculate about which proteins could be targets of 
the H2O2 produced in migrating cells. One attractive candidate was the actin 
binding protein cofilin, which is known to be enriched at the leading edge of 
migrating cells and has previously been reported to be oxidised in T cells treated 
with H2O2 and in cells undergoing apoptosis induced by the oxidant taurine 
chloramine (TnCl) [94, 137, 153]. With the use of the chemical probe dimedone, 
I established that cofilin is oxidised in cells under normal resting conditions and 
the level of oxidation is increased during migration (Figures 4-5 and 4-6). This is 
the first report of cofilin oxidation in cells under physiological conditions (resting 
state and during migration) rather than following treatment with oxidants. The 
only proteins previously identified to be oxidised and to contribute to cell 
migration were the protein tyrosine phosphatases PTP1B, DEP1, PTP-PEST and 
LMW-PTP [262, 276, 290, 291]. These were all shown to be oxidised following the 
activation of signalling pathways that induce and contribute to cell migration. In 
addition to these, the scaffolding protein IQGAP1 is oxidised following 
stimulation of cells with VEGF, however whether this has a role in VEGF-induced 
migration is still unclear [278]. Therefore, my results are the first to detect the 
oxidation of a specific protein in migrating cells, and provide a direct link 
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between increased ROS levels at the leading edge and the dynamic changes in 
the actin cytoskeleton that take place here. 
7.3 Cofilin oxidation and actin dynamics 
Having established that cofilin was oxidised in migrating cells, I wanted to 
determine if this altered its activity to aid cell migration. As a starting point, I 
tested the effect of cofilin oxidation on actin dynamics in vitro using a pyrene 
conjugated actin depolymerisation assay which revealed that the oxidation of 
cofilin inhibited it from severing or depolymerising actin filaments to reduce F-
actin levels (Figure 5-4). This is consistent with data published from another 
group who also reported that the oxidation of recombinant cofilin reduced its 
ability to decrease F-actin levels in vitro [137]. During the process of confirming 
that the recombinant cofilin was oxidised, I discovered that cofilin oxidation 
resulted in the formation of cofilin oligomers (Figure 5-13). A previous study also 
demonstrated, based on results using cross linking agents, a natural tendency of 
cofilin to form oligomers [135]. However, the data I have presented confirms 
this using a physiologically relevant source of oxidation and cross linking through 
disulphide bonds. Pfannstiel et al., also show that cofilin monomers and 
oligomers have different activities when it comes to regulating actin structures. 
While monomers sever and depolymerise F-actin, oligomers induce actin 
bundling [135]. This difference in the activities of monomers and oligomers 
could explain the results I obtained in the actin depolymerisation assay. The 
inhibition in the ability of cofilin to reduce F-actin levels as the concentration of 
H2O2 was increased could be due to a reduction in monomers acting to 
depolymerise the F-actin and an increase in oligomers promoting the bundling of 
F-actin. However, if this were the case, I would have expected at the highest 
concentration of H2O2 (10 mM), where virtually all of the cofilin was present as 
oligomers, that F-actin would be predominantly bundled with negligible amounts 
of depolymerisation, leading to an increase in pyrene actin fluorescence. An 
alternative explanation is that the cofilin monomers depolymerise and sever F-
actin while the oligomers cannot bind to F-actin at all or they bind to F-actin but 
do not depolymerise or sever it. There is conflicting evidence supporting both 
sides of this hypothesis. One in vitro study reported that oxidised cofilin retains 
its actin binding activity while a different cell culture study demonstrated that 
cofilin loses its affinity for actin when oxidised under conditions of oxidative 
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stress [94, 137]. However, the in vitro experiments I completed with the cofilin 
cysteine to alanine mutants provides further insight into this apparently 
conflicting data and will be addressed later. 
As the present literature published on cofilin oxidation is not in agreement about 
which cysteine residues in cofilin are oxidised and potentially involved in 
intramolecular and intermolecular disulphide bonds, I undertook experiments to 
answer these discrepancies. For this purpose, I created cofilin mutants in which 
one or two of the cysteine residues in cofilin were mutated to alanine and 
therefore could not be oxidised and tested their abilities to reduce F-actin levels 
and form oligomers. From these experiments, I concluded that cysteine residues 
139 and 147, but predominantly 147, are oxidised and responsible for the 
inhibition of cofilin activity in the F-actin depolymerisation assay and the 
oligomerisation of cofilin (Figures 5-7, 5-9, 5-10, 5-11, 5-12, 5-14 and 5-15). 
Previous studies that had implicated cofilin oxidation in the induction of cell 
death and T-cell hyporesponsiveness suggested an intramolecular disulphide 
bond forms between cysteine residues 39 and 80 and is required for these 
cellular functions [94, 137]. My findings do not exclude a cysteine 39 to 80 
intramolecular disulphide bond as a possibility, but if it does form it is not 
involved in inhibiting cofilin from reducing F-actin levels or forming oligomers. 
One of these studies also proposed a cysteine 139 to 147 intramolecular 
disulphide bond forms but based on the 3D structure of cofilin this would be 
unlikely  [70, 94, 327]. Another in vitro study suggested cofilin oligomers form 
through intermolecular disulphide bonds between cysteine 39 and 147 [135]. 
Again my data do not disagree with this possibility as the C39/147A cofilin 
mutant was able to rescue the inhibition of cofilin activity seen with oxidised WT 
cofilin and partially prevent oligomerisation (Figures 5-9 and 5-15). It also 
confirmed my conclusion that cysteine 147 is one of the cysteine residues 
oxidised and responsible for the oligomerisation and inhibition of cofilin activity 
when WT cofilin is oxidised. However, my results suggest that cysteine 139 is the 
second residue that is sensitive to oxidation and contributes to the formation of 
oligomers and the inhibition of cofilin activity when WT cofilin is oxidised. 
My conclusion that cofilin cysteine residues 139 and 147 are the most sensitive to 
oxidation is also feasible based on the position of these two residues compared 
to cysteines 39 and 80 in the 3D structure of cofilin [70, 327] (Figure 5-5). As 
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cysteine residues 39 and 80 appear to be tucked away in a small pocket within 
cofilin, it makes sense that these residues would be less accessible to oxidants 
and therefore less likely to be oxidised. Also based on their proximity to each 
other, if one did become oxidised it is possible that they would form an 
intramolecular disulphide bond with each other, as has previously been 
suggested, rather than partaking in an intermolecular disulphide bond. In 
contrast, cysteine residues 139 and 147 are externally positioned and exposed on 
the surface of cofilin and therefore easily accessible to cellular oxidants and 
well placed to be involved in the formation of intermolecular disulphide bonds. 
Consulting a model of cofilin interacting with actin provides further information 
about how the oxidation of cysteines 139 and 147 could prevent cofilin from 
severing and depolymerising F-actin (Figure 7-1). The model was created based 
on the crystal structure of the C147A cofilin mutant and the crystallised complex 
of G-actin and the C-terminal domain of twinfilin [70, 330]. This model predicts 
that cysteine residues 139 and 147 lie at the interface between cofilin and actin. 
Therefore, if these residues were involved in forming a disulphide bond with 
another cofilin molecule, or any other thiol containing molecule e.g. 
glutathione, actin binding would be blocked. However, what would happen if the 
cysteine residues were oxidised to the sulfinic or sulfonic acid states rather than 
forming intermolecular disulphide bonds? Charges and radii of each of the atoms 
of reduced and oxidised cofilin and actin were calculated using PDB2PQR with 
the exception of the oxidised cysteine residues which were calculated using a 
developmental version of PRODRG [331, 332]. This modelling proposes that the 
radii of cysteines 139 and 147 oxidised to the sulfinic acid state are much 
greater than the reduced cysteine residues. Therefore oxidation of cysteine 
residues 139 and 147 to sulfinic or sulfonic acids could sterically interfere with 
the actin binding interface due to an increase in size. This seems particularly 
relevant for cysteine 139 (the upper residue) which sits much closer to actin at 
the interface. In addition to this, based on the electrostatic surface potential of 
actin and the reduced and oxidised cofilin which were calculated using APBS, 
there could be an electrostatic interference between actin and oxidised cofilin 
[333]. Electrostatic surface potential mapping suggests that actin has a very 
negatively charged area around the site that interacts with the cofilin cysteine 
147 residue (the lower residue). In addition to this, as the cysteine residues are 
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oxidised to sulfinic and sulfonic acids, the whole area immediately around them 
becomes more negatively charged. Therefore, as cofilin is oxidised there could 
be repulsive forces acting to disrupt the cofilin actin interaction, particularly 
around cysteine 147. 
My data clearly demonstrate that the cysteine residues on cofilin that are 
sensitive to oxidation and responsible for the formation of oligomers and the 
inhibition of cofilin severing and depolymerising activity in vitro are cysteines 
139 and 147. Based on modelling of the interaction between cofilin and actin, I 
hypothesise that the oxidation of cofilin on these residues prevents it from 
binding to F-actin and severing or depolymerising it. This could be due to 
electrostatic or steric interference if sulfinic or sulfonic acids are the product of 
cofilin oxidation. Alternatively cofilin oxidation could result in its 
oligomerisation, which has not been observed in cells but has been suggested 
could occur in regions of high cofilin oxidation, or the formation of 
intermolecular disulphide bonds with other thiol containing molecules such as 
glutathione, which has been observed in cells [135, 136]. In this situation the 
cofilin actin interface would be completely blocked preventing cofilin binding to 
and severing or depolymerising F-actin. However, to confirm this hypothesis 
actin binding studies in vitro and in cell culture with WT and the cysteine to 
alanine cofilin mutants would need to be carried out.  
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Figure 7-1 Modelling of the interaction between oxidised cofilin and actin 
Model based on crystal structure of the C147A cofilin mutant and the crystallised complex of G-
actin with the C-terminal domain of twinfilin [70, 330]. Charges and radii of each of the atoms of 
reduced and oxidised cofilin and actin were calculated using PDB2PQR with the exception of the 
oxidised cysteine residues which were calculated using a developmental version of PRODRG [331, 
332]. Electrostatic surface potentials were calculated using APBS [333]. Figures were created in 
PyMOL. A) Actin, represented as an electrostatic surface potential map, interacting with cofilin, 
shown in cyan. Sulphur atoms of cysteine 139 (upper residue) and 147 (lower residue) residues 
shown in yellow. B) Model showing increased radii of cysteine residues when oxidised. Sulphur 
atoms shown in yellow and oxygen atoms shown in red. Cofilin in same position and orientation as 
in A). C) – E) Electrostatic surface potential maps of areas around cysteine residues 139 and 147 
when reduced (C) or in sulfenic (D) or sulfinic (E) acid states. Figure courtesy of Mads Gabrielsen.  
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7.4 Cofilin oxidation and cell migration and invasion 
Cofilin is well known to be required for cell migration both under normal 
circumstances and in the context of cancer [65, 161-163, 190]. Since I have 
demonstrated that H2O2 levels are increased in migrating cells particularly at the 
leading edge, cofilin oxidation is increased in migrating cells and the oxidation 
of cofilin inhibits its ability to reduce F-actin levels, I next wanted to determine 
if the oxidation of cofilin was involved in regulating its activity with respect to 
cell migration. For this reason I expressed either WT or C139/147A mutant 
cofilin in cells and measured their ability to migrate. I found that in both cases 
cell migration was impaired (Figure 6-3). This is not surprising as the 
overexpression of cofilin has previously been shown to disrupt the actin 
cytoskeleton at the leading edge and to decrease migration [189]. Although the 
C139/147A cofilin could not be regulated by oxidation it would still be subject to 
regulation by other mechanisms such as phosphorylation and therefore largely 
act as normal. 
As there are many factors, for example protrusion development and cell 
adhesion, that contribute to the overall migration of cells it was decided to 
interrogate if cofilin oxidation contributed specifically to some of these factors. 
An involvement of cofilin oxidation in particular aspects of cell migration might 
not be detected in an assay that just measures overall migration such as the one 
used previously since, as explained in the introduction, cells have a remarkable 
ability to switch migration modes so that migration is not prevented. As cofilin 
has been implicated in the directional migration of cells and in determining the 
direction of lamellipod growth, it was decided to investigate if cofilin oxidation 
was required for establishing cell directionality [155, 156]. By tracking the 
movement of individual WT and C139/147A cofilin expressing cells migrating 
randomly on a 2D surface it was discovered that the C139/147A cofilin cells 
moved in a less directional manner than the WT cofilin or control cells (Figure 6-
4). It has been reported that cofilin is required for the directional migration of 
carcinoma cells towards EGF, and EGF has also been shown to induce the 
production of ROS in cells [156, 245]. Combining this information with the data I 
have presented indicating that cofilin oxidation contributes to directional 
migration, it is reasonable to hypothesise that EGF induces an increase in ROS in 
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cells, this oxidises cofilin which contributes to the directional migration towards 
the source of EGF.  
However in what way does cofilin oxidation actually contribute to directional 
cell migration? The extension of membrane protrusions, such as lamellipodia, is 
the first step that must occur in order for cells to migrate. Cofilin has been 
shown to be required for the development of lamellipodia and particularly for 
the initial production of actin barbed ends that initiate protrusion growth and 
sets the direction of cell movement [147, 148, 155, 156]. The continued activity 
of cofilin has also been suggested to be necessary to maintain the supplies of G-
actin and barbed ends needed for the growth of the lamellipodia [151-154]. I 
hypothesise that while cofilin activity is required for the events I have 
described, the inhibition of cofilin nearer the front of the lamellipodia and 
directly at the leading edge would prevent it severing and depolymerising actin 
filaments enabling more efficient actin polymerisation, lamellipod growth and 
cell migration. The oxidation of cofilin by H2O2 at the leading edge of cells 
migrating at a wound edge or in response to a chemoattractant, such as EGF, 
could provide the local inhibition of cofilin activity required for this to occur. 
The localised control of cofilin activity has already been demonstrated to occur 
in invadopodia where cofilin is inactivated around the edge of invadopodia by 
phosphorylation through a RhoC activated pathway but remains 
unphosphorylated and active in the core of the invadopodia [158]. Therefore it is 
not inconceivable that cofilin activity is also tightly controlled and restricted to 
specific regions in cell protrusions by oxidation. 
Another aspect of cell migration that I investigated to establish whether it 
required cofilin oxidation was cell adhesion. I determined that the C139/147A 
cofilin expressing cells had reduced adhesion compared to WT cofilin and control 
cells (Figure 6-6). The assembly of nascent adhesions is known to require actin 
polymerisation and is proportional to the rate of lamellipodial protrusion [57, 
334]. Therefore, the reduced level of adhesion I observed could also be 
explained by the hypothesis I proposed above. If cofilin oxidation is required to 
allow efficient actin polymerisation and growth of cell protrusions, preventing 
its oxidation could inhibit the extension of protrusions at the same time as 
impairing the assembly of nascent adhesions. However reports have also been 
published suggesting that cofilin is involved in endocytosis and receptor 
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trafficking and so the reduced adhesion could be the result of a defect in the 
recycling or transport of adhesion receptors and components of focal adhesions 
[171, 335]. Additional research would be required to explore this preliminary 
hypothesis, firstly to establish if cofilin was involved in such cellular processes 
and then if this was influenced by cofilin oxidation. 
After finding that cells expressing C139/147A cofilin had impaired directionality 
and adhesion, I anticipated that they might also have an altered ability to invade 
into a 3D matrix since these two factors are involved in invasion and cofilin has 
been implicated in cell invasion [56, 189, 190]. However, results from the 
invasion assays I carried out indicated that there was no difference in the 
invasion of WT or C139/147A cofilin expressing cells compared to control cells 
(Figure 6-7). As in the migration experiments, it is possible that differences 
would only be seen if investigating individual aspects of cell invasion such as 
invadopodia stability or matrix degradation. In addition, carrying out an invasion 
assay in which cells are fully embedded in matrix rather than just overlaid might 
also reveal a requirement for cofilin oxidation in cell invasion. So although initial 
experiments suggest cofilin oxidation is not required for cell invasion, I believe 
further investigation into particular aspects of cell invasion such as those 
discussed above would be important to fully explore this possibility. 
7.5 Final conclusions   
In conclusion I have shown that the ROS, H2O2, is found at elevated levels in 
migrating cells and in particular is localised to the tips of cell protrusions. 
Additionally, I demonstrated that protein oxidation is increased in migrating 
cells and identified one of these oxidised proteins as the actin binding protein 
cofilin. From in vitro experiments I determined that the oxidation of cofilin 
results in its oligomerisation and inhibits its ability to reduce F-actin levels, 
which is dependent on cofilin cysteine residues 139 and 147. Furthermore, the 
oxidation of cofilin in cells is important for migration to determine directionality 
and for adhesion. 
I therefore propose that H2O2 levels are increased at the leading edge of cells 
whether through the activation of NOX enzymes by growth factors, cytokines or 
adhesion receptor pathways or by H2O2 acting directly as a chemoattractant. As 
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a result, cofilin is oxidised in this region of the cell preventing it from binding to 
and severing or depolymerising F-actin, enhancing actin polymerisation near the 
front of the protrusion and promoting protrusion growth. Meanwhile cofilin 
further back from the front of the protrusion can remain active, supplying G-
actin and barbed ends required to fuel the continued growth of the protrusion. 
This localised control of cofilin activity would therefore allow cell protrusions to 
develop as quickly and efficiently as possible to facilitate cell migration (Figure 
7-2). 
ROS are known to enhance cancer progression in particular by promoting 
migration, invasion and metastasis. Additionally EGF signalling, which has been 
shown to positively correlate with the metastatic potential of cancer cells has 
also been reported to induce intracellular ROS production. As these cellular 
processes have been demonstrated to depend on cofilin, the mechanism I have 
proposed where the local inhibition of cofilin by oxidation contributes to cell 
migration could be utilised by cancer cells to enhance migration, invasion and 
metastasis. Although much more work is required to fully understand how cofilin 
oxidation is involved in directional cell migration and whether it contributes to 
invasion and metastasis, such studies could potentially highlight new ways to 
target this stage of cancer progression and other diseases in which cofilin has 
been implicated. Furthermore, I believe this work highlights the importance of 
studying how the oxidation of specific proteins can regulate cellular processes. 
At present this is an area that is very poorly understood but has the potential to 
reveal new ways of treating a number of human diseases. 
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Figure 7-2 Proposed model for the involvement of cofilin oxidation in cell migration 
H2O2 acting directly as a chemoattractant or produced by activated NOX enzymes in response to 
chemoattractants, such as EGF, oxidises cofilin at the leading edge of cells. Consequently cofilin is 
prevented from binding to and severing or depolymerising F-actin, enhancing actin polymerisation. 
Meanwhile cofilin further back from the front of the protrusion remains active, supplying G-actin and 
barbed ends required to fuel the continued growth of the protrusion. This localised control of cofilin 
activity therefore facilitates cell migration by allowing protrusions to develop as quickly and 
efficiently as possible. 
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